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General introduction and outline of the thesis
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Cardiovascular disease
Cardiovascular diseases (CVD) include all heart and blood vessel diseases and are 
the major cause of mortality worldwide. The number of individuals that decease 
globally of CVD still increases due to the aging of population, population growth 
and shifting demographics1, 2. Stroke, myocardial infarction, heart failure and 
cardiomyopathy are all types of CVD, but the main underlying pathology of CVD is 
atherosclerosis3. Atherosclerosis is a chronic inflammatory disease in which plaque 
formation occurs in arteries. Plaques consist of lipids, cholesterol, debris, calcium, 
fibrin and inflammatory cells, which accumulate in the intimal layer of mainly 
large and medium sized arteries4. Atherosclerotic narrowing of an artery resulting 
in impaired blood flow and ischemia distal to the obstruction is entitled occlusive 
arterial disease (OAD). When narrowing in coronary arteries occurs, it is called 
coronary artery disease (CAD)5 and can result in myocardial infarction and (un)
stable angina. Peripheral artery disease (PAD) is the most common OAD affecting 
the lower legs6. Vascular remodeling is an active process of structural changes in 
the vasculature due to e.g. physiologic alterations in blood flow or vessel wall injury, 
which comprises all CVD described in this thesis7.
Neovascularization
To resolve ischemia distal to the atherosclerotic obstruction, neovascularization 
naturally occurs in the body to form new blood vessels and restore blood flow. 
Neovascularization consists of angiogenesis and arteriogenesis. 
Arteriogenesis is mainly driven by shear stress and is the maturation of pre-existing 
arterioles into functional arteries8-11. In addition, inflammation, elevated flow and 
circumferential stretch on the vessel wall induced by atherosclerotic obstructions 
also cause arteriogenesis. More specifically, vessel wall damage will lead to an up 
regulation of monocyte chemoattractant protein-1 (MCP-1) molecules expressed on 
ECs resulting in adherence and invasion of inflammatory cells such as monocytes, 
CD4+ and CD8+ T cells. Subsequently inflammatory cytokine levels such as TNFα 
increase as well as chemokine and growth factor levels, which causes further 
maturation of pre-existing arterioles10, 12-14. The mature collateral arterioles can 
naturally bypass the occluded vessel.
Angiogenesis, the sprouting of new capillaries from a pre-existing vasculature15, is driven 
by hypoxia and mainly occurs far distal to the occlusion in the most hypoxic area. Upon 
ischemia, hypoxia inducible factor 1a (HIF1a) is up regulated to induce transcription of 
growth factors such as vascular endothelial growth factor (VEGF). Nearby vessels that 
express VEGF receptors, particularly VEGFR2 on endothelium, begin to grow toward the 
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1hypoxic area. VEGFR2 directs endothelial cells (EC) from the pre-existing vasculature to 
migrate, grow and differentiate to shape new capillaries16, 17. 
Vasculogenesis involves de novo formation of blood vessels from embryonic 
precursors through differentiation of angioblasts into endothelial cells followed by 
the recruitment of vascular smooth muscle cells (VSMC), which can shape new blood 
vessels18. Vasculogenesis differs from angiogenesis since there is no pre-existing 
vasculature. For optimal neovascularisation in OAD patients, a proper vascular bed 
of pre-existing arterioles is essential, which are initially formed by vasculogenesis 
during embryologic development of the circulatory system. 
Treatment options
If neovascularisation in the body is not sufficient to prevent ischemia after OAD, 
therapeutic treatment options are available. In asymptomatic OAD patients, 
risk factors are addressed including smoking, medication and in case of PAD 
physical exercise, to confine the development of symptomatic or severe OAD19. 
Other therapeutic options for patients with established OAD are pharmaceutical 
interventions including statins, antihypertensive drugs, or aspirin. Symptomatic 
patients can benefit from revascularization interventions such as angioplasty, also 
known as balloon angioplasty, with or without stent placement. 
In patients with severe symptomatic OAD, bypass graft surgery is commonly 
performed. Coronary artery bypass graft (CABG) surgery is the type of surgery 
that improves blood flow to the heart in CAD patients, whereas peripheral artery 
bypass grafting (PABG) surgery is performed in patients with severe PAD20-23. The 
internal mammary artery is the preferred graft for CABG surgery of the left anterior 
descending coronary artery24. However, the great saphenous vein remains the most 
commonly used and preferred conduit for PABG surgery, owing to availability, 
structure and length25. However, surgical treatment is the last therapeutic option for 
OAD patients. Therefore, it is important to identify new therapeutic targets to prevent 
the development of OAD, stimulate natural neovascularization and prevent vein graft 
failure. 
Vein graft disease
Vein graft failure can have several causes. Early after engraftment, acute thrombosis 
is a dominant cause of vein graft failure, usually as a result of technical failures of 
the procedure. Size mismatch of the graft and target vessel as well as rough surgical 
handling of the vein graft during harvesting and the engraftment resulting in 
endothelial cell damage, can cause acute thrombosis26. 
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From one month after engraftment, intimal hyperplasia is the main etiology of vein 
graft failure. After PABG or CABG surgery, arterialization of the engrafted vein graft 
starts, to adapt to the high-pressure arterial environment. This is characterized 
by structural vessel wall remodeling and intimal thickening, which is essential for 
long-term graft patency. However, continuing arterialization can lead to narrowed 
and occluded vein grafts, called vein graft disease (VGD)26, 27. Smooth muscle cells 
(SMC) migrate into the intima and proliferate and subsequently an inflammatory cell 
influx of e.g. macrophages occurs. This inflammatory response plays an important 
role in the development of VGD. Immediately after surgery, inflammatory cells are 
activated which can produce pro-inflammatory cytokines and growth factors. This 
causes extracellular matrix (ECM) deposition and fibrotic changes leading to the 
development of intimal hyperplasia. Late vein graft failure is usually due to progressive 
atherosclerosis. However, if VGD is prevented, late atherosclerosis can hardly develop. 
Therefore, we focussed on targets to prevent the development of VGD. 
Murine models for vein graft disease and neovascularization
To study neovascularization and VGD in vivo several murine models are developed. In 
brief we will discuss the murine models that are used in this thesis. 
A hind limb ischemia (HLI) mouse model was developed to study neovascularization. 
We used a unilateral hind limb ischemia model with single and double ligation. In 
brief, a skin incision was made in the left inguinal region and the femoral artery was 
prepared. In the single ligation model, ischemia was induced by electrocoagulation 
of the left common femoral artery proximal to the bifurcation of the popliteal and 
saphenous artery28-30. In the double ligation model, unilateral HLI was induced by 
electrocoagulation of the left common femoral artery proximal to the superficial 
epigastric artery and proximal to the bifurcation of the popliteal and saphenous 
artery28. To investigate neovascularization, post-ischemic blood flow recovery was 
measured in the left ischemic and right non-ischemic paw with the use of Laser 
Doppler Perfusion Imaging (LDPI) before and after surgery until sacrifice 28 days 
after surgery. At sacrifice the adductor and soleus muscle were harvested and cross 
sections of embedded muscles were made. Adductor muscle sections were stained 
with alpha smooth muscle cell actin to visualize vascular smooth muscle cells (VSMC) 
and quantify arteriogenesis by measuring the diameter of collateral arterioles. Soleus 
muscle sections were stained with CD31 to visualise endothelial cells and quantify 
angiogenesis by counting the number of angiogenic capillaries. 
To study VGD, a murine vein graft model was used. Vein graft surgery was performed 
by donor caval vein interpositioning in the carotid artery of recipient mice as 
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1introduced by Zou et al31. In brief, in this model the right common carotid artery was 
dissected free from its surrounding from the bifurcation at the distal end toward the 
proximal end. After cutting the carotid artery central, cuffs were placed at both ends 
of the carotid artery. Subsequently, the free ends of the carotid artery were everted 
over the cuffs and ligated. The vena cava was harvested of a donor mice and used as 
a graft by sleeving the ends of the vena cava over the carotid artery cuffs and fixing 
them with sutures32. At sacrifice, 28 days after surgery, the vein grafts were harvested 
and embedded. Cross sections were made and vein graft sections were stained with 
Hematoxylin, Phloxin 0.25%, and Saffron 0.3% to quantify the vessel wall thickening, 
total vessel area and lumen area.
Cells of the vessel wall
It is known that immune cells of the innate and adaptive immune system play a pivotal 
role in the vascular remodeling as well as other cells such as endothelial cells (EC) 
and VSMC33, 34. ECs covering the tunica intima layer of the vascular wall are the first 
cells involved in vascular remodeling. Due to changes in blood flow or pressure ECs 
can be activated or damaged. As a result, ECM components underneath the EC layer 
are uncovered. The ECM containing elastin, collagens, proteoglycans and structural 
glycoproteins are essential to provide a structural network in the vessel wall and 
maintain a full functional vessel wall. Exposure of the subendothelial ECM can trigger 
a coagulation process. VSMC, present in the tunica media, can also trigger ECM 
remodeling processes due to their ability to synthesize ECM molecules and protease 
inhibitors. In addition, CVD resulting in ischemia can trigger VSMC which causes VSMC 
to secrete inflammatory and/or growth factors, VSMC apoptosis or can differentiate 
VSMC with a contractile phenotype to a proliferating synthetic phenotype. VSMC 
reside in the tunica media, but VMSC with a synthetic phenotype are able to migrate 
toward the intimal layer and contribute to the development vascular remodeling. 
Other cells primarily reside in the tunica adventitia e.g. dendritic cells (DCs), mast 
cells, natural killer (NK) cells and T and B cells35, but mainly fibroblasts are present in 
the tunica adventitia.
Cells of the immune system
Cells in the tunica adventitia can either migrate towards the affected site or 
contribute to vascular remodeling from the perivascular region. Leucocytes, or white 
blood cells, are the main cell type in the tunica adventitia, besides fibroblasts, and 
can be divided in granulocytes (mast cells, neutrophils, basophils and eosinophils), 
monocytes (macrophages and dendritic cells) and lymphocytes (NK cells, T cells 
and B cells)(figure 1). Mast cells contain granules with histamine, heparin and 
cytokines which are released following mast cell degranulation after IgE activation, 
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and mediate inflammatory responses such as hypersensitivity and allergic reactions 
and in addition, vascular remodeling36. It is observed that activated mast cells can 
produce chemokines that are capable of neutrophil recruitment to affected areas. 
Neutrophils, abundantly present granulocytes (60% of all leucocytes), are able to 
phagocyte foreign cells and subsequently contribute to vascular remodeling together 
with mast cells33. Eosinophils and basophils are mainly involved in allergic reactions 
via the release of respectively IgE and histamine, however, in addition to mast cells 
they can increase vascular leakage and permeability37.
Figure 1. Cells of the innate and adaptive immune system. Natural killer cells and γδ T cells overlap 
both innate and adaptive immunity.
Dendritic cells are central to the initiation of primary immune responses and are 
antigen presenting cells (APC) which are able to process antigen material and 
present it to lymphocytes. Antigen presentation can be in draining lymph nodes, 
but also within the vessel wall. DCs are classical APCs, but in the vessel wall non-
classical APC such as VSMC and EC, can also be functionally active38. Macrophages are 
phagocytic cells and also able to act as classical APC. Macrophages play a pivotal role 
in vascular remodeling. Monocytes can migrate towards inflamed vessels and adhere 
to (damaged) EC, mainly dependent on chemokines CCL2 and CCL5 and intercellular 
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1adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). 
After extravasation monocytes accumulate and differentiate into macrophages. 
In the vessel wall lipid uptake causes macrophages to turn into foam cells and 
macrophage apoptosis can lead to necrotic core formation, both detrimental in 
vascular remodeling and atherosclerosis39. 
Lymphocytes of the adaptive immune system can be activated via (non)-classical 
APC. NK cells can be classified as a member of the innate immune system but due 
to the cytotoxic function, which resembles the cytotoxic T cell function, it is also a 
member of the adaptive immune system. NK cells can act rapidly after an infection 
by releasing perforins and granzymes which induce apoptosis of the intruding cell. 
This cytotoxic function makes NK cells critical regulators of vascular remodeling40, 41. 
T and B cells have been identified in the vessel wall and are differentially involved in 
vascular remodeling. Similar to B cells, T cells also demonstrated diverse functions in 
CVD due to the differential functions of CD4+ and CD8+ T cells and T cell subtypes. 
Innate immunes system; 
The innate immune system is a first line host defense mechanism against many 
common microorganisms42. Cells of the innate immune system, such as macrophages, 
mast cells and NK cells, detect microorganisms and subsequently release cytokines 
and inflammatory mediators to regulate inflammation. Microorganisms are 
recognized by pattern recognition receptors (PRRs) including Toll-like receptors 
(TLRs), Nod-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin 
receptors (CLRs)43. TLRs are transmembrane PRRs and play a crucial roles in the innate 
immune system by recognizing pathogen-associated molecular patterns (PAMPs), 
which are molecular components of micro-organisms44. In addition, TLR recognise 
danger-associated molecular patterns (DAMPs) such as endogenous danger signals 
to alert other cells of the innate immune system. Multiple TLRs showed a role in 
CVD; a role for TLR4 in VGD and accelerated atherosclerosis has been established45, 
TLR2 promotes atherogenesis46, and blocking TLR7 and TLR9 showed reduced post 
interventional remodeling47.
In humans, 10 different TLRs have been identified, whereas 12 distinct TLRs exist in 
mice. TLRs are either expressed on the cell surfaces recognizing mainly microbial 
membrane components or expressed in intracellular vesicles where they recognize 
microbial nucleic acids44, 48. After activation, TLRs signaling is either dependent on the 
TIR domain-containing adaptor molecule MyD88 or TRIF dependent/Myd88 
independent 49 (figure 2). It is demonstrated that TLR3 signals exclusively via a TRIF 
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dependent pathway and TLR2 only via the Myd88 dependent pathway, while TLR4 
signaling can be via either the MyD88 or TRIF pathway44, 50. It is assumed that the 
Myd88 dependent pathway mainly activates nuclear factor kappa-light-chain-
enhancer of activated B cells (NFĸB) which results in pro-inflammatory cytokine 
production. Whereas the TRIF pathway phosphorylates interferon regulatory factor 
(IRF) 3 and IRF7 which results in the production of type-I interferons (IFNs); IFNα and 
IFNβ. Although these are the most common signaling pathways, activation of pro-
inflammatory transcription factors via IRF3 and IRF7 is not excluded51, 52. Previous 
studies showed a protective effect of IRF3 and IRF7 through inhibition of VSMC 
proliferation and neointima formation in a mouse carotid artery wire injury model 
and carotid artery balloon injury model53, 54. In addition, IRF3 and IRF7 were 
demonstrated to have angiogenic properties55, 56
Figure 2. Hypothetic schematic overview 
of the signaling pathways of TLR2, TLR3 
and TLR4, regulating vascular remodeling, 
that will be discussed in parts in this thesis. 
TLR = toll like receptor, TRIF = TIR-domain-
containing adapter-inducing interferon-β, 
Myd88 = Myeloid differentiation primary 
response 88, IRF = Interferon regulatory 
factor, NFĸB = nuclear factor kappa-light-
chain-enhancer of activated B cells, Type I 
IFN = Type I Interferon. Pro inf cytokines = 
pro-inflammatory cytokines.
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1In collaboration with the innate immune system, lymphocytes of the adaptive immune 
system have a highly important role in the development of CVD. The innate immune 
system is responsible for controlling pathogens and infections in the first days after 
contamination. Subsequently after 4–7 days, the adaptive immune response initiates. 
Some immune cells such as NK T cells and γδ T cells even have a function in both the 
innate and adaptive immune system.
Adaptive immune system; T cells, co-stimulation
The lymphocytes of the adaptive immune system provide increased protection 
against re-infection with the same pathogen via memory cells. B cell and T cell 
lymphocytes derive from hematopoietic stem cells in the bone marrow in naive form 
and develop into CD4+ or CD8+ T cells in the thymus. 
In 1970 it was discovered that naive T cells require two signals for activation57, 58. The 
first signal is the interaction of the T cell receptor (TCR) with a cognate peptide-MHC 
complex on APCs59, 60. The second signal is provided via T cell co-stimulation which 
binds co-stimulation ligands expressed on APCs. Additionally, CD8+ T cells can be 
activated via bystander cytokines e.g. IL-12 and type-I IFNs61. 
After activation, naive T cells can differentiate into effector T cells that are actively 
involved in the elimination of a pathogen. After an infection, memory cells are 
formed that can act rapidly if a second infection occurs. Central memory cells and 
effector memory cells, called circulating memory T cells, are present in respectively 
secondary lymphoid organs and tissues. Tissue-resident, non-circulating, memory T 
cells, can also act rapidly if a second infection occurs. Once activated, T cells can be 
polarized into either Th1, Th2, Treg or Th17 cells. T cell subsets can induce differential 
functions in CVD via the production of either pro-or anti-inflammatory cytokines. 
Th1 cells, producing pro-inflammatory cytokines IFNγ and TNFα, are well-known 
for their pro-atherogenic effects. In contrast, Tregs, anti-inflammatory producing IL-
10 and TGFβ, demonstrated mainly anti-atherosclerotic effects, 62-66 and to mitigate 
abdominal aortic aneurysms progression67 and post-interventional restenosis68, 69. 
The functions of Th2 and Th17 cells are less clear. Th2 cells secreting IL-4, IL-5 and 
IL-13 and Th17 cells secreting IL-17A, IL-17F, IL-22 and IL-21, showed both pro- and 
anti-atherosclerotic effects are shown70-76.
T cells are essential in neovascularization and are involved in the development of 
CVDs. However, CD4+ and CD8+ T cells can also have differential functions in CVD. Both 
CD4+ and CD8+ T cells have shown a specific role in arteriogenesis via respectively 
the attraction of monocytes and macrophages and subsequent productions of pro-
18
inflammatory cytokines77, 78 or through the expression of IL-1679. CD8+ T cells are 
also involved in angiogenesis80 and can promote the development of vulnerable 
atherosclerotic lesions81 and enhanced atherosclerotic lesions82. 
Outline of the thesis
The aim of this thesis was to identify the role of the innate and adaptive immune 
system in neovascularization and VGD as well as the underlying mechanism. 
Chapter 2 comprises a review on the pathology of VGD. In this review, we evaluate, 
by discussing both experimental and clinical studies, the pathophysiology behind 
vein graft failure and the latest therapeutic options to improve patency for both 
coronary and peripheral bypasses. In the review in chapter 3, the importance of co-
stimulation and co-inhibition pathways in the pathogenesis of CVD is highlighted 
in (pre-) clinical studies e.g. VGD, myocarditis, graft arterial disease, post-ischemic 
neovascularization and atherosclerosis. The potential use of targeting co-stimulation 
or co-inhibition pathways, with immune checkpoint inhibitors, as a treatment for 
CVD, as well as the cardiovascular benefits and adverse events after treatment is 
discussed. Finally, we emphasize cardiovascular monitoring of patients treated with 
immune checkpoint inhibitors, since there is a close relation between treating cancer 
with immune checkpoint inhibitors and the risk of cardiovascular toxicity. Chapter 
4 describes the role of IRF3 and IRF7 in neovascularization. The main components 
of neovascularization, angiogenesis and arteriogenesis, are driven by ischemia, 
inflammation, cytokines and growth factors, which are thought to be regulated via 
IRF3 and IRF7. Therefore we hypothesise that IRF3 and IRF7 of the innate immune 
system are involved in neovascularization. In addition, it is known that T cells have 
a distinctive role in neovascularization. However, the role of co-stimulation, part of 
the adaptive immune system, in T cell activation in neovascularization has yet to 
be established. Therefore, chapter 5 describes the role of T cell activation via co-
stimulation in angiogenesis, arteriogenesis and vasculogenesis. 
Chapter 6  focusses on TLRs as contributing factors in the development of VGD. 
Toll like receptors (TLRs) can be activated in vein grafts by endogenous ligands 
and activate the innate immune system. Therefore we hypothesise a role of TLRs in 
VGD. TLR2, TLR3 and TLR4 are described with specific attention to TLR3. Chapter 7 
provides an insight in the role of IRF3 and IRF7 in VGD. IRF3 and IRF7 are thought to 
be the transcriptional regulators of type-I IFNs and type-I IFN responsive genes and 
are downstream factors of TLRs. Relatively little is known with regard to the interplay 
of IRFs and TLRs in VGD development. Therefore, chapter 7 describes the role of IRF3 
and IRF7 signaling downstream TLRs and the effect of IRF3 and IRF7 in VGD. Chapter 
8 describes the function of T cells of the adaptive immune system in the development 
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1of VGD with specific attention to CD8+ T cells. In addition, we investigate T cell 
activation pathways via the TCR, co-stimulation and bystander cytokines in vitro and 
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Abstract 
Bypass grafting is a standardized technique to circumvent occlusive atherosclerotic 
lesions. Both CABG surgery and peripheral bypass surgery are performed  on a 
daily basis in hospitals worldwide. Veins are commonly used conduits for surgical 
revascularization, however, they are associated with a high failure rate. Therefore, 
preservation of vein graft patency is essential for long term success. With the 
exception of ‘no touch’ techniques, and lipid lowering and antiplatelet (aspirin) 
therapy, no intervention has hitherto unequivocally proven to be clinically effective in 
preventing vein graft failure. In this Review, we describe both preclinical and clinical 
studies evaluating the pathophysiology behind vein graft failure and the latest 




Occlusive arterial disease is a leading cause of mortality globally owing in part to 
a continually aging population and shifting demographics. Bypass graft surgery 
is, besides balloon angioplasty, the most commonly performed revascularization 
strategy CABG surgery is the standard of care for patients with left main coronary artery 
disease (CAD) and three-vessel CAD, while peripheral artery bypass grafting (PABG) 
surgery is performed in patients with late-stage peripheral artery occlusive disease 
(PAOD)1-4. The internal mammary artery is the graft of choice for revascularization of 
the left anterior descending coronary artery. However, veins (almost exclusively the 
great saphenous vein) remain the most commonly used conduits owing to availability 
and length, especially for PABG surgery (Figure 1a)5. 
Adaptation of vein grafts to its new arterial environment is characterized by structural 
vessel wall remodeling and intimal thickening. The appearance of intimal hyperplasia 
after vein graft surgery was first described by the Nobel prize-winning surgeon Alexis 
Carrel more than a century ago6. Moderate intimal hyperplasia formation is necessary 
for proper arterialization and long-term graft patency. However, why some grafts stop 
remodeling after arterialization while others progress to a clinical stenosis remains 
unclear. Patency rates of vein grafts diminish from 98% immediately after surgery 
to <88% within the first month, owing to acute thrombosis. Intimal hyperplasia, 
atherosclerosis, and rupture of plaques formed in the vein grafts result in an overall 
patency of 60% after 10 years (Figure 1b and c)3, 7, 8. Risk factors associated with vein 
graft failure (VGF) include diabetes mellitus9, hypercholesterolaemia10, 11, chronic 
kidney disease12, age, ethnicity, and sex13-15. Several factors associated with the graft 
surgery are also thought to predict VGF, including increased diameter  and poor 
quality of the vein (such as those affected by pre-existing medial hypertrophy and 
intimal hyperplasia16, 17). Additional factors that can predict VGF include the outflow 
area of the vein, and location of the artery distal to the occlusion where the bypass 
will be attached  (with grafts to the left anterior descending territory performing 
better), as well as surgical handling of the vein graft during harvesting and when 
making the anastomosis18. VGF can be observed in asymptomatic patients, but can 
also cause symptoms of ischemia, depending on the extent of the supplied territory, 
the presence of native artery disease, and the function of other grafts and collaterals.
The most obvious difference between coronary artery grafts and peripheral grafts is 
the anatomic location. In addition, the length of the grafts (up to 60 cm in peripheral 
grafts) and the flow and haemodynamic patterns differ between the locations. 
However, risk factors, patency rates, and the cellular and molecular processes 
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underlying the pathophysiology of vein grafts are comparable between both graft 
types. The similarities and differences between CABG surgery and PABG surgery are 
listed in Table 1. This Review focuses on VGF in general and identifies parallels and 
differences between CABG surgery and PABG surgery.
At present, statins and antiplatelet therapy (specifically, aspirin) are the only 
medications recommended by the ESC and the ACC Foundation/AHA Task Force for 
the prevention of VGF4, 19-21. Despite numerous preclinical studies on potential new 
targets and therapies for the prevention of VGF, an unequivocally effective treatment 
has not been found3, 22. Gene therapy is an attractive option, since graft conduits can 
be treated ex vivo22. In this Review, we discuss the pathophysiological mechanisms 
underlying the development of VGF, including the cellular and molecular processes 
involved in vein graft remodeling and intimal hyperplasia formation, and summarize 
potential therapeutic options that can improve patency from the results of both 
preclinical experimental studies and the latest clinical trials.
Figure 1. Macroscopic and microscopic views of a human vein graft. a Frontal view of a 3D 
reconstruction of a heart via CT scan. This scan is an example of a saphenous vein used as a graft from 
the aorta to the ramus circumflexus (black arrowhead). The left internal mammarian artery (white 
arrowhead) is grafted on the left anterior descending (LAD) coronary artery. b| These histologic 
sections of failed human saphenous vein grafts stained with haematoxylin, phloxin, and saphron 
show extensive smooth muscle cell accumulation and extracellular matrix deposition in the intimal 
hyperplasia. c| Atherosclerosis in a vein graft lesions is characterized by a de-cellularized region 
including a calcified necrotic core (NC), foam cells (hash), and neovessels (asterisk). Abbreviations: 
A, adventitia; M, media;  intimal hyperplasia, intimal hyperplasia; L, lumen.
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Table 1. Characteristics of CABG surgery and PABG surgery
CABG surgery PABG surgery
Typical patient symptoms Angina pectoris Critical limb ischemia
Preferred bypass Arteria mammaria interna Vena saphena magna
Other bypasses used Vena saphena magna Polytetrafluoroethylene
Arteria radialis Dacron
Arteria gastroepiploica Biological veins 
Location proximal graft anastomosis Aorta Arteria femoralis
Bypass length 6 cm (single) – 30cm (jump graft) 40–60 cm
Diameter diseased artery 1.5–3.0 mm 4.0–10 mm
Blood pressure in conduit High Medium
10-year overall patency ≈60% ≈60%
Mechanism of primary stenosis
Thrombosis + +
Intimal hyperplasia ++ +++
Atherosclerosis +++ +/-
Pathophysiology of vein grafting
Preclinical imaging studies using in vivo models have enabled researchers to 
construct a timeline of the events that begins with harvesting of the vein grafts to 
eventual VGF (Figure 2). Immediately after harvesting, venous conduits undergo a 
period of ischemia and reperfusion after engraftment, resulting in endothelial cell 
and smooth muscle cell (SMC) damage23. In situ saphenous vein grafts used in PABG 
surgery do not experience ischemia, since the vasa vasorum are still fully intact. The 
temporary closure of the lumen and reperfusion in these grafts cause damage to the 
vessel wall. Engraftment in the arterial circulation increases flow and longitudinal 
and circumferential shear stress, resulting in additional damage to SMCs and the 
extracellular matrix (ECM)23, 24. Platelets and fibrin are deposited, and circulating 
leukocytes attach and infiltrate the vessel wall. Growth factors are subsequently 
released from platelets, macrophages, and SMCs, leading to increased proliferation 
and migration of SMCs to the intima. Uncontrolled SMC proliferation, extensive ECM 
deposition, and the influx of macrophages all contribute to intimal hyperplasia within 
the vessel wall. Under hypercholesterolaemic conditions, increased uptake of lipids 
promotes foam cell formation. Macrophage apoptosis, and subsequent necrotic core 
formation and intraplaque haemorrhage, further accelerate the process of VGF by 
forming unstable atherosclerotic lesions25, 26.
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Figure 2. Vein graft development over time. 
The vein graft procedure results in damage to the endothelial layer. Within hours, the luminal surface 
is covered by fibrin rich layers, and circulating white blood cells including neutrophils, monocytes, 
and lymphocytes, attach and infiltrate the fibrin layer and intima. Smooth muscle cells in the media 
and fibroblasts in the adventitia are activated and start migrating towards the intima, forming 
the intimal hyperplasia. Growth factors and cytokines released by cells in the vessel wall, such as 
inflammatory cells, enhance proliferation of smooth muscle cells and induce extracellular matrix 
deposition, resulting in further growth of the intimal hyperplasia. Under atherogenic conditions, and 
especially after CABG surgery, macrophages in the vessel wall can uptake lipids to become foam 
cells. A necrotic core is formed by dying foam cells, apoptosis, and cholesterol depositions. The 
atherosclerotic process in vein grafts is depicted in the upper part of the illustration.
De-endothelialisation and thrombosis
As mentioned above, during a bypass procedure, most venous conduits undergo a 
period of ischemia followed by reperfusion, resulting in the generation of damage-
associated molecular patterns (DAMPs) and reactive oxygen species (ROS). Together 
with the damage caused by graft handling and distension during the high-pressure 
check for leakage, ischemia–reperfusion injury increases oxidative stress and 
cytotoxic activation, which culminates in loss of endothelial cells and SMCs27-29. 
Endothelial cells become activated, and express intercellular adhesion molecule 1, 
vascular cell adhesion protein, selectins, thrombomodulin, and growth factors. Some 
endothelial cells might show apoptosis and increased blebbing, vacuolisation, and 
of Golgi and rough endoplasmatic reticulum on electron microscopy30-32. Reduced 
endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) production in the 
damaged endothelium results in impaired vasorelaxation33. In porcine venous grafts, 
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the increase in superoxide production compared with levels in arterial conduits 
was associated with reduced synthesis of NO and decreased superoxide dismutase 
activity34. The increase in oxidative stress and endothelial apoptosis, and the 
subsequent endothelial damage seen in veins (but not in arterial conduits) contributes 
to the unfavourable patency rates of vein grafts in experimental models34-36. 
As a result of endothelial denudation, the underlying ECM proteins (for example, 
collagen, elastin, and proteoglycans) become exposed to the circulation, thus 
promoting platelet and fibrin deposition on the thrombogenic luminal surface. 
Tissue factor proteins become available and initiate thrombin formation. Impaired 
NO and prostacyclin production in the venous conduits further enhance platelet 
aggregation28. Platelets generate a number of thrombogenic, chemotactic, and 
vasoconstricting substances, including platelet derived growth factor (PDGF), 
transforming growth factor-β (TGF-β), fibrinogen, fibronectin, and von Willebrand 
factor28. Activated platelets express adhesion molecules, such as P-selectin and 
E-selectin, and bind circulating leukocytes, which in turn attach to and infiltrate in the 
vessel wall37. The CD40 ligand, which has both prothrombotic and proinflammatory 
activity, is exposed and excreted by activated platelets, further accelerating the 
thrombogenic process38. The deposition and subsequent resolution of fibrin is tightly 
regulated through the thrombogenic and fibrinolytic pathways and play an important 
role in the onset of intimal hyperplasia formation39. Targets to improve endothelial 
function comprise Endothelin-1, eNOS and NAD(P)H oxidase. These mediators are 
all capable of influencing haemodynamics and  intimal hyperplasia formation via 
increasing NO and/or inhibition of superoxide production40-42. 
Re-endothelialisation
Restoration of the endothelial monolayer begins rapidly after initial damage. 
Proliferating endothelial cells can be seen as early as three days after vein graft surgery 
in experimental models31, 32. In these models, the endothelial lining is largely intact 
4 weeks after the surgery23, 32, 35, 43. The duration of the re-endothelialisation process 
in humans is likely to be longer, although the exact time frame is not known and will 
depend on the length of the vein graft segment used44. Murine and human progenitor 
cells from bone marrow and the adventitia have been shown to contribute to the 
re-endothelialisation process45-48. The homing of these progenitor cells is thought to 
be integrin β3-dependent49, 50, and is directed by inflammatory-type macrophages51. 
In addition, inducible nitric oxide synthase can enhance endothelial progenitor cell 
attachment and differentiation52. Evidence of the origin of venous graft endothelial 
cells in humans is still lacking, however, human allografts endothelial cells were found 
to be derived from both host and donor cells53. Endothelial cells in mature human 
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vein grafts display endothelium-dependent relaxation, and thus are seemingly 
functional44. However, how non-host endothelial cells affect the functioning of 
the endothelium in the graft is still unknown. Results from preclinical studies have 
thus far shown that enhanced re-endothelialisation is beneficial in preventing VGF, 
but so far no therapies exist to facilitate this process. The promotion of endothelial 
progenitor cell homing could be a potential future therapeutic target. 
Box 1 Coronary artery bypass grafting 
• Coronary artery disease (CAD) is the most common type of heart disease, and 
occurs when atherosclerotic lesions narrow the coronary arteries leading 
directly, or more common indirectly via thrombi, to reduced oxygenation of 
the myocardium. Symptoms of CAD include chest pain (angina) or myocardial 
infarction. 
• Treatment options include lifestyle changes, medication, percutaneous 
coronary intervention with or without stenting, or CABG surgery 
• Conduit choice in CABG depends on many patient-specific factors, including 
location and severity of the target coronary artery stenosis, comorbidities, 
estimated life expectancy, number of bypasses needed, and availability of 
graft material. 
• When revascularizing the left anterior descending coronary artery, the left 
internal mammary artery (IMA) is the preferred graft for CABG surgery4, 19. 
Alternatives include the right IMA, the radial artery (RA), right gastroepiploic 
artery, and the saphenous vein. 
• The use of the saphenous vein graft is advantageous over arterial conduits 
for several reasons: they are easily harvested, easily handled when making 
anastomoses, are not influenced by vasospasm, do not increase the risk of 
sternal wound infection, and are readily available in most patients. 
• In general, arterial conduits are considered to have higher patency rates296, 
297. RA patency is lower than that of IMA grafts and more dependent on the 
severity of the target coronary artery stenosis298. Furthermore, vasospasm 
can also occur, owing to the muscular nature of the RA wall. 
• Inconsistent results have been reported for patency rates in saphenous vein 
grafts and RA grafts299-301
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Vein graft arterialisation 
In 1964, Sziliagyi and colleagues first suggested that a vein needs to undergo a ≥50% 
increase in dimension to adapt to the increased pressure in the arterial circulation54. 
Although this initial adaptation is necessary for veins to acquire an artery-like 
structure, this process can also lead to substantial VGF. Arterialisation of venous 
bypass grafts involves processes such as intimal hyperplasia, geometric remodeling, 
wall stiffening, and inflammation24.
Arterial and venous blood vessels have a similar structure made up of three distinct 
layers: the adventitia, the media, and the intima. Cellular and fibrous components 
within veins are considerably limited in number and size compared with arteries. 
Furthermore, veins contain valves to prevent blood reflux. The venous wall is highly 
adapted for continuous changes in blood volume, but the pressure and flow in the 
venous system is low compared with the arterial system. Interpositioning of a vein into 
a high pressure and flow arterial environment leads to morphologic and geometric 
changes in the venous conduit55.  Intimal hyperplasia or vessel wall thickening is a 
direct result of SMCs and ECM expansion induced by increased pressure, shear stress, 
and inflammatory responses3. For example, shear stress in the saphenous vein rises 
from 0–4 dynes/cm2 to up to 30 dynes/cm2 after engraftment44. 
The geometric adaptation of the vein is thought to be primarily mediated through the 
endothelium, as it is sensitive to haemodynamic stresses3, 56, 57. The three geometric 
parameters that are generally used to determine the mode of remodeling are lumen 
calibre, wall thickness, and lesion area. The haemodynamic forces together with the 
geometric parameters maintain the vessel in a state of maximum efficiency for the 
transport of blood. According to the law of Poiseuille, circumferential, longitudinal, 
and radial stress results in dilatation of the vessel58. The venous conduit in the arterial 
system has been suggested to direct stress in nine different directions59. Constrictive 
remodeling or loss of lumen calibre is associated with low level of shear stress24, 60. 
Interestingly, Zilla et al. demonstrated that the saphenous vein displays different 
degrees of remodeling in coronary bypasses compared to infrainguinal bypasses, 
owing to different flow patterns, and stress and shear force. They also showed that 
coronary grafts in a nonhuman primate model express a high degree of lumen loss 
and  intimal hyperplasia formation, while infrainguinal grafts display increased 
dilatation61. 
Tomographic intravascular ultrasound (IVUS) imaging enables the visualization of 
the full circumference of the vessels, thus allowing evaluation of early geometric 
vascular remodeling in vivo62, 63. Early wall thickening and expansive remodeling 
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of vein grafts occurs within the first few weeks post-implantation, as observed on 
IVUS, with these changes stabilising after 6 months3, 64. Expansive or positive outward 
remodeling is believed to delay the development of lumen loss, although this is 
frequently inadequate for the preservation of luminal size in the long term65-67. In the 
first year after surgery, a considerable portion of the vein grafts show constrictive or 
inward remodeling, a compensatory response to vessel wall thickening68. Unlimited 
expansive remodeling and inward remodeling are detrimental to vein graft 
arterialisation. Gasper et al. demonstrated that early remodeling was predictive for 
future VGF, and suggested that patients at risk should be closely monitored69. Use of 
an external support that could prevent shear stress and decrease wall tension and 
thereby prevent SMC proliferation, outward remodeling, and  intimal hyperplasia 
formation, has proven to be an potential strategy in both human tissue cultures and 
experimental models,70-74 and will be discussed detail below. 
Intimal hyperplasia formation 
Smooth muscle cells
The intima and media of veins consists of several cell layers. During harvesting and 
after engraftment, SMCs within these layers undergo ischemia and apoptosis23, 
31. Matrix turnover and the proliferation, migration, and death of SMCs are key 
components in intimal hyperplasia formation. During migration from the media to 
the intima, or from the anastomosed artery towards the intima of the graft, SMCs 
change from a quiescent contractile phenotype to a dedifferentiated, proliferating, 
or synthetic phenotype75-77. Smooth muscle-like cells derived from adventitial 
fibroblasts also contribute to intimal hyperplasia formation78, 79.These adventitial 
fibroblasts are highly proliferative and produce higher levels of superoxide compared 
with SMCs, owing to reduced activity of superoxide dismutase34. Veins do not contain 
substantial elastic laminae, and consequently, fibroblasts in the adventitia can easily 
migrate to the intima in veins. However, intact elastic laminae within arteries prevent 
transmural migration, which contributes to the difference in intimal hyperplasia 
formation between arterial and vein grafts. Adventitial and bone marrow-derived 
progenitor cells also contribute to vein graft intimal hyperplasia47, 80-85. Interestingly, 
bone marrow-derived cells are reported to express a SMC phenotype, but do not 
fully acquire the definitive SMC lineage86. The CXC-chemokine ligand CXCL12 (also 
known as stromal cell-derived factor 1)/CXCR4 (also known as platelet factor 4) axis 
is essential for homing of bone marrow-derived cells. Vein grafting in CXCR4-/- mice 
resulted in reduced vein graft thickening87. Most bone marrow cells express fibroblast-
specific protein 1 (FSP-1), which lead the cells to home in a (platelet-derived) CXCL12 
dependent manner. Knock down of FSP-1 in bone marrow cells prevented formation 
of intimal hyperplasia88. 
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SMCs and other cells in the vein grafts express numerous growth factors such as 
vascular endothelial growth factor (VEGF), PDGF, basic fibroblastic growth factor 
(bFGF), TGF-β, and endothelin-1, which are major stimulators of SMC migration, 
proliferation, and apoptosis89-93. Targeting of growth factor receptors in vivo 
interferes with intimal growth93-98. The mitogen-activated protein kinase (MAPK), 
extracellular signal regulated kinase (ERK), and Akt (also known as RAC-alpha serine/
threonin-protein kinase) signaling pathways are critical for the regulation of cell 
cycle progression,99-101 and can also directly influence SMCs and intimal hyperplasia 
formation101, 102. The expression of growth factors and signal transduction pathway 
Box 2 Peripheral artery occlusive disease
• Peripheral arterial occlusive disease (PAOD) is a common circulatory problem 
characterized by narrowing of peripheral arteries owing to atherosclerosis, 
which subsequently reduces blood flow to the lower limbs. 
• Many patients with PAOD are asymptomatic (Fontaine I)302. The most frequent 
presentation of PAOD is intermittent claudication, defined as reproducible 
lower extremity muscular pain induced by exercise and relieved by standing 
still (Fontaine II)303. 
• Several treatment options are available for symptomatic PAOD, including 
exercise therapy and pharmacotherapy. In case of ischaemic rest pain 
(Fontaine III), ulceration or gangrene (Fontaine IV), and when conservative 
treatments are unsuccessful, surgical treatment options are required. 
• Invasive endovascular treatment, such as balloon angioplasty, is 
recommended for these patients. Balloon angioplasty combined with stent 
implantation improve patency rates compared to balloon angioplasty alone. 
• Owing to the length or the location of the occlusion, balloon angioplasty 
is not always an option. In such situations, bypass surgery is the preferred 
treatment strategies. 
• Autologous veins (such as the saphenous vein) are the first conduits of choice 
• Alternative conduits include polytetrafluoroethylene, Dacron grafts, or 
modified decellularized umbilical cords 
• Bypass surgery is only possible when there is sufficient patency of the blood 
vessel distal to the occlusion. 
• When bypass surgery is technically impossible, or in case of critical limb 
ischemia with extensive necrosis or infectious gangrene, amputation is the 
last treatment option.
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factors vary between arterial and venous grafts103-105. For example, higher MAPK and 
Akt activity levels were observed in venous SMCs compared with arterial SMCs,106 
which might contribute to the low patency of venous grafts.
Extracellular matrix
Remodelled vein grafts contain a large repertoire of matrix metalloproteinases 
(MMPs), predominantly MMP2 and MMP9107-110. MMPs degrade collagen and other 
components of the ECM in the vessel wall. Doxycycline, a general MMP inhibitor, 
suppressed intimal hyperplasia formation in murine vein grafts109. Furthermore, 
specific gene silencing of MMP2 and MMP9 in cultured saphenous vein SMCs resulted 
in a decreased cell migration through a Matrigel barrier111. Interestingly, vein grafting 
in mice deficient in MMP9 did not alter intimal hyperplasia growth compared with 
control mice, however, MMP9-deficient mice did show an increase in collagen 
content112. Endogenous tissue inhibitors of MMPs (TIMPs) have also been the focus of 
much research related to vein grafts. Overexpression of TIMP1, 2, and 3 in various vein 
graft models resulted in inhibition of MMP activity and a reduction in SMC migration 
and proliferation, thereby preventing intimal hyperplasia formation25, 113-117. 
Whereas MMPs regulate ECM breakdown, TGF-β is known to enhance matrix 
depositions. During early stages of vein graft adaptation, upregulation of TGF-β is 
associated with increased mRNA expression of C-C motif chemokine (CCL) 2, collagen 
I, and collagen III92, 118. Abrogation of TGF-β signaling in rats resulted in decreased 
intimal hyperplasia and increased MMP expression98. In addition, SMCs also generate 
hyaluronic acid, a glycosaminoglycan and important constituent of the ECM. Human 
saphenous vein grafts are characterized by increased deposition of hyaluronic acid 
and elevated expression levels of all three isoforms of hyaluronic acid synthase119. 
Increased expression of members of the plasminogen activation system has been 
observed in failed human vein grafts120, 121. Aside from their role in fibrinolysis and 
proteolysis, plasminogen activators (PAs) can also exert their activity on SMCs and 
the ECM. Components of the ECM, such as laminin and fibronectin, can be cleaved 
by plasmin that is formed by conversion of plasminogen by plasminogen activators, 
resulting in activation of cell surface receptors and MMPs122. The plasminogen 
activation system consists of two main PAs, urokinase-type PA (uPA) and tissue-
type PA (tPA). uPA is essential in extracellular proteolysis, cell migration, and matrix 
remodeling, while tPA is mainly involved in fibrinolysis123. Overexpression of tPA in 
porcine vein grafts resulted in reduction of early vein graft thrombosis124. Plasminogen 
activator inhibitor 1 (PAI1), through its regulation of PA activity, has been shown to 
regulate proliferation, migration, and apoptosis of SMCs and endothelial cells125. 
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Intimal hyperplasia was enhanced in PAI1 deficient mice owing to increased thrombin 
activity126. 
Given that inhibition of either PAs or MMPs has been shown to reduce intimal 
hyperplasia in vivo, a hybrid protein consisting of TIMP1 and the receptor-binding 
amino terminal fragment (ATF) of urokinase was constructed to more efficiently 
inhibit protease activity locally127. This construct enhanced the inhibitory effect of 
murine vein graft intimal hyperplasia and preservation of luminal area compared 
with their individual counterparts128. A further construct was created by adding 
bovine pancreas trypsin inhibitor (BPTI), a potent protease inhibitor capable of 
inhibiting both MMP and plasmin activity at the cell surface, to the existing TIMP1.
ATF construct, which resulted in retardation of  intimal hyperplasia and outward 
remodeling129. Adenoviral overexpression of the hybrid protein ATF.BPTI also reduced 
intimal hyperplasia formation in human saphenous vein grafts in vitro130.
Inflammatory mediators 
Inflammatory mediators are critical in all phases of vein graft development131, 132. Early 
after-engraftment DAMPs such as proteoglycans, heat shock proteins, and biglycan 
are among the first mediators of inflammation133, 134. Endogenous DAMPs activate Toll-
like receptors (TLRs) that are expressed by endothelial cells, SMCs, and macrophages 
in the vein grafts134, 135. Genetic deletion and RNA silencing of TLR4 in a murine model 
of VGF reduced outward remodeling and  intimal hyperplasia formation, as a result 
of a suppressed inflammatory response134. Interestingly, carotid ligation in TLR4-
deficient mice showed outward remodeling without intimal hyperplasia formation 
in the nonligated artery,136 suggesting that TLR4 affects vascular remodeling 
independently of intimal hyperplasia formation; TLR4, therefore, might have a role in 
haemodynamic adaptations.
Other TLR4 ligands include oxidized LDL (oxLDL) and phosphorylcholine, both known 
for their role in the development of atherosclerosis. The role of oxLDL and subsequent 
lipid retention in VGF has been observed, especially under hypercholesterolaemic 
conditions23. Low levels of natural antibodies against phosphorylcholine in humans 
are associated with VGF, while passive immunization with anti-phosphorylcholine 
antibodies prevents vein graft atherosclerosis in a hypercholesterolaemic murine 
model.137, 138. With the exception of TLR3, all TLRs signal via the myeloid differentiation 
primary response protein 88 (MyD88) pathway, which activates nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFĸB)and results in induction of 
proinflammatory cytokines139. NFĸB is one of the most important transcription factors 
for promotion of inflammatory responses in vein graft remodeling. In experimental 
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models, strategies to inhibit NFκB resulted in attenuation of intimal hyperplasia 
formation by reducing inflammation140-142. NFĸB can activate the cytokines CCL2 
and tumor necrosis factor α (TNFα), both of which have been extensively studied in 
VGF143, 144. A dominant receptor antagonist of CCL2, 7ND-MCP-1, reduced vein graft 
atherosclerosis and monocyte invasion in mice on a hypercholesterolaemic diet145. 
Furthermore, RNA silencing of the CCL2 receptor, CCR2, resulted in reduced SMC 
proliferation and migration in vitro and abrogation of  intimal hyperplasia in vivo145. 
As a result of the early induction of TLRs, TNFα is upregulated in early vein graft 
development. In TNF receptor-1-deficient mice, vein graft  intimal hyperplasia was 
reduced as a result of reduced CCL2 expression and SMC proliferation146. In addition, 
TNF receptor-2-deficient mice showed abrogated vein graft intimal hyperplasia as a 
result of endothelial cell apoptosis147. These studies illustrate the various mechanisms 
that can contribute to reducing vein graft intimal hyperplasia. 
In general, cytokines are proinflammatory mediators that induce cell remodeling 
by activating inflammatory cells, SMCs, and endothelial cells132, 148-150. In their role 
as pattern recognition receptors, TLRs are central in the induction of inflammatory 
responses, and can activate inflammatory cells of both the innate and adaptive immune 
system, in addition to activating complement factors. Like TLRs, complement factors 
are present in the vein graft wall, enhancing cross-talk between these components 
of the innate immune system. Complement factors are expressed in both genes and 
proteins in murine grafts, indicating that they are produced by the vessel wall as 
an extra-hepatic source116, 151. Interference with the key complement factor C3, and 
alternative pathway component C1 and C5 resulted in reduced  intimal hyperplasia 
by preventing endothelial cell damage, inhibiting SMC proliferation, and reducing 
inflammatory signaling in murine vein grafts151-153. Complement factors are thus very 
promising targets for treating VGF in humans. An exploratory analysis of the PRIMO-
CABG I and II trials154 reported that intravenous administration of pexelizumab, an 
antibody against complement factor C5, improved mortality in high-risk surgical 
patients undergoing CABG surgery. 
Inflammatory cells that invade the vein graft reside in specific locations in the 
vessel wall. Neutrophils are found mainly in the fibrin layer that is formed on the 
de-endothelialised lumen during early onset of  intimal hyperplasia formation155, 156. 
Neutrophils produce a wide array of angiogenic growth factors and proteases such 
as MMP-9, but their main role is to regulate neighbouring inflammatory cells such as 
macrophages157. Macrophages represent the vast majority of inflammatory cells in the 
intima and media158. Monocytes roll, attach, and invade the graft via the lumen, but 
can also enter via neovessels in the adventitia. Under the influence of macrophage 
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Figure 3. Inflammation in vein graft failure. Toll like receptors (TLRs), superoxide, and adhesion 
molecules are produced by activated endothelial cells. Monocytes and other inflammatory cells 
respond to locally produced cytokines and chemokines by migrating into the vein graft wall. In 
response to local growth factors, monocytes differentiate into macrophages, which then takes up 
oxidised LDL particles to form foam cells. One or multiple necrotic cores are formed by dying foam 
cells and cholesterol depositions. Danger associated molecular patterns promote the production of 
many proinflammatory molecules by activating TLRs on various cells in the vessel wall, stimulating 
proliferation and migration of smooth muscle cells as well as extracellular matrix (ECM) production. T 
cells, primarily located in the adventitia, undergo activation after interacting with antigen-presenting 
cells, such as macrophages or dendritic cells. Other cells in the adventitia such as mast cells and 
natural killer (NK) cells are activated and enhance the inflammatory process. Fibroblasts in the 
adventitia migrate through the external elastic lamina (EEL) and internal elastic lamina (IEL) to the 
media and intima under the influence of growth factors, contributing to the concentric vessel wall 
thickening. MMP, matrix metalloproteases. 
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colony stimulating factor, monocytes become macrophages, which produce and 
release a broad array of cytokines and growth factors. In the case of vein grafts, SMCs 
are the predominant target of these macrophages159. In rabbit and murine vein grafts, 
indirect inhibition of macrophages, for instance by targeting macrophage activating 
factors, has been shown to be a successful strategy in preventing the inflammatory 
response and VGF141, 160, 161. 
The adventitia, made up of loose connective tissue, small neovessels, and perivascular 
fat, is an important source of inflammatory cells; dendritic cells, T and B cells, mast 
cells and natural killer (NK) cells seem to have a preference for the adventitia162. 
Dendritic cells originate from Ly-6Clo monocytes and specialize in presenting antigens 
to T cells163. Dendritic cells are also capable of triggering T cells by expressing co-
stimulatory factors, and can thereby regulate vein graft remodeling162, 164. Mast 
cells are large granular cells that can actively release granules containing tryptase, 
chymase, and histamine. Aside from the classical activation route of binding to 
immunoglobin E165, mast cells can also be activated via cytokines (TNFα, IL1) and 
complement factors (C3a and C5a)166. Vein grafts are rapidly repopulated with mast 
cells; both resting and activated mast cells can be found within the perivascular 
region in murine vein grafts153, 167. Mast cells have been linked to the development 
of atherosclerosis, but are mostly thought to be effector cells of plaque rupture and 
erosion168, 169. Local activation of mast cells resulted in increased unstable lesions and 
vein graft rupture.153 Furthermore, vein grafts in mast cell-deficient mice have reduced 
intimal hyperplasia153. Also present in the adventitia are NK cells, a small subset of 
lymphocytes initially described for their ‘natural’ capacity to kill cells depending 
on the expression of activating and inhibiting NK cell receptors specific for major 
histocompatibility complex class I molecules. NK cells can be activated by secretion 
of lytic granules containing perforin and granzymes, but also by secretion of various 
cytokines170. Limited numbers of NK cells are found in the perivascular region of vein 
grafts171. BALB/C mice lack crucial NK cell genes of the Ly49 receptor family, resulting 
in a reduced NK cell function. Vein graft surgery performed in BALB/c mice congenic 
for the C57BL/6 NK gene region showed similar degree of intimal hyperplasia 
compared to C57BL/6 mice, while BALB/c mice showed significantly less intimal 
hyperplasia171. This difference was accompanied with a decrease in inflammatory 
cells and interferon-γ expression in the vein graft171. 
In general, components of the innate immune system are known to accelerate intimal 
hyperplasia formation and graft failure (Figure 3). The role of adaptive immunity 
is less clear, although both T and B cells have been identified in vein grafts172, as 
well as the crucial T cell co-stimulatory molecule CD40164. The role of the adaptive 
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immunity in related vascular diseases, atherosclerosis, and restenosis has been well 
established173, 174. Further studies are needed to investigate the role of T and B cells 
in VGF.
Atherosclerosis and rupture 
Atherosclerotic lesion formation is characteristic of late phase VGF175-177. Human 
autopsy studies have shown that coronary vein grafts undergo more rapid 
atherosclerotic lesion development than native arteries8. Coronary vein graft 
atherosclerotic lesions are more concentric and diffuse compared with native 
atherosclerotic lesions, and are more vulnerable to thrombosis and rupture26. In 
contrast to coronary vein grafts, the morphological organisation and development of 
late-phase peripheral vein graft lesions has received less attention and is not as well 
studied. Westerband et al. showed that peripheral lesions have a predominance of 
highly proliferative SMCs178. Furthermore, occluded peripheral grafts are associated 
with high rates of inflammatory cells179. However, to what extent atherosclerosis 
contributes to late phase stenosis in peripheral grafts is unclear. 
Foam cell formation in vein grafts has been observed as early as one year post-graft 
surgery180. A necrotic core tends to develop between 2 to 5 years after surgery, and is 
often accompanied by intraplaque haemorrhage from leaky angiogenic neovessels7, 
180. Yazdani et al. demonstrated that lesions that form post-CABG surgery that 
have a thin fibrous cap and contain large haemorrhagic necrotic cores have a high 
frequency of plaque rupture180. Furthermore, features of late phase failure, such as 
necrotic cores, angiogenic neovessels, intraplaque haemorrhage and rupture, could 
be observed in an experimental vein graft model in hypercholesterolemic mice 
(Figure 4)25. The appearance of plaque neovessels and intraplaque haemorrhage are 
frequently observed in this model (Figure 5), which is rarely seen in atherosclerotic 
experimental models. Upregulation of TIMP1 resulted in improved lesion stability 
and decreased plaque rupture25. Targeting inflammatory factors such as annexin A5, 
mast cells, and complement factor C5a in this murine vein graft model is an effective 
strategy to not only diminish intimal hyperplasia, but also to reduce atherosclerosis 
and plaque rupture by enhancing lesion stability153, 160, 181.
44
 
Figure 4. Murine vein graft lesions in hypercholesterolaemic mice. a. Extensive smooth muscle cells 
accumulate and extracellular matrix deposits in the intimal hyperplasia (IH). b. Atherosclerosis in a 
vein graft lesion is accompanied by a fibrin and blood-filled dissection (arrowhead). c. Atherosclerosis 
in a vein graft lesion is characterized by an eroded endothelium and an intramural thrombus (asterisk). 
Upper panel sections are stained with haematoxylin, phloxin, and saffron. Lower panel sections are 
detailed photographs of murine atherosclerotic vein graft lesions showing plaque rupture features 
such as intraplaque haemorrhage, dissections and erosions (stained with Masson’s trichrome). 
d. Lesions with neovessel (asterisk) and intraplaque haemorrhage (yellow arrowhead) are present 
within the graft. e. Rupture-like dissection connects the lumen (L) and media (M). The connecting 
gap is filled with blood and thrombi. f. Erythrocyte rich intramural thrombus can be observed in this 
28-day-old vein graft lesion. A, adventitia.
Vein graft handling during surgery 
When a vein graft is used for coronary revascularization, the surgeon takes into 
account several technical factors to minimize the risk of early and late VGF. These 
factors include choosing the optimal site for the distal anastomosis (aiming at a 
high outflow target area and minimizing the size discrepancy between the vein and 
the target vessel), and careful measurement of bypass length to prevent kinking 
or flattening that will lead to turbulent or decreased flow. Although sequential 
venous grafting has a potential downside of increased risk of proximal stenosis, this 
technique reduces resistance to graft flow, which might explain the higher patency 
rates of sequential venous grafts compared with single venous grafts182. In general, 
graft patency of sequential vein grafts is highest when the last distal anastomosis is 
made to the coronary artery with the largest runoff. However, proper vein harvesting 
is likely to be at least equally as important in determining vein graft patency.
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Figure 5. Immunohistochemical characterization of hypercholesterolaemic murine vein grafts. a. 
Macrophage (brown) and smooth muscle cell (blue) double staining showing heterogeneous areas 
highly positive for both cell types. b. CD31-stained endothelial cells (red) highlight neovessels in an 
advanced atherosclerotic vein graft lesion. c. Fibrin deposition (brown) in an early (14-day-old) vein 
graft section. d. and e. Immunofluorescent double staining of CD31 positive neovessels (red) and 
erythrocytes (green) showing a lesion with intact matured neovessels. All erythrocytes are within the 
neovessels (d) and a lesion with leaky neovessels displaying intraplaque haemorrhage. Erythrocytes 
are found throughout the lesion and are not restricted by the neovessels (e). 
No touch technique
During harvesting of the saphenous vein, forceful dilatation of the vein to alleviate 
spasm and check for leakage should be avoided, since it damages the endothelium 
(Figure 6). In 1996, the ‘no touch’ technique was introduced, whereby the vein is 
harvested with a pedicle of surrounding tissues, maintaining the vasa vasora and 
the nerves in the adventitia183. This technique improved short-term and long-term 
vein graft patency rates, alongside with reduced  intimal hyperplasia formation in 
a randomized, controlled trial performed in 2002184, 185. Several subsequent trials 
also showed the beneficial effect of the no touch technique on vein graft patency. 
In the PATENT SVG trial186, the no touch technique led to decreased SMC activation. 
Samano et al. reported higher patency rates for grafts harvested using the no touch 
technique compared with veins harvested using the conventional method in a study 
with a mean follow-up of 16 years187. The veins harvested using the newer technique 
had a patency rate of 83%, similar to that of left internal thoracic artery patency rates 
in this study (88%). However, only a limited number of patients (17 and 54 patients 
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respectively) were evaluated in these trials. A larger trial comparing the no touch 
technique to conventional harvesting is currently ongoing in 1550 patients undergoing 
CABG surgery, with primary end points of graft patency and mortality at 1 year188.
Endoscopic versus open vein harvesting
Minimally invasive or endoscopic techniques for vein harvesting have the potential 
benefit of reducing wound-related complications and reducing postoperative pain and 
morbidity compared with conventional techniques189, 190.  The ROOBY trial191 reported 
improved 1-year graft patency with endoscopic saphenous vein harvesting compared 
with open harvesting. However, a higher rate of VGF and long-term mortality has also 
been linked with the minimally invasive endoscopic technique192, 193. Given the discordant 
results, no consensus has been reached on a gold standard method for vein harvesting194, 
195. The ongoing REGROUP trial196 aims to determine the best technique for vein graft 
harvesting with regard to reducing major adverse cardiac events.
Vein preservation
Extensive handling and desiccation during collection of the saphenous vein can result 
in spasm and endothelial damage. Numerous studies have sought to determine the best 
solution to preserve optimal endothelial function of the harvested vein and, therefore, 
maintain high graft patency rates. Many studies consistently demonstrate the detrimental 
effects of saline on vascular endothelium, including a study published in 2015 reporting 
that saline preservation of human saphenous veins led to acute cellular injury197. However, 
this is no clear consensus on whether heparinized autologous whole blood is superior 
to saline as a storage medium198. Randomized, controlled trials are needed to compare 
autologous whole blood with saline for vein graft preservation, and to determine the best 
time and temperature for saphenous vein graft storage. Aside from graft preservation 
fluid, surgical skin markers to orient conduits can also impair physiological function of 
the vein grafts as they contain methylene blue dye199. However, in a study published in 
2015, a nontoxic dye alternative to current surgical skin markers called brilliant blue FCF 
was able to ameliorate vein graph injury in the porcine saphenous vein200.
Graft configuration
Three techniques for saphenous vein graft placement have been  described: reversed, in 
situ, and nonreversed translocated vein graft placement. The reversed graft configuration 
technique is considered the gold standard201. By reversing the saphenous vein graft, by 
connecting the distal end of the graft to the proximal part of the artery and vice versa, 
the venous valves do not obstruct the arterial blood flow. However, there are also 
disadvantages associated with this technique, including the size mismatch between 
the narrow distal end of the saphenous vein graft and the larger diseased artery, a 
shortcoming that is not present in nonreversed translocated vein graft placement. 
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However, in nonreversed saphenous vein grafts, blood flow is disrupted owing to the 
presence of venous valves. In both reversed and nonreversed graft configurations, 
the saphenous vein graft is completely removed and thus might be traumatised or 
twisted and subjected to a period of ischemia. In situ saphenous vein grafts, used in 
PABG surgery, do not suffer from ischemia owing to preservation of the vasa vasorum. 
Previous studies have shown that graft configuration appears to have little influence 
on patency outcomes201-203. 
Preventive strategies 
Established pharmacology
As previously described, venous segments undergo extensive endothelial damage 
during the bypass procedure. The loss of the endothelial cell layer can promote 
platelet adhesion and thrombosis204. Given that platelet activation and thrombin 
production have been shown to be the main cause of early VGF, Antiplatelet therapy 
is thought to be beneficial after surgery to prevent early vein graft thrombosis in 
both CABG surgery and PABG surgery (Table 2). 
The first randomized trials on antiplatelet drugs and anticoagulants were conducted 
in the late 1970s to evaluate their efficacy in improving vein graft patency after bypass 
surgery205-207. In early trials, no beneficial effects of antiplatelet and anticoagulant drugs 
were seen on graft patency, likely owing to late drug administration (typically ≥3 days 
after surgery). Subsequent randomized, controlled trials showed that aspirin alone208 
and dual antiplatelet therapy209 compared to placebo were effective in preventing 
graft occlusion. These positive results might be associated with administration of the 
drugs directly before and after surgery, since the thrombotic process begins during 
the operation when the endothelium becomes damaged. 
Antiplatelet therapy
The ESC recommends low-dose aspirin (75–100 mg/day) for all patients with CAD 
(class of recommendation I, level of evidence A) and PAOD after revascularization 
(class of recommendation I, level of evidence C)20, 210. In the USA, the ACC foundation/
AHA task force advises that 100–325 mg/day of aspirin should be administered to 
patients undergoing CABG surgery, preferably preoperatively, or within 6 hours 
postoperatively to prevent VGF (class of recommendation I, level of evidence A)19. 
Similarly, after PABG surgery, patients should receive antiplatelet therapy indefinitely 
(class of recommendation I, level of evidence A)21. The  optimal dosage of aspirin to 
prevent VGF still needs to be determined. 
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Several antiplatelet agents have been evaluated for their capacity to prevent VGF, 
including clopidogrel and ticlopidine, which are both P2Y12 adenosine diphosphate 
receptor inhibitors. Ticlopidine has been reported to be beneficial for graft patency211, 
212. However, clopidogrel should be used in preference postoperatively if it is available, 
as it has fewer side effects213-215. Currently, clopidogrel is an accepted alternative in 
case of aspirin intolerance after CABG surgery as recommended by the ESC (class 
of recommendation I, level of evidence B).210, and the ACC foundation/AHA task 
force (Class of recommendation IIa, level of evidence: C)19. After PABG surgery, dual 
antiplatelet therapy with aspirin and clopidogrel is recommended for below-knee 
polytetrafluoroethylene grafting, (class of recommendation IIb, level of evidence 
B)20 based on results of the CASPAR trial216. However, antiplatelet therapy was only 
beneficial after prosthetic bypass grafting, whereas no benefit was observed after 
autogenous saphenous vein grafting. Antiplatelet therapy is, therefore, not routinely 
recommended for autogenous vein grafts.
Several studies have reported beneficial effects of adding clopidogrel to aspirin 
therapy on reducing VGF217-220. Currently, dual antiplatelet therapy is recommended 
after CABG surgery in patients with acute unstable angina undergoing urgent surgical 
revascularization, but to date, not all surgeons prescribe dual therapy for this patient 
cohort19. The use of dual therapy is not unequivocally proven to be beneficial for 
patients undergoing PABG surgery.
Given inconsistent results in the literature, whether the addition of dipyridamole, an 
anti-clotting agent, to aspirin has a beneficial effect on graft patency is still under 
debate221-223. In a meta-analysis by Bedenis et al, 16 studies comparing the effect of 
different antiplatelet agents and oral anticoagulants on graft patency and limb salvage 
were reviewed235. The investigators concluded that antiplatelet therapy with aspirin 
or aspirin plus dipyridamole had a beneficial effect on primary graft patency of PABG 
surgery compared with placebo or no treatment. However, dual antiplatelet therapy 
in patients receiving a prosthetic graft, compared with a venous graft, appeared to 
be more beneficial than monotherapy,224 suggesting that dipyridamole should only 
be added to aspirin in the context of prosthetic grafts. However, current European 
guidelines recommend dual antiplatelet therapy of aspirin and dipyridamole only 
after infrainguinal bypass graft surgery, and no distinction is made in graft material20.
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Table 2a. Effect of antiplatelet drugs on vein graft patency after CABG surgery
Antiplatelet drugs Study Randomisation Vein graft patency
Aspirin or dual antiplatelet Pantely 1979205 ASA/DIP vs. OAC No differences
McEnany 1982206 ASA vs. OAC vs. placebo No differences
  Sharma 1983207 ASA/DIP vs. ASA No differences
  Chesebroe 1984209 ASA/DIP vs. placebo Higher patency rates with ASA/DIP
  Goldman1989208 ASA vs. ASA/DIP vs. sulfinpyrazone 
vs. placebo
Higher patency rates with ASA
  Fremes 1993222* ASA vs. ASA/DIP vs. OAC vs. placebo vs. 
no therapy
Higher patency rates with ASA or OAC
  van der Meer 1993221 ASA vs. ASA/DIP vs. OAC No differences
  Lim 2003223 ASA 300-325 mg vs. ASA 75-100mg Higher patency rates with 300-325 mg ASA
Indobufen Rajah 1994227 Indobufen vs. ASA/DIP No differences
  Cataldo G 1998228 Indobufen vs. ASA/DIP No differences
Clopidogrel Ibrahim 2006304 ASA vs. ASA/clopidogrel No differences
  Kulik 2010305 ASA vs. ASA/clopidogrel No differences
  Ebrahimi 2014306 ASA vs. ASA/clopidogrel No differences
  Mujavonic 2009218 ASA vs. ASA/clopidogrel Higher patency rates with ASA/clopidogrel
  Gao 2009307 Clopidogrel vs. ASA/clopidogrel No differences
  Gao 2010219 ASA vs. ASA/clopidogrel Higher patency rates with ASA/clopidogrel
  Sun 2010220 ASA vs. ASA/clopidogrel Higher patency rates with ASA/clopidogrel  
in radial artery grafts
  Mannacio 2012308 ASA vs. ASA/clopidogrel Higher patency rates with ASA/clopidogrel
  Deo 2013217* ASA vs. ASA/clopidogrel Higher patency rates with ASA/clopidogrel
Ticlopidine Chevigné 1984211 Ticlopidine vs. placebo Higher patency rates with ticlopidine
  Limet R 1987212 Ticlopidine vs. placebo Higher patency rates with ticlopidine
Table 2b. Effect of antiplatelet drugs on vein graft patency after PABG
Antiplatelet drugs Study Randomisation Vein graft patency
Aspirin or dual antiplatelet Kohler 1984309 ASA/DIP vs. placebo No differences
  Satiani 1985310 ASA vs. no therapy No differences
  Clyne 1987311 ASA/DIP vs. placebo No differences
  McCollum 1991312 ASA or ASA/DIP vs. placebo or no 
therapy
No differences
  Edmondson 1994313 ASA/DIP vs. LMWH (Fragmin) LMWH higher patency rates
  Algra 2000230 ASA vs. OAC OAC more effective in SVG, ASA more  
effective in PTFE grafts
  Johnson 2002231 ASA vs. ASA/OAC No differences
 Bedenis 2015224* ASA or ASA/DIP vs. placebo or no 
therapy
Higher 1 year patency rates ASA and ASA/
DIP
Indobufen D’Addato 1992 Indobufen vs. ASA/DIP No differences
Clopidogrel Belch 2010216 Clopidogrel/ASA vs. ASA No differences
  Monaco 2012314 Clopidogrel/OAC vs. clopidogrel/ASA Higher patency rates with clopidogrel/OAC
Ticlopidine Becquemin 1997213 Ticlopidine vs. placebo Higher patency rates with ticlopidine
Abbreviations: ASA = aspirin, DIP = dipyridamole, LMWH = Low molecular weight heparin, OAC = oral 
anticoagulant, SVG = saphenous vein graft, PTFE = polytetrafluoroethylene * = meta-analysis
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Indobufen, an antiplatelet agent that prevents platelet aggregation by reversibly 
inhibiting cyclooxygenase, has been investigated as a potential alternative for 
aspirin225. In a crossover study, researchers showed that indobufen was as effective 
as aspirin in inhibiting  platelet aggregation. Several clinical trials have also showed 
similar benefits of indobufen and aspirin plus dipyridamole in preventing VGF226-
228. Whether indobufen could be considered as an alternative treatment for dual 
antiplatelet therapy is still under investigation. No recommendations have been 
made in current guidelines regarding the use of indobufen. 
Oral anticoagulants
Oral anticoagulants are recommended after CABG surgery if the patient is considered 
to be at risk for a thromboembolic event. According to the ESC, anticoagulation 
should be considered for at least three months, with reassessment of stroke risk 
thereafter (class of recommendation I, level of evidence C)4. Oral anticoagulants 
such as vitamin K antagonists, factor Xa inhibitors, or direct thrombin inhibitors can 
inhibit and even prevent thrombus formation on the luminal surface. At present, 
a consensus has not yet been reached regarding the use of oral anticoagulants 
alone or in addition to antiplatelet therapy in the prevention of VGF. Patients 
undergoing infrainguinal venous graft surgery are more likely to benefit from 
vitamin K antagonists than antiplatelet therapy229. In the Dutch BOA study241, oral 
anticoagulation appeared to be more effective in preventing VGF, while aspirin 
prevented cases of polytetrafluoroethylene graft occlusions230. Furthermore, 
Johnson et al. demonstrated that addition of warfarin therapy to aspirin therapy did 
not improve vein graft patency rates231. 
Lipid Lowering
The ESC recommends statin therapy in patients undergoing CABG surgery (class of 
recommendation I, level of evidence A) with an initial LDL-cholesterol goal of <70 
mg/dl (<1.8 mmol/l)210. In addition, the ACC/AHA guidelines recommend an LDL-
cholesterol goal of <100 mg/dL and at least a 30% lowering of LDL-cholesterol (class 
of recommendation I, level of evidence C)19. Statins are also indicated for all patients 
undergoing PABG surgery to strive for a target LDL-cholesterol level of <100 mg/dL, 
and <70 mg/dl for patients with lower extremity PAD at very high risk of ischaemic 
events (class of recommendation IIa, level of evidence B)21. 
The beneficial effect of statin therapy is thought to be based on its inhibitory effects 
on SMC proliferation and its anti-inflammatory effects, which result in decreased 
intimal hyperplasia formation232-236. Statin therapy was also reported to be protective 
against perioperative mortality after CABG surgery237. While most studies focus on 
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lowering LDL-cholesterol level in these patients, the CASCADE trial showed that HDL 
level <40 mg/dl were associated with a trend towards increased VGF, suggesting that 
higher levels of HDL-cholesterol might slow the process of VGF238. 
Emerging treatment strategies
Ticagrelor
Ticagrelor, a P2Y12 antagonist, was reported to be safe and efficient for platelet 
inhibition in a phase II trial in patients with critical limb ischemia239. Hansson et al. 
observed a lower overall incidence of major bleeding complications in patients 
undergoing CABG surgery treated with ticagrelor compared with clopidogrel240. 
Compared with clopidogrel, discontinuing ticagrelor for <24 hours before surgery 
increased the risk of complications, while discontinuing ticagrelor 3 or 5 days before 
peripheral endovascular procedures showed no differences in complications241. 
Furthermore, the PLATO trial showed that combined ticragrelor and aspirin treatment 
was superior to combined clopidogrel and aspirin treatment in patients with acute 
coronary syndrome242. The ongoing TiCAB trial aims to prospectively investigate the 
efficacy and safety of ticagrelor compared with aspirin in patients undergoing CABG 
surgery243, with the primary end point of cardiovascular death, myocardial infarction, 
target vessel revascularization, and stroke. Although the use of ticagrelor after CABG 
surgery has been studied extensively, whether it is beneficial for patients undergoing 
PABG surgery is not yet known.
Direct platelet receptor inhibitors
Platelets play a major role in the development of CAD, PAOD, and VGF. VGF still occurs 
despite dual antiplatelet therapy, likely owing to the complexity of the thrombus 
formed. Thrombin, a potent platelet agonist that acts via protease-activated 
receptors (PAR), might be a potential target to further prevent thrombus formation. 
Antiplatelet drugs do not affect platelet activation mediated by thrombin,244 and thus 
blocking PAR might inhibit VGF. 
Several phase II and III trials have been performed to study the efficacy and safety of 
the PAR-1 antagonists vorapaxar and atopaxar245. In a phase II study published in 
2009, vorapaxar treatment was compared with placebo in patients with CAD 
undergoing balloon angioplasty. Vorapaxar was well tolerated among treated 
patients, and did not increase the risk of bleeding246. The phase III TRA 2°P-TIMI 50 
study247, 248, a randomized, double-blind, placebo-controlled trial, evaluated the 
efficacy and long-term safety of vorapaxar in 26,449 patients with previous 
atherothrombosis. Vorapaxar reduced cardiovascular death, myocardial infarction, or 
stroke in stable patients with a history of previous myocardial infarction247, 248. The 
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subsequent TRACER trial249 reported similar results in patients with non-ST-segment 
elevation acute coronary syndrome who are undergoing CABG surgery. Together, 
these results suggest that vorapaxar might be safe for the prevention CABG-related 
bleeding, but whether vorapaxar has a clinical benefit on vein graft patency in 
patients undergoing bypass grafting remains to be elucidated.
Figure 6. Scanning electron microscopy photographs of saphenous veins. a. An almost uninterrupted, 
continuous layer of endothelial cells in a saphenous vein is shown (magnification x430). b. Part of 
the venous conduit show signs of de-endothelialization (red asterisk) after handling and before 
engraftment, resulting in exposure of collagen fibres (yellow asterisk). The remaining endothelial 
cells show early signs of apoptosis in the form of blebbing (red arrowhead) and vacuolisation (yellow 
arrowhead; magnification x1400). 
The safety and efficacy of atopaxar for patients with acute coronary syndromes and 
chronic CAD has also been evaluated in a phase II trial250. The J-LANCELOT investigators 
reported that atopaxar did not increase clinically significant bleeding compared with 
placebo250. Kogushi et al. demonstrated inhibition of SMC proliferation in vitro  and 
reduced intimal hyperplasia in vivo with atopaxar251. Atopaxar reduced early ischemia 
on Holter monitoring without significantly increasing major or minor bleeding events 
in patients after acute coronary syndrome in a phase II trial published in 2011261. A 
subsequent phase II trial reported more minor bleeding with atopaxar compared 
with placebo, and numerically, but not statistically fewer ischaemic events in patients 
with CAD252, 253. Phase III trials are needed to confirm the beneficial effect of direct 




Figure 7. Angiograms of a patient aged 84 years who underwent CABG surgery 11 years prior 
who is now experiencing unstable angina. A revascularization of the saphenous vein graft from 
the  r. descendens anterior to the  left anterior descending artery is shown, with drug eluting stent 
placement. a. The angiogram shows a very proximal lesion and a more distal lesion in the saphenous 
vein graft. b. Drug-eluting stent placement in the proximal part of the graft c. Drug eluting stent 
placement in more distal part of the graft is indicated by the arrow. d. Angiographic result after stent 
placement shows the restoration of blood flow. 
Inhibition of SMC proliferation and migration 
SMC proliferation and migration to the intima is tightly regulated by growth factors 
such as VEGF, PDGF, TGF-β, and bFGF. SMC proliferation and migration is necessary 
for arterialization that occurs in response to injury after bypass surgery. However, 
excessive SMC stimulation ultimately leads to formation of intimal hyperplasia254. 
Inhibition of SMC proliferation and migration is one of the primary targets for the 
treatment of VGF. The cyclin-dependent kinase inhibitor 1B (also known as p27Kip1), 
plays an important role in maintaining SMC quiescence. p27Kip1 reduction led to 
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diminished intimal hyperplasia formation in experimental vein graft models255, 
256. Interestingly, a single nucleotide polymorphism in the promoter region of the 
p27Kip1 gene is associated with peripheral graft patency257. 
Immunosuppressant drugs such as paclitaxel and sirolimus have also been shown 
to reduce SMC-driven intimal hyperplasia in various experimental models258-260. To 
date, clinical trials assessing the benefit of these anti-proliferative drugs for VGF have 
not yet been performed. However, the use of drug-eluting stents (DES) containing 
paclitaxel or rapamycin to revascularize failing grafts have been proven beneficial, 
and is discussed below. 
E2F transcription factor oligonucleotide decoys
Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription 
factors and, therefore, might prevent intimal hyperplasia formation and VGF. While 
experimental studies have shown favourable results,261 no clinical trials to date 
have demonstrated the benefit of edifoligide for prevention of VGF. Edifoligide has 
been studied in four PREVENT trials. The PREVENT I trial was a pilot study in patients 
(n = 41) undergoing PABG surgery and reported that edifoligide is safe, feasible, and 
could achieve sequence-specific inhibition of cell-cycle gene expression and DNA 
replication262. The PREVENT III trial and PREVENT IV trial were initiated to evaluate 
the efficacy and safety of edifoligide for the prevention on VGF at 1 year in patients 
undergoing PABG surgery (n = 1400) or CABG surgery (n = 3000), respectively. Despite 
promising results of the first two trials, edifoligide was no more effective than placebo 
in preventing VGF in these two patient cohorts after 12–18 months263. Although the 
results of the PREVENT trials were disappointing, they are the first clinical trials to 
evaluate the use of intraoperative gene therapy in preventing VGF. Whether or not 
edifoligide should be used to prevent VGF is still under debate and should be further 
investigated263, 264. 
Future potential treatment strategies
Gene therapy
Gene therapy has emerged as a potential therapy for the treatment and prevention 
of VGF. Saphenous vein grafts are ideally suited for gene therapy because they can 
be genetically modified ex vivo during the surgical procedure and prior to grafting265. 
Direct local delivery of recombinant viral vectors is possible and the risk of systemic 
exposure can be reduced266. Preclinical studies on a number of gene transfer 
strategies using specific genes delivered intraoperatively have been effective in either 
preventing intimal hyperplasia by limiting SMC proliferation or inflammation, or in 
improving endothelial function128, 130, 134, 267. Although these experimental approaches 
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have not been consistently successful, the practical benefits of gene therapy in vein 
grafts make it a promising technique and hopefully promising preclinical trials results 
will be translated into clinical applications in due time22, 261. 
External stenting
External stenting is another promising technique for the prevention of VGF. The use 
of external stents significantly reduced intimal hyperplasia in animal models, as 
discussed previously. In theory, external stenting should reduce wall tension, reduce 
stretching of endothelial cells, and function as a protective outer layer268. Despite the 
promising results obtained in experimental studies, the results from clinical studies 
were less positive. Graft patency rates were low after external stenting269-271, likely 
owing to the stent size and material used, and the use of fibrin glue. Fibrin glue was 
used to attach the external stent to the outer layer of the vein graft; its use is no longer 
recommended as it has been associated with chronic inflammation and VGF272. More 
promising results of external stenting has been published in the past year. Ferrari 
et al. reported positive preliminary clinical results using a newly designed external 
mesh device that could improve long-term graft durability.272 Similarly, Taggart et al. 
showed reduced intimal hyperplasia with use of external stenting 1 year after CABG 
surgery268. The material, stent size, and placement of the external stent is of critical 
importance70. Further studies are needed to investigate the effect of external stenting 
on graft patency rates after bypass surgery. The first-in-human study with the aim of 
testing the preliminary safety and efficacy of the Angioshield wrap, an external vein 
graft support device, is currently ongoing273. 
Graft complications and aneurysms 
Coronary vein graft aneurysms have been described incidentally since 1975, however, 
peripheral vein graft aneurysms have not yet been reported274. Vein graft aneurysms 
might be asymptomatic, though symptoms can arise from associated complications 
such as distal embolization into the grafted artery, vessel rupture, fistula formation 
on adjacent vascular compartments, or compression of neighbouring structures. 
The mechanisms responsible for aneurysmal dilatation of the vein grafts are poorly 
understood, but atherosclerosis and inflammatory factors are known to contribute to 
weakening of collagen in the vessel wall275. A review of 209 cases of aortocoronary 
saphenous vein graft aneurysms showed that in 90% of patients, CABG surgery was 
performed >5 years prior to detection of the aneurysm276. 
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Treatment strategies
Treatment strategies for VGF consists of medical therapy, thrombectomy, redo bypass 
graft surgery, or balloon angioplasty with or without stenting (Figure 7)4, 277. The most 
appropriate treatment modality for each individual patient will depend on severity 
of symptoms, presence and extent of ischemia, and the relative benefits and risks 
involved (such as the patient’s general condition and presence of patent arterial 
grafts). Repeat bypass graft revascularization is associated with a fourfold higher 
mortality rate than primary CABG surgery278, 279. No consensus has been reached 
on how to treat the diseased vein grafts during repeated surgical revascularization. 
Some surgeons prefer to leave them untouched to prevent distal embolization, 
and make a new distal anastomosis on the target artery. When the original distal 
anastomosis is still patent, the vein can be transected at that level and the new graft 
can be anastomosed at this site279. Other surgeons prefer to ligate the diseased vein 
graft, or to completely remove it. However, in redo bypass graft surgery, particular for 
peripheral grafts, the saphenous vein is no longer available and other graft materials 
will need to be used. 
Balloon angioplasty alone has proven to be efficacious for the treatment of VGF, 
although high rates of restenosis and major adverse events have been reported 
for both CABG surgery and PABG surgery280, 281. Mechanical embolic protection 
devices are useful during balloon angioplasty of vein grafts for the prevention of 
distal embolization282,283. Stents are known to dramatically reduce restenosis284. 
The SAVED trial285 was the first study that compared balloon angioplasty with bare 
metal stents (BMS) on clinical outcomes in patients with obstructive disease of 
saphenous vein grafts. BMS reduced the need for revascularization of the target 
lesion and reduced major cardiac events compared with balloon angioplasty285. 
Various studies have compared balloon angioplasty alone, balloon angioplasty with 
BMS and or balloon angioplasty with DES in VGF. Inconsistent results have been 
reported for the use of balloon angioplasty alone or balloon angioplasty with either 
BMS or DES in the treatment of VGF after PABG surgery or CABG surgery280,286-288. No 
specific recommendations have been made by either the European and the American 
guidelines for revascularization after CABG surgery and PABG surgery4, 19-21. However, 
in the clinical setting of CABG surgery, balloon angioplasty with DES is the most 
frequently used technique, and has been shown to be a safe and effective treatment 
for patients with failing saphenous vein grafts289. 
Vein graft interventions are risk-prone procedures that are associated with poor long-
term prognosis; however, the use of these techniques is unavoidable. The preferred 
percutaneous revascularization strategy of uncomplicated stenotic grafts are 
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balloon angioplasty with DES in combination with optimal medical therapy (such as 
antiplatelet therapy) and distal protection devices, when applicable283. Redo bypass 
graft surgery might be the preferred option for old or diffusely diseased venous grafts 
instead of percutaneous revascularisation. The optimal revascularisation strategy 
should ultimately take into account patient-specific and procedure-related factors.
Future perspectives
The barriers in finding a real breakthrough in treatment of VGF are attributable to the 
multifactorial nature of the processes involved in VGF and the frequently observed 
comorbidities in the patients with VGF. Mimicking this complex process using in vitro 
cultured human saphenous vein segments is challenging114, 130, 152, 290. In this respect, 
animal models of VGF that suffer from comorbidities such as hypercholesterolaemia 
or diabetes are crucial for research25, 291. Interestingly, despite the major advances in 
genetic analysis of cardiovascular disease and predictive values of single-nucleotide 
polymorphism analysis for assessment of cardiovascular risk, yet no other genetic 
factors are found that are linked to increased risk of VGF besides p27Kip1257,292. 
New methods for predicting adaptions, remodeling, and even failure of vein grafts 
via a dynamic system that takes into account shear stress have been described293, 
294. Furthermore, advances in imaging technologies such as optical coherence 
tomography definitely will lead to less invasive analysis of vein graft remodeling and 
will provide more insight in the progression of VGF in patients after CABG surgery 
and PABG surgery295.
Conclusions
Vein graft surgery is one of the preferred surgical treatment options for occlusive 
arterial disease. Although the use of vein grafts has diminished over the past few 
years and has been replaced by arterial grafts and balloon angioplasty, a substantial 
number of patients still require one or more vein grafts. Therefore, the issue of low 
patency rates owing to VGF needs urgent attention. Given their anti-inflammatory 
properties and ability to reduce plasma cholesterol levels, statins are recommended 
for the prevention of VGF4, 19-21. New therapies for the treatment of VGF, such as gene 
therapy and external stenting are promising, but require more research. Although 
the PREVENT studies did not show increased patency rates with the use of E2F 
oligonucleotide decoys as initially hypothesized, the results provided much insight in 
the development of VGF. The vein graft harvesting technique, duration of the surgery, 
graft handling, and the size and condition of the conduit and target vessel are all 
predictors of VGF. Preclinical and histopathological studies of human vein grafts 
further demonstrate that constrictive remodeling, intimal hyperplasia formation, 
and unstable atherosclerotic lesions contribute to long-term VGF. These studies have 
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shown that inflammatory components, especially those from the innate immune 
system, are crucial in all stages of vein graft development and failure, and have thus 
suggested targeting inflammatory mediators for treatment of VGF. Furthermore, VGF 
can also be treated by preventing endothelial cell damage, stimulating endothelial 
regrowth, and inhibiting SMC migration and proliferation. Additional studies are 
required to unravel the full potential of these treatment targets in preventing VGF 
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Abstract
It is generally accepted that cardiovascular diseases (CVD) are (partially) driven 
by inflammation. Immune cells, including T cells, are influenced by inflammatory 
signals and play an important role in the onset and progression of CVD. T cells 
activation is modulated by T cell co-stimulation and inhibition pathways. The 
introduction of immune checkpoint inhibitors (ICIs) targeting the inhibition 
pathways revolutionized cancer treatments and improved cancer survival. However, 
ICIs may induce cardiovascular toxicity via T cell re-invigoration, since detrimental 
cardiovascular effects relate to the activation of T cells. With the rising use of ICIs 
for cancer treatment, a timely overview of the role of co-stimulation and inhibition 
molecules in CVD is desirable. In this review, the importance of these molecules in the 
pathogenesis of CVD will be highlighted in (pre-) clinical studies including vein graft 
disease, myocarditis, graft arterial disease, post-ischemic neovascularization and 
atherosclerosis. The review will discuss the potential use of targeting co-stimulation 
and inhibition pathways as a treatment for CVD, as well as the cardiovascular benefits 
and adverse events after treatment. Finally, we emphasize cardiovascular monitoring 
of patients treated with ICIs, since there is a close relation between treating cancer 




The inflammatory nature of several cardiovascular diseases (CVDs) is well known. 
Recently the inflammation and immune modulation in CVD regained more attention 
with the presentation of an effective anti-inflammatory drug for atherosclerosis 1. 
In addition, T cells of the adaptive immune system and their activation pathways 
also received growing interest because of their differential functions in CVD. After 
stimulation naïve T cells differentiate into effector T cells that migrate to the affected 
area. Memory cells that subsequently are formed have acquired the ability to respond 
more rapidly if a second infection occurs. Circulating memory T cells consist of 
central memory cells located mainly in the secondary lymphoid organs, and effector 
memory cells, which are mainly located in tissues. Non-circulating memory T cells, 
termed tissue-resident, have an activated phenotype similar to effector memory cells 
and can respond rapid to infection and tissue damage. Differential functions of CD8+ 
s and CD4+ T cell subtypes such as Th1, Th2, Treg and Th17 T cells are described in 
CVD (box 1). The modulating function of co-stimulation and inhibition pathways in 
CVD are however still being discovered. With the rising use of immune checkpoint 
inhibitors (ICIs) targeting these pathways in cancer therapy, a timely overview of the 
role of co-stimulation and inhibition pathways in CVD is desirable.
The initiation of co-stimulation popularity was founded in 1970 when Bretscher and 
Cohn introduced the two-signal model2. Lafferty and Cunningham extended this 
model specifically for T cell activation and discovered that naive T cells require two 
signals to become highly activated3, otherwise T cell anergy appears. The first signal 
is provided by antigenic stimulation which occurs via the T cell receptor (TCR) upon 
binding to cognate peptide-MHC complexes on antigen presenting cells (APC) e.g. 
macrophages, vascular smooth muscle cells (VSMC) and especially dendritic cells 
(DC)4, 5. The second signal is provided via co-stimulation receptors expressed on 
T cells upon binding to co-stimulation ligands expressed on APCs. Co-stimulation 
signals influence cell proliferation, differentiation, survival and cell-cell cooperation6. 
Cytokines like IL-12 and type I interferons (IFNs) can provide a third signal for CD8+ T 
cell activation7. In fact, in absence of their cognate antigen and co-stimulation, cytokine 
alone can also activate CD8+ T cells leading to production of IFN gamma (IFNγ)8-10. 
After the discovery of CD2811-13, numerous other co-stimulation molecules were 
discovered and assigned to either the immunoglobulin (Ig)-superfamily (IgSF) or the 
tumor necrosis factor (TNF) receptor superfamily (TNFSF)14-17 (FIG 1). Interestingly, with 
the discovery of co-inhibition molecules cytotoxic T cell-associated protein 4 (CTLA-
4), an inhibitory CD28 homolog, and programmed cell death protein 1 (PD-1) the two-
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signal model of Lafferty and Cunningham was extended18, 19. It became apparent that 
co-stimulation was essential for the formation of T cell responses, while co-inhibition 
appeared to be crucial to counter-balance T cell activation to safeguard tolerance and 
induce immune homeostasis20. Co-inhibition pathways became, along with the co-
stimulation pathways, the key mediators in immune responses to infections21 and of T 
cell exhaustion that progresses during cancer20, 22. 
In recent years, modulation of the immune response against malignant cells has been 
successfully introduced in cancer treatment and showed beneficial effects20, 23. Several 
T cell inhibition molecules are inducible expressed on T cells such as CTLA- 4 and PD-
124. Cancer cells express a large quantity of programmed cell death ligand 1 (PD-L1), 
which binds to PD-1 and prevents immunological clearance by T cells25. By blocking 
CTLA-4 or the PD-1 pathway with monoclonal antibodies (called ICIs), however, 
cancer cell lysis by T cells can be enhanced26, 27. Monoclonal antibodies that trigger co-
stimulation receptors are also potent in activating T cells leading to clinical benefit. For 
certain types of cancer, the introduction of ICIs revolutionized cancer treatment and 
improved survival. ICIs are altering the balance between T cell activation and inhibition 
mediated by co-stimulation and inhibition molecules via reduction of the inhibitory 
signals and/or enhancing co-stimulation signals resulting in enhanced cancer cell 
clearance. However, reduction of inhibitory signals can also activate T cells located in 
non-tumor bearing tissues leading to immunopathology including auto-immunity. 
Since it has been shown that activating some types of T cells may be detrimental for 
CVD, as excellently reviewed by Varricchi et al. and others28-30, it should be realized that 
ICI treatment could be harmful for CVD patients. 
Nowadays, several ICIs are already in use in clinical settings and even more ICIs are 
tested in clinical trials for several cancer types, despite the unknown magnitude of 
possible vascular effects and risks. This review will highlight, and place into perspective, 
the current knowledge on co-stimulation and co-inhibition pathways and their role in a 
number of CVDs, e.g. graft arterial disease, vein graft disease, remodeling, post ischemic 
neovascularization, myocarditis, dilated cardiomyopathy and atherosclerosis. All CVD 
that will be discussed have at least a partial inflammatory pathophysiology. However 
for the development of individual CVD, acute and chronic inflammation should be 
distinguished. The development of e.g. atherosclerosis is a chronic process compared 
to acute inflammation that occurs in myocarditis or post interventional remodeling. 
When clinical symptoms occur, treatment is indicated. However, the initiation of 
treatment can differ in several CVDs. Hence, also with co-stimulation or co-inhibition 
targeted therapy, it should be taken into consideration, whether to treat the patient 
shortly after intervention or disease onset, or lifelong. 
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Figure 1. Co-stimulation and co-inhibition pathways. 
Co-stimulation and co-inhibition molecules that are described, are shown. On top, members of the 
immunoglobin superfamily (IgSF) are shown. The members of the B7/CD28 family are shown in red. 
CD80-CD86 on antigen presenting cells (left) can bind to CD28 leading to T cell (right) activation or 
CTLA-4 inducting T cell anergy. CD80 can also bind to the inhibition molecule PD-L1. PD-L1 and PD-
L2 also bind to PD-1. The B7/CD28 family member ICOS, binds to ICOSL. The T cell immunoglobulin 
and mucin (TIM) family shown in purple consist of 3 discovered members in human. TIM4 expressed 
on APC can bind to TIM1 on T cells, whereas TIM3 expressed on T cells binds to galectin-9 (Ga-9). In 
light blue the CD2/Signaling lymphocyte activation molecule (SLAM) family is shown. Several SLAM 
members expressed on APC binding to their namesake receptors on T cells; SLAM binding SLAM, CD84 
binding CD84 and CRACC binding CRACC. Only CD48 binds CD2, and BLAME expressed on T cells 
binds to an unknown receptor on APCs. Below, members of the tumor necrosis factor (TNF) receptor 
superfamily (TNFSF) are shown. In dark blue member of the type V family are shown. CD70, expressed 
on APCs binds to CD27, stimulates T cell survival. OX40L binding to OX40 and 4-BBL binding to 4-1BB 
are interesting targets to inhibit co-stimulation. CD30L binding to CD30 and GITRL binding to GITR 
are less well described. The most well described co-stimulation molecule of the Type-L family, shown 
in orange, is CD40L binding to CD40L. CD40 is a popular target for the treatment of atherosclerosis 
and in mainly involved on monocyte recruitment. The function of other members, TL1A binding DR3, 
HVEM binding LIGHT and LTβR binding both LIGHT and LTα1β2, are less investigated.
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The differential functions and effects of co-stimulation and inhibition pathways of 
the IgSF e.g. CD80, CD86, CD28, CTLA4, PD-1, PD-L1, PD-L2, ICOS, ICOSL, TIM1, TIM3, 
TIM4, CD2 and SLAM, and the TNFSF e.g. CD27, CD70, OX40, 4-1BB, CD40, HVEM and 
DR3, in several CVD will be highlighted initially in pre-clinical trials and subsequently 
in clinical trials. The opposing functions of co-stimulation and inhibition pathways 
Box 1. CD4+ and CD8+ T cell (subtypes) in cardiovascular 
disease e.g. atherosclerosis.
T cells are identified in the vessel wall of several CVDs and can act either directly 
via their effector molecules such as inflammatory cytokines, or indirectly via the 
activation of B cells, producing antibodies. However, T cell subsets produce either 
pro-or anti-inflammatory cytokines, which make T cell subset functions in CVD 
differential. To highlight the differential functions of the CD4+ and CD8+ T cells 
(subsets), we here show their roles in atherosclerosis. 
Naïve CD4+ T cells can be polarized into either Th1, Th2, Treg or Th17 cells. Th1 
cells showed pro-atherogenic effects via production of IFNγ and TNFα, while Tregs 
showed mainly anti-atherosclerotic effects via secretion of IL-10 and TGFβ50, 186-189. 
Furthermore, IL-10 secreted by Tregs was shown to mitigate abdominal aortic 
aneurysms progression190 and post-angioplasty restenosis191, 192. Th2 cells secrete 
IL-4, IL-5 and IL-13. It was shown that Th2 cells and IL-4 may be associated with 
advanced atherosclerosis in ApoE-/- mice193. In contrast, also anti-atherosclerotic 
effects were observed in Il4-/-Ldlr-/- mice and in ApoE-/- mice194, 195. This is similar 
to the inconsistent and undefined functions of Th17 in atherosclerosis. Th17 
cells secrete e.g. IL-17A and IL-17F. Inhibition or blockade of IL-17 in ApoE-/- mice 
resulted in pro-atherogenic effects196-198. However, Il-17A-/-ApoE-/- mice accelerated 
unstable atherosclerotic lesions formation199.
Besides CD4+ T cells and their subsets, CD8+ T cells are also involved in 
atherosclerosis. CD8+ T cells can secrete cytotoxins e.g., perforin and granzymes. 
It was shown that cytotoxins can induce apoptosis of macrophages, smooth 
muscle cells, and endothelial cells and thereby promote the development of 
vulnerable atherosclerotic lesions200. Moreover, mice treated with CD137 agonist 
showed increased numbers of CD8+ T cells and enhanced atherosclerotic lesions 
201. In contrast, also immunosuppressive CD8+ Tregs were discovered202. So both 
protective and pathogenic roles of CD8+ T cells are shown in atherosclerosis203.
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in several CVD will be discussed in more detail to clarify the complex functions of 
these pathways. The therapeutic options of blocking co-stimulation to dampen the 
T cell response and concerns regarding ICIs that enhance T cell activity (e.g. abatacept, 
pembrolizumab and nivolumab) on vascular diseases will be outlined all in order to 
provide better insights and to direct future (co) treatment.
Immunoglobulin Superfamily (IgSF)
B7/CD28 family; CD80, CD86, CD28 and CTLA4
A major group of IgSF co-stimulation receptors are molecules of the B7/CD28 family, 
with CD80 (or B7.1) and CD86 (or B7.2) as the best characterized co-stimulation 
molecules. CD80 and CD86 are transiently expressed on APCs after activation16, 31, 
32. Both CD80 and CD86 can bind to the co-stimulation receptor CD28, expressed 
constitutively on T cells, and to the co-inhibition receptor CTLA-4 (or CD152), 
expressed by activated T cells. CTLA-4 binds the CD80/86 molecules with a much 
higher affinity leading to regulation of the response. 
The role of the B7/CD28 family in CVD has been differentially described. CD80/86 
was observed to be involved in CD8+ T cell activation in vein grafts. Deficiency of 
both CD80/86 and CD70 resulted in a decrease in intimal hyperplasia formation 
in a vein graft disease model (Simons VGD, manuscript in preparation). This effect 
was independent of the TCR but involved by bystander cytokines in synergy with 
co-stimulation signals. Reduced intimal lesion development in CD80/CD86 deficient 
mice was also observed in a femoral artery cuff mouse model for post-interventional 
remodeling. In addition, systemic treatment with abatacept, a CTLA-4Ig which 
blocks CD80/86 co-stimulation and thereby inducing non-activated T cells, prevented 
intimal thickening by almost 60% 33. 
Besides remodeling in vein grafts, CD80/86 co-stimulation also plays a role in graft 
arterial disease (GAD) after heart transplantation. GAD is characterized by chronic 
remodeling of allograft arteries 34. Especially Th1 cytokines, such as IFNγ, influence 
vascular remodeling causing reduced luminal flow and eventually GAD35. Co-
stimulation was thought to be involved in GAD since blocking co-stimulation resulted 
in non-reactive T cells or T cells that underwent programmed cells death36, 37. It has 
been shown that blockade of CD80/86 with CTLA-4Ig early after transplantation 
resulted in improved long-term graft survival and mitigated the development of 
graft arteriosclerosis via a decrease in T cell and macrophage activation38. Kim et 
al. determined the different effects on GAD between early and late post-transplant 
co-stimulation blockade treatment since GAD may also occur in a late phase. 
Late blockade of CD80/86 or selective blockade of CD80 alone attenuated the 
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development of GAD, most likely due to a decrease in T cell activation. Early graft loss 
was not prevented by blockade of CD80 alone, in contrast to CD80/86 blockade 39. 
Along this line, a decrease in GAD was observed in MHC class II-mismatched allograft 
hearts that were transplanted in CD80 and CD80/86 deficient mice, but not in CD86 
deficient mice 40, both highlighting the important and differential functions of CD80 
and CD86 in vivo. 
In addition, it was also demonstrated that CTLA-4Ig abatacept decreased the 
progression and severity of cardiac dysfunction in a mouse heart failure model41. 
This was realized via a reduction of cardiac infiltration and activation of T cells and 
macrophages, leading to a decrease in cardiomyocyte death.
In atherosclerosis, the role of co-stimulation can be differential. With the discovery of 
CD80, CD86 on macrophages in atherosclerotic lesions in human 42 and mouse43, and 
on monocyte-derived DCs of coronary artery disease patients 44, a clear indication of a 
role for co-stimulation in atherosclerosis was provided. High expression of CD80 and 
CD86 was associated with vulnerable atherosclerotic lesions, shown in human carotid 
arteries45. However, it was suggested that the expression of co-stimulation might vary 
depending on the cell type, the presence of stimulating ligands e.g. toll like receptor 
ligands, or on the level of hypercholesterolemia 46. Buono et al. showed that CD80 
and CD86 regulate the development of atherosclerosis by priming T cells 47. They 
showed reduced atherosclerotic lesions in Cd80/86-/-Ldlr-/- mice compared to control 
Ldlr-/- mice on a high cholesterol diet. In addition, HSP60 stimulated CD4+ T cells of 
Cd80/86-/-Ldlr-/- mice subsequently secreted lower levels of IFNγ in vitro, indicating a 
role for CD80/86 on CD4+ T cell activation, next to the previously discussed role for 
CD80/86 on CD8+ T cells in vein graft disease (Simons et al., 2018 VGD manuscript 
in preparation). An important role for CD80/CD86 co-stimulation and CTLA-4 was 
also shown in accelerated atherosclerosis development. Hypercholesterolemic 
ApoE3*Leiden mice treated with CTLA-4Ig abatacept showed a reduction of almost 
80% in accelerated atherosclerosis development, with decreased activation of CD4+ 
T cell. In contrast, CTLA-4 blocking antibodies increased vascular lesion size by almost 
70% 33. CTLA-4-Ig treatment also resulted in reduced homocysteine-accelerated 
atherosclerosis 48 and reduced atherosclerosis in mice with constitutive expression of 
CTLA-4 on T cells 49. All pre-clinical studies described above show a beneficial role of 
co-stimulation blockade, which inhibits T cell activation, in atherosclerosis. 
Interestingly, Ait-Oufella showed opposing results with increased atherosclerotic 
lesions in Cd80/86-/-Ldlr-/- bone marrow chimeras and Cd28-/-Ldlr-/- chimeras compared 
to control mice due to lack of Tregs. Pre-clinical studies described above did not 
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distinguish between T cell subtypes, but CTLA-4 is also expressed on Tregs and 
may contribute to an anti-atherogenic function50-52. This is in contrast to the effects 
of CD80/86 deficiency on atherosclerosis shown before, and might be due to the 
delicate balance between the pro-atherogenic T cells and the anti-atherogenic Tregs. 
As already pointed out by Lichtman et al. CD80, CD86 are partially essential in the 
thymus to develop Tregs34. The lack of CD80 and CD86 in the Cd80/86-/-Ldlr-/- bone 
marrow chimeras used by Ait-Oufella, can result in a Treg deficiency.
In conclusion, in vein graft disease, GAD and post interventional remodeling, 
blocking CD80/86 and thereby decreasing T cell activation showed beneficial effects. 
The opposing effects of CD80/86 on atherosclerosis may relate to putative targeting 
of Tregs, and make the design of therapeutic strategies challenging. Blocking co-
inhibition with ICIs would cause increased T cell activation, and based on these pre-
clinical studies, might result in disadvantageous cardiovascular effects. Alternatively, 
blocking co-stimulation, instead of co-inhibition leading to a decrease in T cell 
activation, could be therapeutically interesting and feasible.
B7/CD28 family; PD-1, PD-L1 and PD-L2
The B7/CD28 family also includes the co-inhibition molecule PD-1 (or CD279), which 
can bind to PD-L1 (or B7-H1 or CD274) or PD-L2 (or B7-DC or CD273). In high-level 
chronic virus infection and in cancer, the activation of the PD-1/PD-L1 axis can lead 
to T cell exhaustion. PD-L1 can also bind to CD80 executing a similar inhibition 
function25, 53. The role of PD-1 in CVD has mainly been described by blocking PD-1 or 
PD-L1/PD-L2. 
It has been shown that PD-1 and PD-L1 mediate tissue damage in a cardiac injury 
model. Ischemic-re-perfused cardiac cells expressed high levels of PD-1 and PD-
L1. Besides an inhibition of T cell proliferation, an increase in cardiomyocyte death 
through a paracrine mode of action was observed in cardiac cells expressing high 
levels of PD-1 and PD-L1 54. 
In a mouse model for dilated cardiomyopathy, it was shown that two-third of mice 
deficient of PD-1 died within 30 weeks compared to 0 mice with PD-1. Mice deficient 
of PD-1 are not able to inhibit T cell activation and express high levels of activated 
T cells. Histological examination showed that the hearts of PD-1 deficient mice had 
dilated ventricles with thin right ventricle walls and a severely decreased contraction 
function 55. Subsequently, it was discovered that the cardiomyopathy in PD-1 
deficient mice was caused by autoantibodies against cardiac troponin I, which led to 
chronic stimulation of Ca2+ influx in cardiomyocytes 56. T cell-mediated myocarditis 
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can chronically lead to dilated cardiomyopathy. Tarrio et al. showed in two distinct 
models of myocarditis that PD-1 protects against inflammation and cardiomyocyte 
damage 57, most likely via the function of PD-1 to inhibit inflammatory T cell 
activation. Murphy Roths Large (MRL) mice are genetically predisposed to systemic 
autoimmunity and were used to demonstrate a role for PD-1 and PD-L1 respectively 
in the development of myocarditis 58, 59. Both Pd-1-/--MRL mice and Pd-L1-/--MRL mice 
developed fatal myocarditis, indicating that blocking PD-1 or PD-L1 with ICIs might 
be lethal. Juchem et al. also raised their concerns on blocking PD-L1, since in the 
absence of PD ligands, both effector memory T cells and naive T cells induced late-
onset myocarditis in a graft versus host disease model 60. 
Similarly as described before for the CD80/86 deficiency, blocking PD-1 can promote 
pro-atherogenic T cell activation and promote anti-atherogenic Treg responses. 
Increased atherosclerotic lesions were observed in Pd-1-/-Ldlr-/- mice in the aortic sinus 
and aorta, indicating that blocking PD-1 can exacerbate atherosclerosis61, 62. The effect of pro-
atherogenic CD4+ T cell was stronger than the anti-atherogenic Treg responses61, 
which neutralized the anti-atherogenic Treg response. Deficiency of PD-1 ligands, 
also showed increased atherosclerotic lesions in the aorta of Pd-L1/2-/-Ldlr-/- mice 
compared to control mice. In the atherosclerotic lesion increased numbers of CD4+ 
T cells and CD8+ T cells were observed, with increased numbers of activated CD4+ T 
cells 63. This indicates that PD-1 interactions with its ligands PD-L1 and PD-L2 have an 
important role in protecting atherosclerotic lesion development. 
In conclusion, all the pre-clinical research described, showed a protective role 
of PD-1, PD-L1 and PD-L2 in CVD and blocking these molecules might result in 
disadvantageous cardiovascular effects. Thus, in addition to the concerns raised by 
Juchem et al. on blocking PD-L1, we raise our concerns on blocking PD-1, PD-L1 and 
PD-L2 and with regard to cardiovascular outcomes. 
B7/CD28 family; ICOS and ICOSL
Another member of the B7/CD28 family is inducible co-stimulation molecule ICOS (or 
CD278) that binds to ligand ICOSL (or CD275). ICOS is expressed on activated CD4+ T 
cells and CD8+ T cells and Tregs, 64. The role of ICOS in CVD remains partially elusive 
due to the homology between ICOS, co-stimulation molecule CD28 and co-inhibition 
molecule CTLA-4. Yet, only pre-clinical research is performed to show the role of ICOS 
and ICOSL in atherosclerosis. 
In murine atherosclerotic lesions, ICOS and ICOSL are abundantly expressed 42, 65. 
Increased aortic lesion size of almost 40% was observed in ApoE-/- mice fed a high 
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fat diet, after blocking ICOS with anti-ICOS antibodies compared to control ApoE-/- 
mice fed a high fat diet66. Gotsman et al. supported this by showing that lethally 
irradiated Ldlr−/− mice, injected with bone marrow cells of Icos−/− donor mice, 
developed enlarged atherosclerotic lesions compared to control mice. In the iliac 
lymph nodes and the spleen the number of Tregs was reduced in mice transplanted 
with Icos−/− cells compared with control mice, however, the reduced number of Tregs 
could not be shown in the atherosclerotic lesions67. Interestingly, ICOS deficiency 
resulted in increased atherosclerotic lesions, opposed to results shown with other 
co-stimulation members of the B7/CD28 family previously. As described before, this 
might be due to the bone marrow chimeras used, since there can be a deficiency 
in Treg development in this model. Subsequently, it was concluded that ICOS is 
essential for the development and function of anti-atherogenic Treg and promotion 
of Treg proliferation, survival and maintenance68. Thus a deficiency of ICOS will lead 
to a decrease in anti-atherogenic Tregs, causing an increase in atherosclerotic lesion 
development. Thus, stimulating ICOS might be beneficial in CVD via stimulation of 
Tregs. However, agonistic ICOS antibodies cannot (yet) be used since this will also 
influence other T cells than Tregs, which may limit its clinical effect.
T cell immunoglobulin and mucin (TIM) family; TIM1, TIM3 and TIM4.
Eight members of T cell immunoglobulin and mucin domain (TIM), also known as 
Hepatitis A virus cellular receptor 1 (HAVCR1), of the TIM family are discovered in mice 
(TIM1-8), while only three TIM genes (TIM1, TIM3 and TIM4) have been identified in 
humans. Therefore in this review we will mainly focus on TIM1, TIM3 and TIM4. Both 
co-stimulation and co-inhibition functions are described for the TIM family69, but only 
limited studies describe the role of the TIM family in CVD. 
In the Han Chinese population it was shown that TIM1 polymorphisms are associated 
with dilated cardiomyopathy susceptibility and prognosis 70. Lind et al. showed that 
there was also an association between TIM1 and atherosclerotic lesions occurrence 
in carotid arteries71. TIM1 can be expressed on activated T cells and regulatory B cells 
and binds to TIM4 mainly expressed on APCs. A recent genome-wide association 
study showed that TIM4 genetic variants were associated with the risk of coronary 
heart disease and ischemic stroke 72. In pre-clinical studies, TIM1 together with 
TIM4 showed involvement in the development of atherosclerosis. Enhanced 
atherosclerotic lesions were observed in Ldlr−/− mice treated with antibodies against 
TIM1 or TIM4 compared to untreated mice, caused by impaired efferocytosis and an 
increased amount of CD4+ T cells in the lesions. TIM1 effects were mainly based on the 
Th1/Th2 balance and regulation of Tregs 73. TIM3 is highly expressed on Th1 cells and 
in low levels expressed on monocytes, NK, and NK T cells74. Blocking TIM3 increased 
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myocarditis abundantly, in a mouse model for myocarditis. This was partly due to 
a reduced expression of CD80 on macrophages, resulting in a decreased amount of 
anti-inflammatory Tregs in the heart 75. In addition, less TIM3 was expressed on mast 
cells, macrophages and CD4+ T cells in the inflamed heart, following coxsackievirus 
B3 infection, in male compared to female mice 76. 
All preclinical studies on TIM1, TIM3 and TIM4 describe unfavourable cardiovascular 
effects when blocking TIM. This might imply that TIM has more co-inhibitory functions 
than stimulatory. However, since the function of TIM is not completely clear yet, the 
best possible way to exploit TIMs as a treatment to prevent CVD requires further 
investigation.
CD2/Signaling lymphocyte activation molecule (SLAM) family; CD2, CD48 
and SLAM 
The CD2/SLAM is a broad family that consists of SLAM (CD150 or Slamf1), CD48 (or 
Slamf2), 2B4 (CD244 or Slamf4), Ly9 (CD229 or Slamf3), CD84 (or Slamf5), NK-T-B-antigen 
(NTB-A, or CD352 or Slamf6), CD2-like receptor activating cytotoxic cells (CRACC, also 
known as CD319 or Slamf7), B lymphocyte activator macrophage expressed (BLAME 
or Slamf8), and SF2001 (CD84H or Slamf9). Despite the number of family members, 
the experimental studies performed on the CD2/SLAM family is limited77. In human 
carotid endarterectomy samples the expression of CD2/SLAM family genes was 
compared between stable and unstable atherosclerotic segments within one sample. 
The expression of BLAME and CRACC was >5-fold up regulated in areas of stable 
compared to unstable atherosclerotic lesion segments78. In contradiction, Levula et 
al. showed an up regulation of BLAME in human advanced atherosclerotic (AHA type 
V-VI) lesions, using gene set enrichment analysis 79. This indicates that there might 
be an association between SLAM genes and atherosclerosis. However, similar to 
the TIM family members, the exact role of the CD2/SLAM family members has yet to 
be determined with regard to CVD. 
Butyrophilin (BTN) family; BTNL1 and BTNL2
Family members of the Butyrophilin (BTN) family such as butyrophilin/B7-like molecule 
1 and 2 (BTNL1 and BTNL2) are the latest members of the IgSF 80. Despite the structural 
resemblance to the B7/CD28 family, the function remains to be determined. It has 
been suggested that BTNL1 and BTNL2 are co-inhibition molecules 81, 82. However, 
BTNL2 is mainly expressed in the digestive tract tissue, which questions their role in 
CVD82. Due to lack of experimental studies, the BTN family can be added to the list 
of sparsely investigated molecules in CVD, together with the TIM and SLAM family.
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Tumor Necrosis Factor (Receptor) Super Family (TNFRSF)
The TNF super family consist of several subfamilies of which the type V and type L 
family members are co-stimulation and co-inhibition molecules that functions as 
T cell (de)activators. The interaction of members of the TNFSF and their receptors 
belonging to the TNFRSF, induce diverse biological responses implicated in CVD. TNF 
receptor activation induces the expression of pro-inflammatory cytokines, adhesion 
molecules, tissue factor and matrix metalloproteinases. Some members of the TNFSF, 
such as CD27, OX40, 4-1BB, CD40, CD30, DR3 and lymphotoxin β Receptor (LTβR), 
are co-stimulation molecules, inducing T cell activation and survival. Upon ligation 
to their receptors located in the plasma membrane, TNF receptor-associated factors 
(TRAFs) are recruited to the cytoplasmic tail. TRAFs enhance pro-inflammatory 
signaling by mitogen-activated protein kinases and nuclear factor kappa B83.
Type V; CD27 and CD70 
CD27 and CD70 (CD27L) are the best described co-stimulation members of the TNFSF/
TNFRSF, type V family in CVD. CD70 is expressed on activated CD4+ and CD8+ T cells, 
B cells, macrophages and DCs upon stimulation by pattern recognition receptors or 
antigens via the TCR32. CD27, the receptor for CD70, is expressed on naïve and mature 
T cells, activated B cells and NK cells and mainly induces cell survival. The function of 
CD27 and CD70 in CVD has been described in several pre-clinical studies. 
Sardella et al. observed that CD27 expressed on Tregs is associated with ST-
elevated myocardial infarctions (STEMI). The percentages of both CD27+ Tregs and 
CD27- Tregs were significantly lower in these patients in comparison with controls. 
However, the Treg ratio was skewed toward the CD27- population 84. It was suggested 
that CD27 deficiency could lead to the dysfunction of T cell immunity to limit the 
ongoing inflammation, and that coronary revascularization was associated with 
partial reconstitution of the peripheral Treg pool. 
In vivo, the CD27-CD70 T cell co-stimulation pathway appears to be the most 
important co-stimulation pathway in pre-existing collateral formation and post-
ischemic blood flow recovery, by induction of arteriogenesis and angiogenesis 
85. This has been described in a hindlimb ischemia mouse model; Cd70-/- mice and 
Cd70-/-Cd80-/-Cd86-/- mice showed a hampered blood flow restoration in the paw after 
ligation of the femoral artery.
In addition to post-ischemic blood flow recovery and STEMI, CD27-CD70 also 
appeared to play a role in atherosclerosis. A putative protective role for CD70 has 
been observed in humans. Higher CD70 expression was detected in stable plaques 
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compared to ruptured plaques in the carotid arteries of atherosclerotic patients. 
These atherosclerotic plaques with a distinct lipid core showed a gradual decrease 
in the expression of CD70, CD80, and CD86 towards the atheroma. Macrophages 
immediately adjacent to the atheroma did not express CD70, CD80 and CD86. 
Interestingly, a high number of CD27+ T cells were observed in the atherosclerotic 
plaques suggesting the clearance of pro-inflammatory monocytes 42. 
Furthermore, in hyperlipidemic ApoE-/- mice, histological analysis revealed that CD70 
was highly expressed on macrophages located in atherosclerotic plaques and the 
expression was most evident in the superficial layers of the fibrous cap 86. It was 
shown that Cd70-/- mice displayed larger atherosclerotic plaques characterized by 
lower cellularity and a more advanced plaque phenotype compared to control ApoE-
/- mice. It was suggested that a chronic CD27 stimulation by CD70 overexpression 
ameliorates atherosclerosis by enhanced apoptosis of circulating, pro-inflammatory 
Ly6Chi monocytes. In addition, van Olffen et al. reported that overexpression of 
CD70 is atheroprotective in CD70 transgenic ApoE*3-Leiden mice 87. Macrophages 
of CD70 transgenic ApoE*3-Leiden mice had no defects in phagocytosis or in TNF 
production, but monocytes were more prone to apoptosis. This reduced viability of 
monocytes suggests that CD70 signaling promotes macrophage survival and thus 
CD70 overexpression has been stated as atheroprotective. 
In conclusion, CD27 and CD70 are likely protective in vascular remodeling due to 
their pro-survival and stimulating effects on T cells. CD27/CD70 may also contribute 
to post-ischemic blood flow recovery. Therapeutic stimulation of the CD27-CD70 co-
stimulation pathway might thus be interesting for the treatment of CVD.
Type V; OX40 and OX40L
Another co-stimulation member of the type V family is OX40 (or CD134), binding to 
OX40 ligand (OX40L or CD252). OX40 is able to potentiate T cell receptor signaling 
of CD4+ and CD8+ T cells leading to their activation in response to their specific 
antigen. Binding of OX40 to its ligand OX40L, which is mainly expressed by APC and 
ECs88, increases the proliferation, differentiation and cytokine production by T cells89. 
In an experimental mouse model of aortic banding induced cardiac hypertrophy, 
it was demonstrated that OX40 regulates pressure overload-induced cardiac 
hypertrophy and remodeling via CD4+ T cells90. The extent of perivascular and 
interstitial cardiac fibrosis in response to aortic banding in Ox40-/- mice was 
remarkably decreased, compared to control mice. OX40-/-CD4+ T cells were less 
proliferative and produced decreased levels of inflammatory cytokines TNFα, IL-1β 
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and IL2 and enhanced levels of anti-inflammatory cytokine IL-10 after activation with 
agonistic antibody CD3 and CD28. Also, the mRNA expression levels of TNFα, IL-1β, 
and IL-6 as well as CD4+ and CD8+ T cell influx were significantly decreased in OX40-
/- mice hearts compared with control mice hearts. From the other perspective, Ox40-
/- mice that received reconstituted CD4+ T cells presented excessive perivascular and 
interstitial fibrosis compared to control mice90. This indicated that OX40 contribute to 
the progression of cardiac remodeling via CD4+ T cells.
In coronary heart disease (CHD) patients, OX40 and OX40L mRNA levels were 
increased and correlated with clinical pathological features of CHD 91. OX40 and 
OX40L mRNA levels also correlated with known risk factors for CHD, such as gender. It 
was demonstrated that patients with an acute coronary syndrome or stable angina 
pectoris have increased OX40L blood levels 92. In addition, it was observed that 
soluble OX40 ligand (sOX40L) measured in the circulation correlated with troponin 
I and the increase in sOX40L (>40ng/ml) was associated with a higher risk for acute 
myocardial infarction (ACS), sudden death or recurrent angina pectoris 93, 94. 
Kotani et al. observed an increase in the chemokine CCL5 expression measured by 
flow cytometry in ECs treated with sOX40L in vitro. 95. The chemokine CCL5 is able 
to regulate T cell adhesion to EC and subsequently T cell extravasation. This soluble 
form of OX40L might play a role in mediating a systemic pro-inflammatory state in 
which T cells extravasate and drive cardiovascular diseases. 
Dumitriu et al. demonstrated that patients with ACS, but not patients with stable 
angina pectoris, have an expansion of highly inflammatory CD4+ CD28- T cells. These 
T cells lack CD28, needed for optimal T cell function96. CD4+CD28- T cells from ACS 
patients express higher levels of the alternative co-stimulation receptors OX40 and 
4-1BB compared to classical CD4+CD28+ T cells. CD4+CD28- T cells were present in all 
atherosclerotic plaques studied and constituted up to 23% of all CD4+ T cells resident 
in the plaque. Importantly, these CD4+CD28- T cells expressed OX40 and 4-1BB co-
stimulation receptors, which regulated perforin and granzyme B release. Ligands to 
OX40 and 4-1BB are available in the microenvironment of atherosclerotic lesions that 
results in the activation of these CD4+ CD28- T cells 97. These CD4+CD28- T cell subset, 
activated via OX40 and 4-1BB, might be a contributing factor to plaque rupture in 
atherosclerotic patients. 
In addition, Foks et al. demonstrated that blockade of the OX40-OX40L pathway with 
anti-OX40L antibodies reduced the number of T cells in atherosclerotic plaques, 
reduced plaque size and reduced the Th2 responses in Ldlr-/- mice. An increase in 
oxLDL specific IgM antibodies was observed in these anti-OX40L treated mice due to 
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the production of IL-5 by Th2 cells 88. This implicated that the blockade of the OX40-
OX40L pathway reduces the development of atherosclerotic plaques in vivo. 
Genetic deletion of the OX40-OX40L signaling pathway suppresses the development 
of vasa vasorum neovascularization in the arterial wall and inhibits the development 
of atherosclerosis in vivo98. The vasa vasorum serves as a mediator of transport of 
cellular and non-cellular pro-inflammatory components into the vessel wall by the 
expression of adhesion molecules 99 and may be the origin of plaque infiltrating 
angiogenic vessels100, 101. Nakano et al., observed similar results as Moreno et al. since 
blockade of OX40L by anti-OX40L antibodies in ApoE-/- mice also showed reduced 
aortic atherosclerotic plaque formation compared to untreated ApoE-/- mice because 
of the OX40/OX40L dependent neovascularization in the vasa vasorum102.
In conclusion, Ox40-/- mice and mice treated with anti-OX40L antibodies showed 
beneficial outcomes on CVD in pre-clinical studies. OX40 mRNA expression levels or 
soluble OX40 was demonstrated to be elevated in several CVDs. Thus, OX40 seems 
to be a promising therapeutic target for CVD, and future research on pre-clinical and 
clinical trials blocking OX40 should be encouraged. 
Type V; 4-1BB (CD137) and 4-1BBL
The third co-stimulation member of the type V family is 4-1BB (or CD137), which 
binds uniquely to 4-1BBL (or CD137L). Activated CD4+ T cells, DCs, and NK cells 
express 4-1BB, while 4-IBBL, is expressed on B cells, DCs, and ECs. Activation results in 
expansion of T cells and pro-inflammatory cytokine expression103. 
4-1BB expression was detected in human atherosclerotic plaques on T cells and 
induced by pro-inflammatory cytokines in ECs and SMC. Elevated levels of soluble 
4-1BB were measured in blood and peripheral monocytes from patients with ACS 104, 
105. An increase in soluble 4-1BB was demonstrated to be associated with an increased 
risk of ACS and suggested to be a potential prognostic marker for ACS. 
Furthermore, human genetic evidence for the involvement of 4-1BB in atherosclerosis 
has been identified in the IMPROVE cohort consisting of 3418 patients. The minor 
T allele in the 4-1BB gene was associated with increased intima-media thickness in 
the common carotid artery independently of the subject vascular risk factors 106. 
However, this allele was not associated with an increased risk for CAD or MI in the 
PROCARDIS/WTCCC case-control cohort 107.
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As described before, Dumitriu et al demonstrated that patients with ACS have an 
expansion of highly inflammatory CD4+ CD28- T cells, which express higher levels of 
4-1BB 96. Although there is an association between 4-1BB, atherosclerosis, and ACS; 
pre-clinical trials demonstrated adverse effects on experimental atherosclerosis with 
the activation of 4-1BB. Treatment of ApoE-/- mice with a 4-1BB agonist induced an 
increase in vascular inflammation; T cell infiltration, expression of pro-inflammatory 
cytokines and MHC class II molecule up regulation in atherosclerotic lesions. 
Activation of the 4-1BB pathway resulted in EC and SMC proliferation108. 
ApoE-/- 4-1BB-/- and Ldlr-/- 4-1BB-/- mice had smaller atherosclerotic plaques compared 
to control mice, which was attributed to a down-regulation of IFNγ, MCP1, VCAM, 
ICAM, and IL-6. Stimulation of 4-1BB signaling induced the production of pro-
inflammatory cytokines by macrophages in the atherosclerotic vessels in vivo109. In 
perspective, 4-1BB is able to regulate T cell activation as a co-stimulation receptor but 
also mediates atherosclerosis via effects on ECs and macrophages because 4-1BBL is 
expressed in other cell types, including DCs and activated B cells.
In conclusion, deficiency of 4-1BB in vivo leads to reduced atherosclerosis and 
blocking of the 4-1BB - 4-1BBL co-stimulation pathway may be a valuable target to 
reduce the development of atherosclerosis. However, pre-clinical trials should point 
out whether this is also effective in other CVD than atherosclerosis. 
Type V; CD30 and CD30L
CD30 (or tnfsf8) is expressed by activated CD4+ and CD8+ T and B cells, while its 
ligand CD30L (or CD153) is also expressed on macrophages and DCs. Signaling via 
CD30 is complex as it can lead to either proliferation or apoptosis. Interaction via 
CD30L induces pro-inflammatory cytokine release from CD30+ CD4+ T cells resulting 
in a potent helper activity for B cell antibody production 110. 
Human alloreactive T cells reside within the CD30+ population indicating a regulatory 
role of T cell immune responses via CD30L. Strong expression of CD30L, CD70, 4-1BBL 
and weak to moderate expression of OX40L was found in the cardiac myocytes of 
patients with acute myocarditis. Moderate expression of CD30L, CD27L, 4-1BBL 
and weak expression of OX40L was found on the cardiac myocytes of patients with 
dilated cardiomyopathy 111. 
CD30 was regarded as a regulator of atherosclerosis. Treatment of Ldlr-/- mice with 
anti-CD30L antibodies resulted in a reduction of atherosclerotic plaques in the aortic 
roots compared to control mice. Also, a reduced amount of CD3+ T cells in spleens 
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and in the adventitial layers were observed, while no differences in the collagen of 
macrophage content were identified. This indicates that the function of the CD30-
CD30L pathway is largely inhibiting T cell responses 112. 
Thus, CD30 is involved in CVD and anti-CD30 treatment is able to modulate 
atherosclerosis formation and could be used to inhibit atherosclerosis plaque 
development and, although not investigated yet, may also prevent other CVDs.
Type V; GITR and GITRL
Glucocorticoid-induced tumor necrosis factor receptor (GITR, also known as CD357), 
a multifaceted regulator of immunity belonging to the TNF(R)SF, is expressed on 
activated CD4+ T cells and binds to GITR ligand (GITRL). The mechanism of GITR 
signaling is thoroughly reviewed elsewhere 113.
GITR and GITRL are considered pro-atherogenic since they were observed to be 
mainly expressed in atherosclerotic plaques rich in macrophages. GITR signaling in 
macrophages induced the expression of TNFα, and MMP9 via NF-κB114. In addition, 
it was shown that Ldlr-/- mice constituted with bone marrow from B cell-specific 
GITRL transgenic mice showed significantly smaller atherosclerotic lesions than in 
control mice 115. Although the role of GITR and GITRL in cardiovascular disease is 
only characterized in a limited amount of pre-clinical studies, it is described more 
comprehensively in other diseases. A murine model of cortical infarction showed that 
GITR triggering on CD4+ T cells increased post-stroke inflammation and decreases 
the number of neural stem/ progenitor cells induced by ischemia 116. Depletion of 
the GITR high cells induced autoimmune myocarditis at a high incidence in BALB/c 
mice in addition to other organ-specific autoimmune diseases, such as gastritis and 
thyroiditis, which are commonly produced by depletion of CD25+ Tregs 117.
Type L; CD40 and CD40L 
The type-L family CD40 (or tnfsf5) is expressed by APCs and binds to CD40L (or 
CD154) that is expressed by activated (follicular) T helper cells, macrophages, B cells 
and ECs. In the latter cells, activation results in the induction of ICAM, VCAM, and 
E-selectins and may promote the development of atherosclerosis. CD40L is also 
expressed by activated thrombocytes and induces recruitment of monocytes to the 
inflamed endothelium. This is important for platelet-leukocyte aggregate formation, 
which can contribute to the progression of atherosclerosis 118. 
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Increased levels of CD40L were observed in patients with unstable angina, 
asymptomatic hypercholesterolemia and more importantly, acute myocardial 
infarction 119, 120. Lutgens et al. showed that the CD40-CD40L co-stimulation pathway 
is an important pathway in atherosclerosis development. ApoE-/- mice treated with 
agonistic CD40 antibodies resulted in smaller atherosclerotic plaques compared 
to untreated ApoE-/- mice. These atherosclerotic plaques contained low numbers 
of inflammatory cells with considerable fibrosis indicating a stable phenotype 121. 
In addition, Mach et al. showed that anti-CD40L antibodies were able to stabilize 
atherosclerotic plaques because the CD40 pathway induces inflammation via 
stimulation of pro-inflammatory cytokine release from macrophages122. Activation of 
the CD40 pathway induced the production of matrix metalloproteinase, aggravating 
plaque destabilization, plaque rupture and arterial occlusion. 
ApoE-/-Cd40-/- mice with a deficiency in the CD40-TRAF2/3/5 binding showed no 
differences in atherosclerotic plaque development compared to control mice. In 
contrast, deficiency in the CD40-TRAF6 abrogated atherosclerosis as measured by a 
reduced recruitment of Ly6C+ monocytes in the arterial wall and reduced blood counts 
of Ly6C+ monocytes. Besides monocytes, macrophages were also identified in the 
arterial wall but these macrophages were polarized towards the anti-inflammatory 
M2 phenotype 123. This could be due to the anatomic difference since TRAF1/2/3/5 
is recruited to the proximal cytoplasmic domain of CD40 while TRAF6 is recruited to 
the distal end.
Since CD40-TRAF6 inhibition showed promising pre-clinical results, strategies were 
developed to target this pathway. Seijkens et al. successfully used nanotherapy to 
target the CD40-TRAF pathway in an atherosclerotic mice model leading to a decrease 
in atherosclerotic plaque development124. In the future, it would be interesting to 
translate this approach to other CVDs. 
Type L; DR3 and TL1A
A second molecule of the type-L family is DR3, expressed on lymphocytes, NK 
cells, endothelial cells, and macrophages. Its known ligand, TL1A, is expressed on 
macrophages and DCs and can drive inflammatory disease progression 125, 126. TL1A 
promotes foam cell formation in human macrophages in vitro by increasing both 
acetylated and oxidized low-density lipoprotein uptake, via enhancing intracellular 
total and esterified cholesterol levels and reducing cholesterol efflux 127. Signaling 
through DR3 induces both apoptosis and activation of NF-kB 128. This indicated that 
DR3 and TL1A may contribute to atherosclerosis development.
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Effect in cardiovascular disease
IgSF B7/CD28 CD80, 
CD86
CD28 Cd80/86/70-/- mice ↓intimal hyperplasia in VGD mouse model (Simons et al.)
Cd80/CD86-/- mice ↓intimal lesion in femoral artery cuff mouse model for post-interventional 
remodeling33
Cd80-/- and Cd80/86-/- mice ↓ GAD after MHC class II-mismatched allograft heart transplantation40
Cd80/86-/-Ldlr-/- mice ↓ atherosclerotic lesions in aortic arch and descending aorta47
Cd80/86-/-Ldlr-/- bone marrow chimeras and Cd28-/-Ldlr-/- chimeras ↑ atherosclerotic lesions due to ↓ 
Tregs50
IgSF B7/CD28 CD80, 
CD86
CTLA4 CTLA-4Ig blocking CD80/86 treatment ↓intimal lesion in femoral artery cuff mouse model for 
post-interventional remodeling and ↓ accelerated atherosclerosis in a model of accelerated 
atherosclerosis in hypercholesterolemic ApoE3*Leiden mice33
CTLA-4Ig blocking CD80/86 treatment ↓ GAD in a Lewis (LEW) to Fisher (F344) rat cardiac transplant 
model38
CTLA-4Ig blocking CD80/86 treatment or CD80 blockade with mutant fusion protein Y100F ↓ GAD in 
a LEW to F344 rat cardiac transplant model39
CTLA-4Ig blocking CD80/86 treatment ↓ cardiac dysfunction in a mouse heart failure model41.
CTLA-4Ig blocking CD80/86 treatment ↓ homocysteine-accelerated atherosclerosis in ApoE3-/- 
mice48
CTLA-4Ig blocking CD80/86 treatment ↓ atherosclerosis in mice with constitutive expression of 
CTLA-4 on T cells49
IgSF B7/CD28 PD-L1, 
PD-L2
PD-1 Ischemic-reperfused cardiac cells expressed high levels of PD-1 and PD-L1 in a cardiac injury mouse 
model54
Pd-1-/- mice ↑ dilated ventricles and ↓ contraction function In a spontaneous model of dilated 
cardiomyopathy55
Pd-1-/- mice ↑ cardiomyopathy caused by autoantibodies against cardiac troponin I56
Pd-1-/- mice CD8+ T cells cause ↑ myocarditis in a disease CD8+ T cell-mediated adoptive transfer 
model for myocarditis and Pd-1-/- mice ↑ myocarditis in an experimental autoimmune myocarditis 
model57
Pd-L1-/--MRL mice ↑ development of fetal autoimmune myocarditis in Murphy Roths Large (MRL) 
mice59
Pd-1-/--MRL mice in the development of fetal autoimmune myocarditis in Murphy Roths Large (MRL) 
mice58
Pd-L1/2-/- mice, both effector memory T cells and naive T cells induced late-onset myocarditis in a 
GVHD model60
Ldlr−/−Pd-1−/− mice ↑ atherosclerotic lesion size in the aortic sinus and aorta61, 62
Pd-L1/2-/-Ldlr-/- mice ↑ atherosclerotic lesions in the aortic sinus and arch63
IgSF B7/CD28 ICOSL ICOS ICOS and ICOSL are abundantly expressed in murine atherosclerotic leions42, 66
Ldlr-/- mice transplanted with bone marrow of ICOS-/- mice ↑ lesion size in aortic sinus67
IgSF TIM TIM4 TIM1 Ldlr−/− mice treated with antibodies against TIM1 or TIM4 ↑ atherosclerotic lesions73
TIM4 variants are associated with the risk coronary heart disease and ischemic stroke72
IgSF TIM Unknown TIM3 In a mouse model for myocarditis, blocking TIM3 increased myocarditis abundantly in BALB/c 
mice75
IgSF CD2/SLAM CD48 CD2 Unknown
IgSF CD2/SLAM CRACC CRACC The expression of CRACC was ↑ in areas of stable compared to unstable atherosclerotic lesion 
segments78
IgSF CD2/SLAM Unknown BLAME The expression of BLAME was ↑ in areas of stable compared to unstable atherosclerotic lesion 
segments78
↑ expression of BLAME in human advanced atherosclerotic (AHA type V-VI) lesions79





TNFSF Type V CD70 CD27 CD27+ T cells are present in atherosclerotic lesions42
ApoE-/- mice reconstituted with Cd70-/- mice bone marrow displayed ↑ atherosclerotic lesions86
Overexpression of CD70 in CD70 transgenic ApoE*3 Leiden mice↓atherosclerotic lesions209
Cd70-/- mice ↓ post-ischemic blood flow recovery, ↓ vasculogenesis, ↓ angiogenesis, ↓ arteriogenesis 
in a hindlimb ischemia mouse model85 
TNFSF Type V OX40L OX40 Patients with an acute coronary syndrome or stable angina pectoris ↑ OX40L blood levels92
↑in (soluble) OX40L (>40ng/ml) is associated with ↑risk for acute myocardial infarction, sudden 
death and recurrent angina pectoris93, 94
OX40/OX40L mRNA levels ↑ in coronary heart disease patients and correlated with some clinical 
pathological features of coronary heart disease 91
↑ OX40 expression in pressure overload-induced hypertrophic murine hearts regulated via 
CD4+ T cells90
Ldlr-/- mice treated with OX40L antagonist ↓ number of T cells in atherosclerotic lesions and ↓ 
atherosclerotic lesion size88
↑ levels of OX40 characterize CD4+CD28null T cells in patients with acute coronary syndrome96
BALB/C mouse treated with anti-OX40L blockade ↓myocarditis progression in a myocarditis mouse 
model 149
In ApoE-/- treated with OX40L-specific neutralizing antibody and ApoE-/- Ox40l-/- ↓ extent of aortic 
atheroma102 
TNFSF Type V 4-1BBL 4-1BB ApoE-/-CD137-/- and Ldlr-/-CD137-/- mice ↓ in atherosclerotic lesions in atherosclerosis mouse models109
ApoE-/- mice treated with CD137 agonist ↑ atherosclerotic lesions108
TNFSF Type V CD30L CD30 Ldlr-/- mice treated with CD30L blocking antibody ↓ atherosclerotic lesion formation in the aortic 
arch112
Expression of CD30 was up regulated on T cells in patients with acute myocarditis and dilated 
cardiomyopathy111
TNFSF Type V GITRL GITR GITR and GITRL are expressed in macrophage-rich areas of human atherosclerotic lesions114
Lethally irradiated Ldlr−/− mice reconstituted with bone marrow from B cell specific GITRL transgenic 
mice ↓ atherosclerotic lesions115
BALB/c mice receiving cells depleted of GITRHIGH ↑autoimmune myocarditis 117
TNFSF Type L CD40L CD40 ↑ levels of soluble CD40L in the peripheral blood from patients with unstable angina210
ApoE-/-Cd154-/- mice ↓ advanced atherosclerotic lesions211.
ApoE-/- mice treated with anti-CD40L antibody induces a stable atherosclerotic lesion phenotype212
Ldlr-/- mice treated with antibody against CD40L ↓ aortic atherosclerotic  lesions213
Human atherosclerotic  lesions showed expression of CD40L on EC, VSMC, and macrophages214
Cd40-Traf6-/-ApoE-/- ↓ development of atherosclerosis123
TNFSF Type L TL1A DR3 TL1A and DR3 are expressed in carotid endoarterectomy atherosclerotic  lesions. TL1A and DR3 are 
involved in atherosclerosis via the induction of pro-atherogenic cytokines and ↓ in atherosclerotic 
lesion stability by inducing extracellular matrix degrading enzymes129
TNFSF Type L HVEM LIGHT, 
LTβR
In human plasma samples, atherosclerosis reproduced by the amount of coronary calcium, aortic 
wall thickness and aortic atherosclerotic lesion size correlated with the level of circulating 
LTβR134
LTβR signaling has been linked to the formation of tertiary lymphoid organs in the aortic adventitia 
of ApoE-/- mice and protection against atherosclerosis via VSMC–LTβR signaling135
ApoE-/-Ltβr-/- mice ↓ aortic atherosclerotic  lesion burden136




In human atherosclerotic plaques, TNFα induced the expression of TL1A. Both TL1A 
and DR3 were identified in regions rich in foam cells in carotid endarterectomy 
tissues129. The expression of DR3 was induced by activated monocytes and 
macrophages by atherogenic stimuli. In addition, Kim et al. observed that the vascular 
inflammation is accelerated by TL1A and DR3 ligation resulting in the induction 
of MMP-9, TNFα, IL-8, and MCP-1 and subsequently, progression of atherosclerotic 
plaques130. 
Type L; LTβR and LTα1β2 
The biologically active heterotrimer Lymphotoxin (LT)α1β2 is unique in the TNF 
superfamily131. LTα1β2 possesses two binding sites for the LTβ receptor (LTβR, also 
known as TNFRSF3) with distinct affinities. Dimerization of LTβR by LTα1β2 is necessary 
and sufficient for signal transduction via TRAF3132. Surface LTα1β2 is detected on 
subsets of activated T and B cells and NK cells133. LTβR is expressed on ECs, SMCs, and 
cells of the myeloid lineage. Communication via LTβR dictates interactions between 
immune cells and modifies correct trafficking of lymphoid cells. 
In humans, plasma LTβR was measured in blood from 3215 patients enrolled in the 
Dallas Heart Study. Higher levels of LTβR were observed in patients with increased 
coronary calcium, aortic plaques and aortic wall thickness measured by computed 
tomography 134. This indicated that LTβR might be associated with atherosclerotic 
plaque development, although a causal relation still needs to be established. 
Hu et al. observed an increase in atherosclerotic lesions in 32-35 weeks old ApoE-/-LTβR-/- 
mice compared to ApoE-/- mice 135. Grandoch et al. obtained comparable results from 
the aortic root of 23 weeks old ApoE-/-LTβR-/- mice. Fewer macrophages were invading 
the aorta, whereas the relative distribution of M1 and M2 macrophages remained 
unchanged 136. In contrast, with the use of aged 78 to 85 weeks old ApoE-/-LTβR-/- mice, 
Hu et al. revealed an acceleration of atherosclerosis compared to age-matched ApoE-
/- mice. In vivo, this indicates that LTβR signaling may be atheroprotective in a site-
specific and age-dependent way. 
Therapeutic targeting of co-stimulation
Anti-CD80/86
Most pre-clinical studies described above, show beneficial effects of blocking co-
stimulation on CVD. Therefore, investigating co-stimulation blockade as a therapeutic 
approach to prevent CVD should be encouraged. Anti-CD80 was the first antibody to 
block co-stimulation, however, since both CD80 and CD86 can bind to the co-
stimulation receptor CD28, blocking only one co-stimulation molecule was not 
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effective137. The second developed co-stimulation blocker was a CD28Ig, blocking the 
interaction between CD28 and CD80/86138. However, because of the low affinity of 
CD28 for CD80/86, CD28Ig was unsuccessful. Subsequently, based on the fact that 
CTLA-4 binds CD80/86 with a much higher affinity, CTLA4-Ig was developed as a 
suitable candidate to block CD80/86 co-stimulation. CTLA4-Ig is a fusion protein 
consisting of the extracellular domain of CTLA-4 linked to the Fc region of 
immunoglobulin G1 (IgG1), and effectively blocks CD80/86 thereby inhibiting T cell 
activation 139. Two CTLA4-Igs, abatacept and belatacept, are the first US Food and 
Drug Administration (FDA) approved co-stimulation blockers (FIG 2a). CTLA4-Ig is a 
fusion protein consisting of the extracellular domain of CTLA-4 linked to the Fc region 
of immunoglobulin G1 (IgG1), blocking CD80/86 and thereby inhibiting T cell 
activation. Abatacept was FDA approved in 2005 for the treatment of rheumatoid 
arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis and systemic lupus 
erythematosus (SLE) (BOX 2). Belatacept was FDA approved in 2011 for adult patients 
receiving a kidney transplant. Subsequently, abatacept and belatacept made their 
appearance in the cardiovascular research field.
Figure 2. Therapeutic treatment options to target co-stimulation pathways and co-inhibition 
pathways. a. Therapeutic targeting of co-stimulation to block T cell activation can be via blocking co-
stimulation molecules on antigen presenting cells (APCs) or T cells (antibodies shown in light blue). 
Abatacept and Belatacept are CTLA4-Ig fusion proteins consisting of the extracellular domain of 
CTLA-4 linked to the Fc region of immunoglobulin G1 (IgG1), blocking CD80/86 of the B7/CD28 family 
(in red) and thereby inhibiting T cell activation. Members of the type-L family of the TNFSF e.g., CD40 
expressed on T cells can be blocked via a CD40-TRAF6 inhibitor. In addition anti-OX40 blocks the 
OX40-OX40L interaction which induces T cell anergy similar to anti-4-1BB antibodies blocking 4-1BB. 
b. In addition to the co-stimulation blockers abatacept and belatacept, several immune checkpoint 
inhibitors (ICIs) are already FDA approved. Blocking inhibitory pathways, leading to enhancement 
of T cell activation, can be accomplished via antibodies blocking inhibitory molecules on antigen 
presenting cells (APCs) or T cells (antibodies shown in yellow). The most well described ICIs block the 
co-inhibition pathways of CTLA-4 and PD-1 or PD-L1. Ipilimumab is a monoclonal antibody blocking 
CTLA-4 expressed on T cells, inducing T cell activation. Nivolumab and pembrolizumab block PD-1 
expressed on T cells and atezolizumab blocks PD-L1 expressed on APCs, inducing T cell activation. 
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BOX 2 co-stimulation blockers in SLE and RA patients 
Abatacept, a CTLA-4Ig fusion protein, selectively blocks CD80/CD86 co-
stimulation, inhibiting T cell activation via CD28. Several autoimmune diseases 
such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) 
might benefit from abatacept due to their anti-inflammatory properties. 
Abatacept was FDA approved in 2005 for SLE and RA, and subsequently made 
their appearance in the cardiovascular research field 
In RA patients, the effect of abatacept has been shown in several clinical trials. 
In the ADJUST study, abatacept reduced anti-CCP antibody levels in RA patients 
and maintained the inhibition of radiographic and MRI progression for more 
than 6 months after treatment in patients with very early RA204. In the AGREE trial, 
treatment with abatacept plus methotrexate (MTX) increased the proportions 
of patients achieving remission, even in the RA patient population at high risk 
of disease progression 205. In the AVERT trial, patients treated with abatacept 
plus MTX achieved significantly higher rates of disease activity score defined 
remission, compared to MTX treatment alone. A small but significantly higher 
number of these patients achieved an absolute, drug-free, disease activity score 
defined remission following a withdrawal of all RA treatment206. Abatacept plus 
MTX was also able to inhibit radiographic disease progression in patients with 
early RA that are at high risk for disease progression207. 
In SLE patients, abatacept was able to prevent severe articular flares in 
comparison to placebo. In a subgroup of patients treated with a low dose 
of prednisone less than 7.5 mg/day, the proportion of patients who did not 
develop a new flare was higher in the abatacept group than in the control group. 
In addition, abatacept improved fatigue and sleep disturbance 208. These clinical 
trials in patients with RA and SLE showed benefit of inhibiting co-stimulation in 
disease progression and this could be beneficial in other autoimmune diseases.
CTLA-4Ig has shown to reduce GAD, post interventional remodeling, heart failure 
and accelerated atherosclerosis in experimental models33, 38, 41, 48, 140, but has not 
been tested yet in clinical trials for CVD. Interestingly, in addition to abatacept and 





Although anti-CD40 showed promising results in pre-clinical studies, and may cause 
an even higher immune suppression compared to CTLA-4Ig142, 143, in clinical trials 
severe side effects occurred in patients such as thromboembolic events. As described 
before, the CD40-TRAF6 signaling pathway is the preferred pathway. Nanotherapy was 
used as a therapeutic approach to target the CD40-TRAF pathways in macrophages. 
TRAF-STOP 6877002, incorporated into recombinant HDL nanoparticles, reduced 
atherosclerosis in ApoE-/- mice after 6 weeks124 and was demonstrated as a safe and 
efficient target for atherosclerosis in both mice and non-human primates 144. In 
addition, CD40-TRAF6 inhibitors were successfully used in the treatment of obesity-
associated insulin resistance and other inflammatory diseases in experimental 
models145-147. This makes CD40-TRAF6 inhibitors potentially interesting for the 
treatment of CVD. 
Anti-OX40
Another potentially interesting co-stimulation blocker is anti-OX40, which showed 
promising results in pre-clinical studies. OX40Ig blocks the OX40-OX40L interaction 
and induces T cell anergy. The use of OX40Ig resulted in beneficial outcomes in 
atherosclerosis 88 and other diseases such as acute renal allograft rejection 148. 
In addition, blocking OX40 with an anti-OX40L antibody which also inhibits T cell 
activation, protected mice from myocarditis149, atherosclerosis150 and has been shown 
to inhibit graft rejection and graft-versus-host disease (GVHD)151, 152. Although the 
results of blocking OX40 in experimental models seems promising for CVD treatment, 
clinical trials are not on-going yet due to the limited amount of pre-clinical data. 
On the other hand, an anti-OX40 agonistic antibody GSK3174998, stimulating OX40 
induced T cell activation, instead of the preferred T cell inhibition in CVD, is now 
being tested in a clinical trial for patients with selected advanced solid tumors153. 
Close supervision of the potential cardiovascular risks thus seems warranted. 
Anti-4-1BB
Inhibition of T cell activation with anti-4-1BB-antibodies, showed promising pre-clinical 
cardiovascular results in atherosclerotic mouse models109. However, only agonistic 
4-1BB antibodies, activating T cells, are currently being tested in cancer clinical trials. 
Utomilumab and urelumab target 4-1BB which stimulates clearance of cancer cells 
by T cell activation. A phase I study was successfully completed and showed that 
utomilumab was safe and efficient as an anti-cancer treatment154. Urelumab showed 
beneficial results in patients with locally advanced or metastatic solid tumors in a 
phase I study. However, an additional phase II study had to be terminated due to fatal 
hepatoxicity 155, 156. Currently several clinical trials with utomilumab and urelumab 
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are ongoing for several cancer types alone or in combination with other ICIs such 
as pembrolizumab157. Although cardiovascular side effects are not reported in these 
studies, a pre-clinical study showed that agonistic 4-1BB antibodies promoted 
atherosclerosis in hypercholesterolemic mice108 which is in line with the pre-clinical 
data of Jeon et al. who showed a decrease in atherosclerotic lesion development in 
4-1BB deficient mice. This indicates that both utomilumab and urelumab might result 
in disadvantageous effects in CVD. Thus, the development of antagonistic 4-1BB 
antibodies, inhibiting T cell activation, should be encouraged and cardiovascular side 
effects of agonistic 4-1BB antibodies, activating T cells, should be monitored.
Conclusion therapeutic targeting of co-stimulation
Although targeting the IgSF and TNF(R)SF co-stimulation molecules seems promising 
in pre-clinical studies, clinical studies should learn us whether the cardiovascular 
outcomes are as promising as expected. Anti-CD80/86 treatment with CTLA4-Ig, 
such as the FDA approved abatacept and belatacept, and CD40-TRAF6 inhibitors are 
already well developed, but blocking of OX40 and anti-4-1BB co-stimulation could 
be interesting entrants. However, it should be taken into account that blocking 
co-stimulation can also lead to unwanted side effects. As previously described by 
Bluestone et al. 158, anergic T cells will no longer be able to clear viral infections, 
since the co-stimulation-mediated immune response is blocked. This might have 
detrimental long-term consequences. Furthermore, co-stimulation blockade can also 
lead to a decrease in activated Tregs, which can result in opposing cardiovascular 
outcomes. Thus, although promising, the effects on CVDs of therapeutic targeting of 
co-stimulation should be thoroughly clinically investigated.
Cardiovascular toxicity after immune checkpoint inhibitors treatment
In addition to co-stimulation blockers abatacept and belatacept, several co-inhibition 
blockers (ICIs) are already FDA approved and used as a cancer treatment (FIG 2b). 
The described ICIs block co-inhibition pathways involving of CTLA-4 and PD-1 or PD-
L1. The first clinically FDA approved ICI was ipilimumab in 2011 for the treatment 
of unresectable or metastatic melanoma 159. Ipilimumab is a monoclonal antibody 
blocking CTLA-4 and is currently undergoing several clinical trials for the treatment of 
other cancer types e.g. non-small cell lung carcinoma (NSCLC), small cell lung cancer 
(SCLC), bladder cancer and metastatic hormone-refractory prostate cancer. Other 
clinically FDA approved immune checkpoint inhibitors for several cancer types, are 
nivolumab and pembrolizumab blocking PD-1, and atezolizumab blocking PD-L1160, 
161. Several other ICIs are currently in clinical or preclinical development such as an 
anti-TIM-3 antibody, dual anti-LAG-3/anti-PD-1 antibody, anti-lymphocyte-activated 
gene-3 (LAG-3, CD223) or anti-BTLA antibody 161.
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The therapeutic potential of ICIs in several types of cancer is due to their anti-cancer 
response by blocking co-inhibition molecules expressed on tumor-reactive T cells. In 
physiological conditions, this prevents T cells from being activated by healthy cells 
in the human body, but in a cancer environment it causes a boost of (cytotoxic) T cell 
activation and cancer cell clearance23. Unfortunately, there are no clinical trials on 
CVD (safety) for these FDA approved drugs. Most pre-clinical, experimental studies 
mentioned above describe a protective role of CTLA-4, PD1 or PD-L1 and PD-L2 in 
CVD, and blocking these molecules may lead to severity of CVD. Boosting CD8+ T 
cell responses is beneficial in clearing cancer cells, but the accompanied increase in 
inflammation might be detrimental for cardiovascular outcomes in cancer patients 
treated with ICIs. 
Since the proportional use of ICIs, several studies on the harmful cardiovascular effects 
of PD-1 blockers are reported. Lethal myocarditis was reported in a study of two 
patients diagnosed with a melanoma, treated with a combination of ipilimumab and 
nivolumab 29. Post mortem analysis of the myocardium revealed an increase in PD-L1 
expression on the myocardial epithelium. Interestingly, in a pre-clinical study Grabie 
et al. observed that PD-L1 up regulation on the myocardial endothelium was involved 
in the regulation of cardiac injury162. The cardiovascular toxicity in these patients was 
caused by the T cells activated by ipilimumab and nivolumab. It was observed that 
these T cells target an antigen shared by the tumor, skeletal muscle, and the heart 
that resulted in both tumor-and muscle (cardiac and skeletal) cell recognition and 
clearance163. However, in the safety databases of Bristol-Myers Squibb Corporate they 
observed that only 0.27% of the patients treated with a combination of ipilimumab 
and nivolumab developed myocarditis, with only 0.17% fatal events. Treatment with 
nivolumab alone resulted in significantly lower percentage of myocarditis (0.06%)29. 
Although combination treatment of ipilimumab and nivolumab has beneficial 
effects on tumor reduction, in the study of Postow et al. and Larkin et al., 52% and 
36.4% respectively of the patients could not continue treatment of ipilimumab and 
nivolumab combined due to drug-related toxicity/side effects164, 165. 
Described in a case report, smoldering myocarditis was detected in a patient with an 
elevated troponin I level, after use of ipilimumab and nivolumab 166. In this case, the 
myocarditis could be treated with high dose glucocorticoid therapy and troponin 
I levels rapidly decreased along the patients recovery. Interestingly, it was shown 
previously in a pre-clinical study that elevated cardiac troponin I was associated with 
cardiomyopathy in PD-1 deficient mice56.
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Furthermore, several other studies and case reports described fatal cardiac arrest164, 
myocardial fibrosis 167, left ventricular dysfunction168 and Takotsubo cardiomyopathy169, 
after treatment of metastatic melanoma with ipilimumab. Also, several other reports 
on the induction of cardiovascular toxicity by ipilimumab are described 170.
In addition, cases of acute heart failure were reported after pembrolizumab treatment 
for metastatic melanoma171 and NSCLC172. Zimmer et al. described atrial flutter, left 
ventricular systolic dysfunction and stable angina pectoris in cases of patients treated 
with pembrolizumab and sudden asystolia after treatment with nivolumab 30. 
Acute myocarditis after treatment with nivolumab is described after treatment of 
metastatic melanoma and NSCLC 173-176. Also combination therapy of both ipilimumab 
and nivolumab showed myocarditis as an adverse event in a patient treated for 
metastatic melanoma 177. Here we reviewed all the 27 cases mentioned above and 
described that 10 patients died from drug-related toxicity (table 2).
Besides the fact that ICIs can cause cardiovascular toxicity, it is also suggested that ICIs 
aggravate atherosclerosis, by increasing effector T cell responses and reducing Treg 
functions178, but this will probably only become more clear at prolonged survival/
follow up. 
In conclusion, it can be stated that if cardiovascular adverse side effects of ICIs occur, 
they are often severe, fulminant and even can be lethal. Although these case reports 
and studies described events of cardiovascular toxicity after ICI treatment, the 
substantial incidence of cardiovascular toxicity after ICI treatment should be further 
examined in order to apply proper additional (counter) therapies.
Future perspectives
There is a close relation between treating cancer with ICIs and the risk of cardiac 
injury. Treating cancer with ICIs may be lifesaving, however, cardiovascular 
toxicity is an underlying complication that can be lethal. ICI related cardiovascular 
toxicity can occur since the ICI targets are not unique to cancer cells. Therefore, 
oncologists, cardiologists and immunologist should work closely together when 
patients are treated with ICIs. Several cardio-oncology societies such as the British 
Cardio-oncology society (BS-OS), Canadian Cardiac Oncology Network (CCON) and 
International Cardioncology Society, North America (ICOSNA) were already launched 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Currently, colleagues are developing recommendations for the treatment of immune 
therapy related myocarditis since no guidelines are available yet 179-181. Although this is 
highly appreciated, we also recommend focusing on preventing cardiovascular toxicity 
and clinical trials to test ICIs or co-stimulation therapy in CVD. Many clinical trials 
excluded patients with pre-existing CVD. Therefore, the incidence of cardiac toxicity 
after ICI treatment may be even higher than we now think. Interestingly, cardiovascular 
toxicity is usually reported shortly after the first ICI treatment. Future studies should 
also focus on late-onset cardiovascular toxicity and include patients with pre-existing 
CVD. Furthermore, a difference between short-and long-term CVD treatment should be 
taken into account. Cardiovascular interventions such as vein graft bypass surgery and 
percutaneous transluminal angioplasty should be treated shortly after intervention 
since VGD and restenosis can start to develop in the first weeks after intervention and 
can be probably limited in time. In contrast, atherosclerosis develops over the years and 
it is not clear when to start the treatment to prevent atherosclerosis. However, when 
clinical symptoms develop, long-term and even lifelong atherosclerosis treatment is 
indicated. So also with co-stimulation or co-inhibition targeted therapy, it should be 
taken into consideration, whether to treat the patients shortly after intervention, of life 
long with a good eye for the balance between benefit and risk. 
With the expected increased use of ICIs in the future, several questions raised and 
should be answered. Since we know that combination treatment of anti-CTLA4 and 
anti-PD-1 drugs is associated with higher frequency of toxicities182, it might be an 
option to only allow mono checkpoint inhibitor therapy instead of a combination of 
checkpoint inhibitors. To prevent systemic immune (de)activation, local ICI therapy 
may be a good solution183. Moreover, focusing on the stimulation of Tregs might have 
an important protective role in CVD184 and can be therapeutically interesting.
As suggested by Brüstle et al., patients treated with ICI therapy should receive pre-
therapeutic screening to assess cardiovascular risk factors. When treated, it would 
be good if they receive regular surveillance tests to check for signs of cardiovascular 
toxicity. Cardiac parameters and troponins levels are not routinely measured, but 
routine surveillance by cardiologist of patients treated with ICIs may be a solution 
to better monitor these patients and mitigate potential cardiac injury. The initiation 
of the EACVI/HFA Cardiac Oncology Toxicity registry, which registers all anti-cancer 
drug-related cardiovascular toxicity in breast cancer in Europe, is the first step towards 
excessive monitoring of cardiovascular toxicity185. However, since prevention is always 
better than cure, it is suggested that the focus of future (pre-) clinical trials should 
be on the development of co-stimulation blockers for CVD and not the treatment of 




Blocking of co-stimulation pathways might be interesting therapeutic targets for 
CVD. On the other hand, inhibition of the co-inhibition pathways and stimulation of 
co-stimulation receptors might poses serious cardiovascular risks. Thus, although ICIs 
are revolutionary in cancer treatment, the risk of cardiovascular toxicity should be 
taken into consideration. Subsequently, focussing on the inhibition of co-stimulation 
pathways in the future could be world-shattering for the treatment of CVD. 
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To elucidate the role of interferon regulatory factor (IRF)3 and IRF7 in 
neovascularization. 
Methods
Unilateral hind limb ischemia was induced in Irf3-/-, Irf7-/- and C57BL/6 mice by 
ligation of the left common femoral artery. Post-ischaemic blood flow recovery in the 
paw was measured with Laser Doppler Perfusion Imaging (LDPI). Soleus, adductor 
and gastrocnemius muscles were harvested to investigate angiogenesis and 
arteriogenesis and inflammation. 
Results
Post-ischaemic blood flow recovery was decreased in Irf3-/- and Irf7-/- mice compared 
to C57BL/6 mice at all time points up to and including sacrifice, 28 days after surgery 
(t28). This was supported by a decrease in angiogenesis and arteriogenesis in soleus 
and adductor muscles of Irf3-/- and Irf7-/- mice at t28. Furthermore, the number of 
macrophages around arterioles in adductor muscles was decreased in Irf3-/- and 
Irf7-/- mice at t28. In addition, mRNA expression levels of pro-inflammatory cytokines 
(tnfα, il6, ccl2) and growth factor receptor (vegfr2), were decreased in gastrocnemius 
muscles of Irf3-/- and Irf7-/- mice compared to C57BL/6 mice.
Conclusion
Deficiency of IRF3 and IRF7 results in impaired post-ischemic blood flow recovery 
caused by attenuated angiogenesis and arteriogenesis linked to lack of inflammatory 





Occlusive arterial disease is the narrowing of an artery, resulting in impaired 
blood flow and ischemia distal to the obstruction. To prevent or resolve ischemia, 
neovascularization is induced spontaneously to restore blood flow. Angiogenesis 
and arteriogenesis are the main components of neovascularization and are induced 
under pathological conditions, such as peripheral arterial disease and myocardial 
infarction. 
Angiogenesis, the sprouting of new capillaries from pre-existing vasculature1, responds 
to hypoxia by up regulating pro-angiogenic growth factors such as vascular endothelial 
growth factor (VEGF)2. These growth factors induce endothelial cells from the pre-
existing vasculature to migrate, grow and differentiate to shape new capillaries3, 4. 
Arteriogenesis, the maturation of pre-existing collaterals into arterioles5-8, is induced 
by inflammation, shear stress and circumferential stretch on the vascular wall after 
occlusion, mainly proximal to the occlusion. Inflammatory cells such as macrophages, 
monocytes, but also CD4+ and CD8+ T cells adhere and invade into the vascular wall and 
produce inflammatory cytokines, chemokines and growth factors, which cause further 
maturation of arterioles and induce angiogenesis. Subsequently, smooth muscle cells 
proliferate and migrate towards the vessel wall, resulting in full functional arterioles7, 9, 
10. Both angiogenesis and arteriogenesis are essential for accurate neovascularization, 
to restore blood flow after arterial occlusions. 
For the production of inflammatory cytokines, chemokines and growth factors, 
inflammatory cells require activation. Substantial activators are pattern recognition 
receptors, such as toll like receptors (TLR)11, 12. TLR3 expressed in intracellular vesicles 
recognizes dsRNA, which activates a Toll/interleukin-1 receptor domain-containing 
adapter-inducing interferon-β protein (TRIF)-dependent pathway. The TLR3-TRIF 
pathway induces type-I IFN production, via interferon regulatory factor (IRF)3 and 
IRF7 phosphorylation, and pro-inflammatory cytokine production via transcription 
factors nuclear factor kappa-light-chain-enhancer of activated B cells (NFĸB)12-15. 
IRF3 and IRF7 are mainly phosphorylated downstream TLR3, but might also be partly 
activated via other TLRs (e.g. TLR4, TLR7, TLR9)12, 15. It is assumed that NFĸB activation 
results in pro-inflammatory cytokine production and IRF3/IRF7 phosphorylation 
results in type-I IFN production. However, it is observed that TLR3 can also activate 
pro-inflammatory transcription factors via IRF3 and IRF7 and may be potential 
regulators of cell proliferation and survival16-19. Since neovascularization is mainly 
induced by pro-inflammatory cytokines and growth factors, we hypothesise an 
important role for IRF3 and IRF7 in arteriogenesis and angiogenesis. 
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In the current study we aimed to elucidate the role of IRF3 and IRF7 in vivo in post-
ischaemic neovascularization in a hind limb ischia (HLI) mouse model using wild type 
C57BL/6, Irf3-/- and Irf7-/- mice. 
Material and methods
Mice
This study was performed in compliance with the Dutch government guidelines and 
the Directive 2010/63/EU of the European Parliament. All experiments were approved 
by the committee on animal welfare of the Leiden University Medical Center (Leiden, 
the Netherlands). For the experiments 10 to 18 week old male mice were used. 
C57BL/6 mice were purchased from Charles River Laboratories and Irf3-/- and Irf7-/- 
mice were kindly provided by Dr. Taniguchi (University of Tokyo, Japan) and bred in 
our facility20. Mice were fed a chow diet ad libitum. 
Murine HLI model
Mice were anesthetized with an intraperitoneal injection of midazolam (8 mg/kg, 
Roche Diagnostics), medetomidine (0.4 mg/kg; Orion), and fentanyl (0.08 mg/kg; 
Janssen Pharmaceuticals). Unilateral hind limb ischemia (HLI) was performed. In brief, 
a single ligation model was performed by electrocoagulation of the left common 
femoral artery proximal to the bifurcation of the popliteal and saphenous artery21, 
22. After surgery, anaesthesia was antagonised with flumazenil (0.7 mg/kg, Fresenius 
Kabi). Buprenorphine (0.1 mg/kg, MSD Animal Health) was given after surgery to 
relieve pain in a fixed regime and when circumstances required this was repeated. 
Number of total operated mice was 11 per group, however, in the C57BL/6 group 5 
mice deceased during or after surgery and 2 and 4 mice respectively in the Irf3-/- and 
Irf7-/- group. Mice characteristics of Irf3-/-, Irf7-/- and C57BL/6 mice are shown in table 
S1. Body weight at day of the surgery (t=0) and at sacrifice (t=28) was similar in the 
Irf3-/- and Irf7-/- mice compared to C57BL/6 mice.
Laser Doppler Perfusion Imaging
Post-ischemic blood flow recovery was measured in the left ischemic and right non-
ischemic paw of Irf3-/-, Irf7-/- and C57BL/6 mice with the use of Laser Doppler Perfusion 
Imaging (LDPI) (Moor Instruments)23. Blood flow was measured before and directly 
after surgery and at day 3, 6, 9, 14, 21 and 28. Paw perfusion was expressed as a ratio 
of left ischemic to right non-ischemic paw24. Before LDPI, mice were anaesthetised 
as described before25, 26 with an intraperitoneal injection of midazolam (8 mg/
kg) and medetomidine (0.4 mg/kg). After LDPI, anaesthesia was antagonised by 
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subcutaneous injection of flumazenil (0.7mg/kg). Mice were sacrificed 28 days after 
surgery after the last LDPI via cervical dislocation after subcutaneous admission of 
analgesic fentanyl (0.08 mg/kg). The adductor, soleus and gastrocnemius muscles 
were harvested for either (immuno)histochemical analysis or RT-qPCR. 
Immunohistochemistry 
Adductor muscles were fixed in 4% formaldehyde and embedded in paraffin, soleus 
and gastrocnemius muscles were snap frozen on dry ice and stored at -80°C. 
Cross sections of 6 μm were made throughout the embedded adductor muscle. 
Adductor muscle sections were stained with alpha smooth muscle cell actin 
(aSMActin, DAKO) to visualize vascular smooth muscle cells (VSMC). Stained slides 
were photographed (20x magnification) with microscope photography software 
(Axiovision, Zeiss) and analysed with ImageJ (FIJI) by counting the number of 
arterioles and measuring the diameters of each arteriole with a visible lumen to 
determine arteriogenesis25. In addition, adductor muscle sections were stained with 
alpha smooth muscle cell actin (pink) and MAC3 (green) (BD Pharmingen) to visualize 
macrophages around arterioles. Images were acquired on a Philips Ultra Fast Slide 
Scanner (Philips Digital Pathology Solutions, Best) and analysed by counting the 
number of macrophages around the arterioles divided by the circumference of the 
arteriole (presented as macrophages/μm). 12 sections, in the same area in all mice 
were analysed per mice per leg and the average was used for analyses.  Negative 
controls were performed by omitting either the secondary antibody of aSMActin or 
MAC3, or PBS. 
Fresh-frozen soleus muscles were cross sectioned in 6 μm slices with a cryostat and 
sections were fixated in acetone. To visualise endothelial cells, soleus muscle sections 
were stained with CD31 (BD Pharmingen). Stained slides were photographed (20x 
magnification) with microscope photography software. The number of CD31+ 
structures was analysed with ImageJ, which was used to determine angiogenesis and 
was presented in absolute numbers of CD31+ structures per area.
RNA isolation, cDNA synthesis and RT-PCR from adductor muscles
RNA was isolated from snap frozen gastrocnemius muscles 28 days after surgery 
as described before27. In brief, muscle tissues were crushed with mortar and 
pestle, while using liquid nitrogen to preserve sample integrity. RNA was isolated 
according to manufacturer’s protocol using TRIzol Reagent (Life Technologies) 
(FFPE RNA isolation kit, Qiagen), after which sample concentration and purity were 
examined by nanodrop (Nanodrop Technologies). Complementary DNA (cDNA) 
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was synthesized using a High-Capacity cDNA Reverse Transcription Kit according 
to the manufacturer’s protocol (Applied Biosystems). To measure the expression 
of tnfα (forward TGAACTTCGGGGTGATCGG, reverse CTCCTCCACTTGGTGGTTTG), 
ccl2 (forward TATTGGCTGGACCAGATGCG, reverse GGACACTGGCTGCTTGTGAT), il6 
(forward TCCGGAGAGGAGACTTCACA, reverse TTGCCATTGCACAACTCTTTTC), il1β 
(forward AGCTTCCTTGTGCAAGTGTC, reverse TGGGGTCCGTCAACTTCAAA), sdf1 
(forward TTTCACTCTCGGTCCACCTC, reverse AGCTCAGGCTGACTGGTTTAC), vegf164 
(forward AACGATGAAGCCCTGGAGTG, reverse GACAAACAAATGCTTTCTCCG), vegfr1 
(forward GTCTCTTCGCGGTTAGCTCC, reverse AAAAGAAGCCCAGAGAGAGGT) and 
vegfr2 (forward CGTTAAGCGGGCCAATGAAG, reverse CTAGTTTCAGCCGGTCCCTG), RT-
qPCR was performed using QuantiTect SYBR Green PCR Kit (Qiagen). GAPDH (Applied 
Biosystems) was used as a housekeeping gene. All RT-qPCRs were performed on a 
7500/7500 Fast Real-Time PCR System (Applied Biosystems) and the 2-ΔΔCt method 
was used to analyse the relative changes in gene expression.
Statistical analysis
All data are presented as mean ± SEM. In statistics software GraphPad Prism 7.0, 
statistical analyses on parametric data were performed by using a 2-tailed Student’s 
t-test to compare individual groups, Mann-Whitney test was used for nonparametric 
data. A 1-way ANOVA was performed on parametric data comparing more than 2 
groups and a Kruskal-Wallis test was performed on nonparametric data, followed by 
Tukey’s post hoc test. P value of <0.05 was considered significant.
Results
Impact of IRF3 and IRF7 on post-ischaemic blood flow recovery
To study the role of IRF3 and IRF7 in post-ischaemic blood flow recovery, we ligated the 
left femoral artery in C57BL/6, Irf3-/- and Irf7-/- mice and analysed paw perfusion before 
ligation and 3, 6, 9, 14, 21 and 28 days after ligation. Results of the LDPI, expressed 
as the left ischemic/ right non-ischemic ratio, are shown in figure 1. After ligation, 
the paw perfusion decreased tremendously in all groups to ratios of approximately 
0.05. The fact that these ratios are similar in all groups, suggests that the number of 
pre-existing collaterals, that allow residual blood flow to the paw after ligation, is 
similar. C57BL/6 mice already recovered almost 50% 3 days after surgery, whereas the 
Irf3-/- (P=.0005) and Irf7-/- (P=.01) mice only recovered 20%. Both Irf3-/- (P=.006) and 
Irf7-/- (P=.006) mice also showed an impaired blood flow recovery compared to C57BL/6 
mice 6 days after ligation. C57BL/6 mice already reached their maximal recovery 6 
days after surgery, showing a similar paw perfusion as before the ligation, which 
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Figure 1. Post-ischemic blood flow recovery. Laser Doppler perfusion imaging was used to measure 
paw perfusion in Irf3-/-, Irf7-/- and C57BL/6 mice. Paw perfusion was measured in the left and right 
paw before ligation of the left femoral, and 3, 6, 9, 14, 21 and 28 days after ligation. Paw perfusion is 
expressed as a ratio of the left ischemic to right non-ischemic (L/R) paw perfusion. Data is presented 
as mean SEM; * p<0.05, ** p<0.01, ***p<0.001, Mann-Whitney test was used. C57BL/6 n=6, Irf3-/- n=9, 
Irf7-/- n=7.
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did not change until sacrifice. After 9 days, Irf3-/- and Irf7-/- mice reached their maximal 
recovery of respectively 78% and 75% which did not further increase up to the time of 
sacrifice, 4 weeks after surgery. Both Irf3-/- and Irf7-/- mice did not manage to reach the 
same level of post-ischemic blood flow recovery as C57BL/6 mice. This indicates that 
IRF3 and IRF7 have an important role in post-ischaemic blood flow recovery.
Angiogenesis in soleus muscles
To investigate the underlying cause of the reduced post-ischemic blood flow recovery 
in Irf3-/- and Irf7-/- mice, we determined the angiogenic capillary formation in the soleus 
muscles of Irf3-/-, Irf7-/- and C57BL/6 mice. Soleus muscles of the left ischemic and 
right non-ischemic calf were stained with CD31 (figure 2a-c). The number of CD31+ 
cells, expressed as left ischemic/right non-ischemic, in the soleus muscle of Irf3-/- mice 
(P=.02) and Irf7-/- mice (P=.04) was decreased compared to C57BL/6 mice 28 days after 
surgery (figure 2d). This suggests a decrease in angiogenesis. The number of CD31+ 
cells in the left ischemic calf was significantly decreased in the soleus muscle of 
both Irf3-/- (p<0.0001) and Irf7-/- (P=.003) mice compared to C57BL/6 mice (figure 2e). 
The right non-ischemic calf showed no differences in number of CD31+ cells (figure 
Figure 2. Angiogenesis in CD31+ stained soleus muscles. Representative image of the left ischemic 
soleus muscle stained with CD31 (20x magnification) of a. C57BL/6 mice b. Irf3-/- mice and c. Irf7-
/- mice sacrificed 28 days after surgery d. Ratio of the number of CD31+ cells in the soleus muscle 
of left ischemic/right non-ischemic is shown. e. The number of CD31+ cells in the soleus muscle of 
the left ischemic calf is shown. f. the number of CD31+ cells in the soleus muscle of the right non-
ischemic calf is shown. Data is presented as mean SEM; * p<0.05; ** p<0.01, ***p<0.001. ****p<0.0001, 
a 2-tailed Student’s t-test was used. C57BL/6 n=6, Irf3-/- n=9, Irf7-/- n=6.
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2f ) in Irf3-/- and Irf7-/- compared to C57BL/6 mice, indicating that there is no genetic 
difference in angiogenesis between Irf3-/-, Irf7-/- and C57BL/6 mice. 
Arteriogenesis in adductor muscles
In addition to angiogenesis, arteriogenesis also is an important process during 
neovascularization. To investigate arteriogenesis, adductor muscles were stained with 
aSMActin (figure 3a-c) and the diameter of arterioles were measured (figure S1a-b) 
together with the number of arterioles. The diameter of the aSMActin+ arterioles, 
expressed as left ischemic/right non-ischemic, was smaller in Irf3-/- mice (P=.04) and 
Irf7-/- mice (P=.02) compared to C57BL/6 mice 28 days after surgery (figure 3d).The 
diameter of the aSMActin+ arterioles was decreased in the individual left ischemic 
adductor muscles of Irf3-/-(P=.005) and Irf7-/- (P=.02) mice compared to C57BL/6 mice 
(figure S1c). No significant differences were observed in the diameter of the aSMActin+ 
arterioles of the right non-ischemic adductor muscle of C57BL/6 compared to Irf3-/- 
and Irf7-/- mice. (figure S1d). The number of arterioles was increased in the adductor 
Figure 3. Arteriogenesis in aSMActin stained adductor muscles. a. Representative image of the left 
ischemic adductor muscle of C57BL/6 mice sacrificed 28 days after surgery, stained with aSMActin 
(20x magnification) and b. Irf3-/- mice and c. Irf7-/- mice.  d. Left ischemic/right non-ischemic ratio is 
shown of the αASMActin positive arteriole area (µm2). e. Left ischemic/right non-ischemic ratio is 
shown of the number of arterioles. Data is presented as mean SEM; * p<0.05; ** p<0.01, a 2-tailed 
Student’s t-test was used. C57BL/6 n=6, Irf3-/- and Irf7-/- n=7.
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muscles of Irf3-/- mice (P=.007) after 28 days compared to C57BL/6 mice but was not 
significantly different in Irf7-/- mice compared to C57BL/6 mice adductor muscles 
(figure 3e). Interestingly, the number of arterioles was similar in adductor muscles 
of Irf3-/-, Irf7-/- and C57BL/6 mice in both the individual left ischemic and right non-
ischemic muscle, indicating no differences in the number of pre-existing collaterals 
(figure S1e-f ). In conclusion, these results suggest an important role for IRF3 and IRF7 
in arteriogenesis.
Figure 4. Macrophages around arterioles. An immunohistochemical double staining was performed 
on adductor muscles of Irf3-/-, Irf7-/- and C57BL/6 mice sacrificed 28 days after HLI. aSMActin (pink) 
was used to show the arterioles and MAC3 (green) to show the macrophages around the collaterals. 
Representative images of the left ischemic adductor muscle of a. C57BL/6 mice, b. Irf3-/- mice and c. 
Irf7-/- mice stained with aSMActin and MAC3 is shown (1cm=100μm) and a zoom in of the arterioles 
of the concerned d. C57BL/6 mice, e. Irf3-/- mice, f. Irf7-/- mice adductor muscle is shown (1cm=10µm). 
g. Ratio (left ischemic/right non-ischemic) of the number of macrophages per μm circumference 
of arterioles in the adductor muscle is shown h. Number of macrophages per μm circumference 
of arterioles in the left ischemic adductor muscle is shown i. Number of macrophages per μm 
circumference of arterioles in the right non-ischemic adductor muscle is shown. Data is presented 
as mean SEM; * p<0.05; ** p<0.01, Mann-Whitney test was used. C57BL/6 n=5, Irf3-/- n=7, Irf7-/- n=7.
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Perivascular accumulation of inflammatory cells.
Perivascular inflammation was demonstrated by the number of macrophages around 
the arterioles. An immunohistochemical double staining was performed on adductor 
muscles of Irf3-/-, Irf7-/- and C57BL/6 mice sacrificed 28 days after HLI. aSMActin 
was used to show the arterioles and MAC3 to show the macrophages around the 
collaterals (figure 4a-f and S2). The number of macrophages per μm circumference, 
expressed as left ischemic/right non-ischemic, in the adductor muscle of Irf3-/- mice 
(P=.003) and Irf7-/- mice (P=.003) compared to C57BL/6 mice 28 days after surgery was 
decreased (figure 4g). The number of macrophages per μm circumference in the left 
ischemic adductor muscle was also significantly decreased in both Irf3-/- (P=.002) and 
Irf7-/- (P=.005) mice compared to C57BL/6 mice (figure 4h). In the right non-ischemic 
adductor muscle, Irf3-/- and Irf7-/- mice showed no differences in macrophages per μm 
circumference compared to C57BL/6 mice. (figure 4i). 
mRNA expression of essential genes for arteriogenesis and angiogenesis 
RNA from the gastrocnemius muscles was isolated and the mRNA expression of tnfα, 
ccl2, il6, il1β, sdf1, vegf164, vegfr1 and vegfr2 was measured with qPCR as genes 
essential for angiogenesis and arteriogenesis. The relative mRNA expression of 
Figure 5. mRNA expression of essential genes for arteriogenesis and angiogenesis. RNA was isolated 
of gastrocnemius muscles of Irf3-/-, Irf7-/- and C57BL/6 mice sacrificed 28 days after HLI, and used 
for RT-qPCR analysis. Relative mRNA expression is shown of a. tnfα, b. ccl2, c. il6, d. il1β, e. sdf1, f. 
vegf164, g. vegfr1, and h. vegr2. Relative expression of mRNA is shown to GAPDH of the left ischemic 
gastrocnemius muscle . Data is presented as mean SEM; * p<0.05; ** p<0.01, a 1-way ANOVA and a 
Kruskal-Wallis test was used. n=5-8.
136
inflammatory cytokines tnfα, ccl2 and il6 was decreased in left ischemic gastrocnemius 
muscles of Irf3-/- and Irf7-/- mice compared to C57BL/6 mice (figure 5a-c). Il1β and 
sdf1 were not differentially expressed in gastrocnemius muscles of Irf3-/-, Irf7-/- and 
C57BL/6 mice (figure 5d-e). However, VEGF and the first receptor (VEGFR1) showed 
a trend towards a down regulation in gastrocnemius muscles of Irf3-/- and Irf7-/- mice 
compared to C57BL/6 mice (figure 5f-g). Interestingly, the mRNA expression levels 
of the second receptor (VEGFR2) were decreased in the left ischemic gastrocnemius 
muscles of Irf3-/- and Irf7-/- mice compared to C57BL/6 mice (figure 5h). No differences 
were observed in the mRNA expression of tnfα, ccl2, il6, il1β, sdf1, vegf164, vegfr1 
and vegfr2 in the right non-ischemic gastrocnemius muscles of Irf3-/- and Irf7-/- mice 
compared to control mice (figure S3). These results demonstrate that IRF3 and IRF7 
regulate the expression of several genes essential for angiogenesis and arteriogenesis. 
Discussion
In the present study we observed a decreased post-ischemic blood flow recovery in 
Irf3-/- and Irf7-/- mice compared to C57BL/6 mice using a HLI model. This was supported 
by a decrease in angiogenesis and arteriogenesis in respectively soleus and adductor 
muscles of the Irf3-/- and Irf7-/- mice. Furthermore, mRNA expression levels of several 
pro-inflammatory cytokines (tnfα, il6, ccl2) and growth factor receptor (vegfr2) that 
are essential for the induction of angiogenesis and arteriogenesis, were decreased 
in the gastrocnemius muscles of Irf3-/- and Irf7-/- mice. This indicates a decreased 
post-ischemic blood flow recovery caused by an impairment in angiogenesis and 
arteriogenesis due to lack of inflammatory components in the ischemic tissue.
Angiogenesis provides a better distribution of blood to ischemic tissue. Since we 
observed a decreased post-ischemic blood flow recovery in the paw of Irf3-/- and 
Irf7-/- mice compared to C57BL/6 mice, we hypothesised attenuated angiogenesis 
in soleus muscles of Irf3-/- and Irf7-/- mice. This was confirmed when we measured a 
reduced angiogenic capillary formation in the soleus muscles of Irf3-/- and Irf7-/- mice 
compared to C57BL/6 mice. The reduced number of capillaries was only observed 
in the left ischemic calf and not in the right non-ischemic calf. This indicates that 
the genetic baseline in all mice was similar and the decreased ischemia-induced 
angiogenesis in the ischemic muscles of Irf3-/- and Irf7-/- mice was purely based on the 
effects of IRF3 and IRF7. 
137
4
Previously, a role of IRF3 and IRF7 in angiogenesis was indicated. A phenotypic 
genome-wide screening performed on human umbilical vein endothelial cell by 
Korherr et al. identified factors that induce angiogenesis. Amongst these factors was 
well-known factor VEGF as well as TRIF, kinase TBK1 and IRF3 28. This indicates that the 
TRIF/TBK/IRF3 pathway has angiogenic properties. In addition, IRF7 is also involved 
in angiogenesis since Jin et al also showed that IRF7 over-expression increased 
tumor formation with increased angiogenesis and cell heterogeneity by inducing 
inflammatory cytokine expression (IL6, CCL2 and CXCL1)29. This latter is in line with 
our results where we show an attenuated inflammatory response in absence of IRF7. 
Since angiogenesis is induced via VEGF, it is interesting that we found a down 
regulation of VEGR2 in the ischemic muscles of IRF3 and IRF7 deficient mice. VEGF can 
bind to VEGR1, VEGFR2 and VEGFR3, but VEGFR2 is the main receptor transmitting 
VEGF signals30. The lack of VEGFR2 in the ischemic tissue can (partly) explain the 
decrease in angiogenesis in IRF3 an IRF7 deficient mice compared to C57BL/6 mice. 
Interestingly, previously a relation between interferons, regulated by IRF3 and IRF7, 
and VEGF was observed. IFNs were able to mediate VEFG production from human 
mast cells31 and also in chronic myeloid leukemia patients, imatinib in combination 
with pegylated-IFN-α2a was able to regulate VEGF levels32. 
Arteriogenesis is induced by inflammation, which results in the maturation of pre-
existing collaterals into arterioles6. For optimal neovascularization and thus post-
ischemic blood flow recovery, both angiogenesis and arteriogenesis are essential21. 
We observed reduced arteriogenesis in the adductor muscles of Irf3-/- and Irf7-
/- mice compared to C57BL/6 mice. The number of arterioles was only increased in 
Irf3-/- mice compared to C57BL/6 mice. However, the diameter of the arterioles was 
significantly decreased in Irf3-/- and Irf7-/- mice compared to C57BL/6 mice, which is 
characteristic for arteriogenesis since this is defined as the maturation of pre-existing 
collaterals21. Interestingly, we showed a decrease in inflammatory cells around the 
arterioles and decreased mRNA expression of inflammatory cytokines tnfα, ccl2 and 
il6 in the gastrocnemius muscles. It is shown that several inflammatory cytokines and 
components are essential in the regulation of arteriogenesis such as TNFα33, as well 
as the CCR7‐CCL19/CCL21 Axis7, NK cells and CD4+ T cells34 and CD27-CD70 T cell 
co-stimulation25. We previously demonstrated that IRF3 regulates pro-inflammatory 
cytokines downstream TLR4 activation in vitro, in VSMCs and macrophages, prominent 
inflammatory cell types involved in arteriogenesis15. Together with the diminished 
inflammatory response observed here, this partly explains how IRF3 and IRF7 affect 
neovascularization.
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The regulation of pro-inflammatory cytokines via IRF3 and IRF7, in general goes via the 
TRIF-NFĸB pathway12, 35. TRIF is also involved in TLR3-mediated type-I IFN production via 
IRF3 and IRF7 activation. It is suggested that activation of TLR3-TRIF can also suppress 
angiogenesis via initiation of apoptotic cell death36-39. The ability of TRIF to induce 
apoptosis however, was not dependent on its ability to activate either IRF3 or NFĸB 
but was dependent on RIP, Fas-associated death domain, caspase-8-dependent and 
mitochondrion-independent pathway and the presence of an intact RIP homotypic 
interaction motif 36, 37. Thereby, it was suggested that TRIF-IRF3-IRF7 pathway activation, 
TRIF-NFĸB pathway activation and apoptosis pathways are uncoupled and this can 
explain the differential functions of TLR3-TRIF in neovascularization. Remarkably, we 
showed a regulation of pro-inflammatory cytokines via IRF3 and IRF7, which indicates 
that there may be a linkage between the TRIF-IRF and TRIF-NFĸB pathways.
After phosphorylation downstream TLR3, IRF3 and IRF7 can produce type-I IFNs, such 
as IFNβ. However, the role of type-I IFNs and IRF3 and IRF7 in neovascularization is 
not identical. Schirmer et al. observed attenuated post-ischemic blood flow recovery 
7 days after HLI in mice treated with type-I IFN, IFNβ40. In addition, blocking IFNβ 
demonstrated to stimulate arteriogenesis via VSMC proliferation41 and Ifnar-/- mice, 
deficient of the IFNβ receptor, improved blood flow recovery 7 days after induction of 
hind limb ischemia. Teunissen et al. observed that Ldlr-/- mice treated with monoclonal 
antibodies blocking IFN-α/β receptor subunit 1 (IFNAR1) improved post-ischemic blood 
flow recovery via augmented arteriogenesis42. These pre-clinical results are seemingly 
in contrast with our results since we show an impaired blood flow recovery after HLI in 
Irf3-/- and Irf7-/- mice. However, IRF3 and IRF7 do not only produce type-I IFNs, such as 
IFNβ, but can also regulate pro-inflammatory cytokine production, as we show in the 
gastrocnemius muscles of Irf3-/- and Irf7-/- mice. As we previously showed, TRIF- NFĸB 
mediated pro-inflammatory cytokines are important regulators of neovascularization9, 
10, 34. In this respect, our results can only be partly explained by the effects of IFNβ and 
their IFNAR receptor. In addition, post-ischemic blood flow recovery was measured in 
the paw of the mice, which was used to determine arteriogenesis. Both angiogenesis 
and arteriogenesis are essential for accurate neovascularization and post-ischemic 
blood flow recovery21. In addition to arteriogenesis, which we determined by measuring 
the diameter of the arterioles in the adductor muscles of the Irf3-/-, Irf7-/- and C57BL/6 
mice, we also measured angiogenesis in the soleus muscles.
The findings of the present study indicate that deficiency of IRF3 and IRF7 results in 
impaired post-ischemic blood flow recovery caused by an attenuated angiogenesis 
and arteriogenesis linked to lack of inflammatory components in ischemic tissue. In 
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Supplemental table and figures
  Control Irf3-/- Irf7-/-
Total number analysed 6 9 7
Sex Male Male Male
Body weight t=0 28.16±0.76 27.01±0.31 28.01±0.34
Body weight t=28 29.15±0.76 27.21±0.28 28.61±0.25
Table S1. Mice characteristics of Irf3-/-, Irf7-/- and control mice. Total number of analysed mice is shown 
(n=), as well as sex (male or female), body weight at day of the surgery (t=0) and at sacrifice (t=28). 
Body weight is shown as mean±SEM. Body weight at t=0 and t=28 was not significantly different in 
the Irf3-/- and Irf7-/- mice compared to control mice.
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Figure S1. Arteriogenesis in aSMActin stained adductor muscles. a. Representative image of the left 
ischemic adductor muscle of control mice sacrificed 28 days after surgery, stained with aSMActin (20x 
magnification) and b. zoom in (40x magnification) with an arrow showing the way of measuring the 
diameter from outer membrane till outer membrane. c. αASMActin positive arterioles area of the left 
ischemic and d. right (non-ligated leg) adductor muscles is shown (µm2). Number of arterioles of the 
e. left ischemic and f. right non-ischemic adductor muscles stained with aSMActin is shown. Data is 
presented as mean SEM; * p<0.05; ** p<0.01, a 2-tailed Student’s t-test was used. Control n=6, Irf3-
/- and Irf7-/- n=7. 
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Figure S2. Inflammatory macrophages around collateral arterioles. An immunohistochemical double 
staining was performed on adductor muscles of Irf3-/-, Irf7-/- and control mice sacrificed 28 days after 
HLI. SMCA was used to show the collateral arterioles and MAC3 to show the macrophages around the 
collaterals. Representative image of a. an unstained adductor muscle. b. only MAC3 stained adductor 
muscle c. only SMCA stained adductor muscle is shown. (scale bar=50μm). 
Figure S3. mRNA expression of essential genes for arteriogenesis and angiogenesis. RNA was isolated 
of gastrocnemius muscles of Irf3-/-, Irf7-/- and control mice sacrificed 28 days after HLI, and used for RT-
qPCR analysis. Relative mRNA expression is shown of a. tnfα, b. ccl2, c. il6, d. il1β, e. sdf1, f. vegf164, 
g. vegfr1, and h. vegr2. Relative expression of mRNA is shown to GAPDH of the right gastrocnemius 
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T cells have a distinctive role in neovascularization, which consists of arteriogenesis 
and angiogenesis under pathological conditions and vasculogenesis under 
physiological conditions. However, the role of co-stimulation in T cell activation in 
neovascularization has yet to be established. The aim of this study was to investigate 
the role T cell co-stimulation and inhibition in angiogenesis, arteriogenesis and 
vasculogenesis. 
Methods and Results 
Hind limb ischemia was induced by double ligation of the left femoral artery in 
mice and blood flow recovery was measured with Laser Doppler Perfusion Imaging 
in control, CD70-/-, CD80/86-/-, CD70/80/86-/- and CTLA4+/- mice. Blood flow recovery 
was significantly impaired in mice lacking CD70 compared to control mice, but was 
similar in CD80/86-/-, CTLA4+/- and control mice. Mice lacking CD70 showed impaired 
vasculogenesis, since the number of pre-existing collaterals was reduced as observed 
in the pia mater compared to control mice. In vitro an impaired capability of vascular 
smooth muscle cells (VSMC) to activate T cells was observed in VSMC lacking 
CD70. Furthermore, CD70-/-, CD80/86-/- and CD70/80/86-/- mice showed reduced 
angiogenesis in the soleus muscle 10 days after ligation. Arteriogenesis was also 
decreased in CD70-/- compared to control mice 10 and 28 days after surgery. 
Conclusions 
The present study is the first to describe an important role for T cell activation via 
co-stimulation in angiogenesis, arteriogenesis and vasculogenesis, where the CD27-
CD70 T cell co-stimulation pathway appears to be the most important co-stimulation 
pathway in pre-existing collateral formation and post-ischemic blood flow recovery, 




Peripheral arterial disease (PAD) is characterized by the formation of atherosclerotic 
plaques in lower extremities and is a major cause of morbidity and mortality1, 2. The 
body can restore the blood flow to ischemic tissues by initiating neovascularization, 
which is a similar mechanism that occurs in patients after myocardial infarction. 
Neovascularization consists of angiogenesis and arteriogenesis under pathological 
conditions, such as PAD or myocardial infarction, and vasculogenesis under 
physiological conditions. Angiogenesis is the process of sprouting of new capillaries 
from pre-existing microvasculature, which is due to hypoxia and occurs mainly far 
distal to the occlusion3. Arteriogenesis initiates by inflammation, shear stress and 
circumferential stretch on the vascular wall, which causes inactive pre-existing 
arterioles, formed by vasculogenesis, to mature into functional collateral arteries, 
which occurs mainly nearby the occlusion4, 5,6. Vasculogenesis is the formation of 
new blood vessels during embryogenesis through differentiation of angioblasts into 
endothelial cells followed by the recruitment of vascular smooth muscle cells (VSMC), 
which can shape new blood vessels7. In PAD patients, for collateral artery formation a 
proper vascular bed of pre-existing arterioles is essential. These pre-exiting arterioles 
are formed by vasculogenesis. Therefore, this is an important process in PAD. The 
maturation of pre-existing collateral arteries by arteriogenesis, together with the 
angiogenetic sprouting of new capillaries, can restore blood flow towards ischemic 
tissues8, 9. 
We and others have shown a specific role of CD4+ T cells in arteriogenesis by 
using a hind limb ischemia (HLI) model10, 11. CD4+ T cells have the capacity to 
attract macrophages and monocytes to the site of occlusion, which in turn triggers 
arteriogenesis through the release of inflammatory cytokines. Various studies showed 
increased release of VEGF by hypoxic cells triggered through inflammatory cytokines, 
indicating a possible role of CD4+ T cells in angiogenesis as well12, 13. CD8+ T cells 
also contribute to the early phase of arteriogenesis and recruit CD4+ mononuclear 
cells through the expression of IL-1614. Others also suggest a role for CD8+ T cells in 
angiogenesis15. A previous study further showed that T cells play an important role 
in vasculogenesis16. However, it is still unknown what the activation mechanism of T 
cells in vasculogenesis, angiogenesis and arteriogenesis is.
For T cell activation, different T cell co-stimulation and inhibitory pathways are 
described. Co-stimulatory molecules of the B7 family, such as CD80 and CD86, were 
the first described and are the most well-known and studied molecules17. CD28 is a 
co-stimulation receptor expressed constitutively on the cell-surface of T cells, which 
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interacts with both CD80/CD86 proteins present on antigen presenting cells (APC)18 
and promotes T cell activation and proliferation 19. As a counteracting system, CTLA4 
is an inhibitory receptor on T cells, which down regulates the immune response 
by binding to CD80/86 with a higher affinity than CD2817. CD27 is a second co-
stimulation receptor located constitutively on the surface of T cells, which interacts 
with CD70 proteins on APC to activate T cell20. In contrast to their receptors, co-
stimulatory ligands CD80, CD86, and CD70 are transiently up regulated upon 
activation. The signaling pathway of CD27 in T cells is different compared to CD28 
and CD27 promotes T cell survival via up regulation of anti-apoptotic factors21, 22. 
The CD28-CD80/86 T cell co-stimulation pathway and CD28-CTLA4 T cell inhibitory 
pathway were shown to regulate the development of both native atherosclerosis23, 
24 as well as post-interventional accelerated atherosclerosis25. But this pathway was 
also shown to be involved in other vascular diseases26, graft arterial disease27,28,29 
and inflammatory diseases such as rheumatoid arthritis30. The CD27-CD70 T cell co-
stimulation pathway is less investigated, however, immune activation via the CD27-
CD70 T cell co-stimulation pathway showed to protect against atherosclerosis31. 
In the current study we aimed to elucidate the role of the CD27-CD70 and CD28-
CD80/86 T cell co-stimulation pathway, and CD28-CTLA4 T cell inhibitory pathway 
in post-ischaemic neovascularization and vasculogenesis. By visualising pre-existing 
collaterals in the pia mater of CD70-/-, CD80/86-/- and CD70/80/86-/- mice we observed 
a particular effect of CD27-CD70-mediated T cell co-stimulation on vasculogenesis. 
Furthermore, CD27-CD70-mediated T cell co-stimulation was also important for 
optimal blood flow recovery, angiogenesis and arteriogenesis.
Materials and methods 
Mice 
This study was performed in compliance with Dutch government guidelines and the 
Directive 2010/63/EU of the European Parliament. All experiments were approved by 
the committee on animal welfare of the Leiden University Medical Center (Leiden, the 
Netherlands). For the experiments 10 to 18 week old male mice were used. C57BL/6 
mice were purchased from Harlan Laboratories. CD70-/-32, CD80/86-/- 33 and CTLA4+/- 
mice were bred in house to the obtained C57BL/6 background34. CD70/80/86-/-34 mice 
were generated by crossing CD70−/− with CD80/86−/− mice. Ovalbumin-specific T cell 
receptor (TCR) transgenic OT-I mice35 were obtained from The Jackson Laboratory. 
Mice were fed a chow diet ad libitum. 
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Murine HLI model 
Mice were anesthetized with an intraperitoneal injection of midazolam (8 mg/kg, 
Roche Diagnostics), medetomidine (0.4 mg/kg; Orion), and fentanyl (0.08 mg/kg; 
Janssen Pharmaceuticals). Unilateral HLI was induced by electrocoagulation of the 
left common femoral artery proximal to the superficial epigastric artery and proximal 
to the bifurcation of the popliteal and saphenous artery (double ligation model)36. 
After surgery, anaesthesia was antagonised with flumazenil (0.7 mg/kg, Fresenius 
Kabi). Buprenorphine (0.1 mg/kg, MSD Animal Health) was given after surgery to 
relieve pain in a fixed regime and when circumstances required this was repeated. 
Mice were sacrificed 10 days after surgery (n=46) or 28 days after surgery (n=48) to 
investigate neovascularization in time. 
Laser Doppler perfusion 
Blood flow recovery was measured in the paw of the mice with the use of Laser 
Doppler Perfusion Imaging (LDPI) (Moor Instruments). Blood flow was measured 
before and directly after ligation and at day 3, 7, 10, 13, 21 and 28. Before LDPI, 
mice were anaesthetised with an intraperitoneal injection of midazolam (8 mg/
kg) and medetomidine (0.4 mg/kg). After LDPI, anaesthesia was antagonised by 
subcutaneous injection of flumazenil (0.7mg/kg). Paw perfusion was expressed as a 
ratio of left (ischemic) to right (non-ischemic) paw.
After the last LDPI measurement at day 10 or day 28, analgesic fentanyl (0.08 
mg/kg) was administered subcutaneously and mice were sacrificed via cervical 
dislocation. Blood, lymph nodes, spleen and femur and tibia (to isolate bone marrow 
macrophages) were harvested for FACS analysis. The adductor and soleus muscles 
were harvested for (immuno)histochemical analysis. Adductor muscles were fixed in 
4% formaldehyde and embedded in paraffin, soleus muscles were snap frozen on dry 
ice and stored at -80°C. 
Immunohistochemistry 
Cross sections of 6 μm were made throughout the embedded adductor muscle. 
Adductor muscle sections were stained with alpha smooth muscle cell actin 
(aSMActin, DAKO) to visualize vascular smooth muscle cells (VSMC). Stained slides 
were photographed (20x magnification) with microscope photography software 
(Axiovision, Zeiss) and analysed with ImageJ (FIJI) by counting the number of arterioles 
and measuring the diameters of each arteriole with a visible lumen to determine 
arteriogenesis. Arterioles were divided in two groups; diameter <20 μm2 and >20 μm2. 
Fresh-frozen soleus muscles were cross sectioned in 6 μm slices with a cryostat and 
sections were fixated in acetone. To visualise endothelial cells, soleus muscle sections 
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were stained with CD31 (BD Pharmingen). Stained slides were photographed (20x 
magnification) with microscope photography software. The number of endothelial 
cells was quantified with ImageJ, which was used to determine angiogenesis levels. 
Immunofluorescent double staining was performed to identify the presence of T cells 
in close proximity of capillaries in the soleus muscle. Soleus muscle samples were 
stained for CD31 (Abcam) and CD3 (AbD Serotec). Slides were covered with Invitrogen 
Diamond Antifade Mountant (Invitrogen) with 4’,6-diamidino-2-phenylindole (DAPI). 
Pre-existing collateral density in pial circulation 
Pre-existing collateral density was determined in pial circulation of the pia mater. 
Pre-existing collateral density in the cerebral pial circulation is representative for 
collateral density in skeletal muscle37. Mice were anesthetized with midazolam (8 
mg/kg), medetomidine (0.4 mg/kg) and fentanyl (0.08 mg/kg) via intraperitoneal 
injection and heparinized via intramuscular injection, after onset of anaesthesia. The 
thoracic aorta was cannulated retrograde and the circulation was maximally dilated 
by perfusion with sodium-nitroprusside (30 μg/ml) and papaverine (40 μg/ml) in 
PBS at approximately 100 mm Hg prior to vascular casting. After craniotomy Yellow 
Microfil (Flow Tech Inc.) was infused under a stereomicroscope. The dorsal cerebral 
circulation was fixed with topical application of 4% paraformaldehyde (PFA) to 
prevent any degradation in vessel dimensions after Microfil injection. The brains were 
fixed overnight in 4% PFA and were subsequently incubated in Evans Blue (2 μg/ml 
in 4% PFA) for several days to improve contrast for visualization of the vasculature. 
Digital images were acquired of the dorsal brain surface and processed with ImageJ 
software (NIH). Collateral density was calculated by counting the total number of 
pial collaterals between the anterior cerebral artery (ACA)-middle cerebral artery 
(MCA) and MCA-posterior cerebral artery (PCA) as described elsewhere38-41 divided 
by the dorsal surface area of the cerebral hemispheres. Hemispheres that sustained 
damage, were incompletely filled, or were otherwise uncountable, were excluded 
from analysis. 
Cell culture
VSMCs were acquired by isolating VSMCs from mice aortas. VSMCs were cultured in 
medium containing DMEM Glutamax with 20% FCS (Gibco® by Life Technologies), 
non-essential amino acids (MEM 100x, Gibco® by Thermofisher) and 100 U/mL 
Penicillin/streptomycin (Gibco® by Life Technologies). T cells were isolated from the 
spleens of OT-I mice. In total 50.000 VSMCs per well in a 24-wells plate were added 
with SIINFEKL peptide(0.3ug/ml, the CD8 OT-I T cell epitope of chicken ovalbumin) 
for 4 hours, after which 250.000 OT-I T cells were added and cells were stimulated 
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with 100ng/ml Lipopolysaccharide from Escherichia coli K-235 (LPS) purchased from 
Sigma-Aldrich (MO). Supernatant was removed after 24 hours after which IFN-ɣ 
concentrations were measured using ELISA assays (BD Biosciences).
Flow cytometry
Flow cytometry was performed on spleen, lymph nodes, bone marrow macrophages 
(BMM) and blood of 6 mice per group sacrificed after 10 and 28 days. BMM were 
acquired by isolating monocytes from femur and tibia bone marrow. Single-cell 
suspensions were prepared from spleens, lymph nodes and BMM by mincing the 
tissue through a 70 um cell strainer (BD Biosciences). Cells were washed with 10 ml 
IMDM Glutamax with 8% FCS and 100 U/mL Penicillin/streptomycin. Erythrocytes 
were lysed in red blood cell lysis buffer (hypotonic ammonium chloride buffer). 
Conjugated monoclonal antibodies to mouse CD3 (V500), CD62L (Allophycocyanin 
[APC]), CD8 (Alexa Fluor 700), KLRG1 (PE-Cy7), CD4 (Brilliant Violet 605/Qdol605) 
were purchased from eBioscience or BD Biosciences. Dead cells were excluded by 
positivity for 7-aminoactinomycinD (7-AAD) (Invitrogen). Flow cytometric acquisition 
was performed on a BD LSR II flow cytometer (BD Biosciences). Data were analysed 
using FlowJo V10.1 software.
Statistical analysis 
All data are presented as mean SEM. In statistics software GraphPad Prism 7.0, 
statistical analyses on parametric data were performed by using a 2-tailed Student’s 
t-test to compare individual groups, Mann-Whitney test was used for nonparametric 
data. A 1-way ANOVA was performed on parametric data comparing more than 2 
groups and a Kruskal-Wallis test was performed on nonparametric data. P value of 
<0.05 was considered significant.
Results 
Differential impact of co-stimulation pathways on T cell activation in lymphoid 
organs and blood. Initially, we determined if co-stimulation has a differential impact 
in lymphoid organs and blood, by analyzing the T cell activation levels in blood, bone 
marrow, lymph node and spleen of control CD80/86-/-, CD70-/-, CD70/80/86-/- and 
CTLA4+/- mice. The phenotypical markers KLRG1+ CD62L- were used to determine 
the percentage of activated CD4+ or CD8+ T cells in each compartment. CD4+ and 
CD8+ T cell activation in bone marrow, lymph node and spleen of CD80/86-/- and 
CD70/80/86-/- mice was significantly decreased. In CD70-/- mice, CD4+ T cells in the 
bone marrow and CD8+ T cells in the lymph nodes and spleen showed significantly 
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decreased T cell activation compared to control (figure S1 and S2), indicating a more 
important role of the CD28-CD80/86 co-stimulation pathway compared to the CD27-
CD70 co-stimulation pathway in lymphoid organs. This was also demonstrated by a 
trend towards increased T cell activation in lymphoid organs, blood and bone marrow 
in both CD4+ and CD8+ T cells of CTLA4+/- mice compared to control mice. However, 
CD80/86-/-, CD70-/- and CD70/80/86-/-, all showed no difference on T cell activation 
in blood. Together, these results demonstrate a differential effect of co-stimulatory 
pathways on T cell activation in bone marrow and lymphoid organs compared to the 
blood circulation.
Impact of CD27-CD70-mediated T cell co-stimulation on post-ischaemic 
blood flow recovery.
The above descibed results confirm that co-stimulatory pathways have distinct 
effects in lymphoid organs and blood, but whether such differential effects also 
occur in peripheral (non-lymphoid) tissues such as blood vessels or the formation 
thereof remains to be elucidated. Here we aimed to address the (differential) role 
of co-stimulation in neovascularization. First, we studied post-ischaemic blood flow 
recovery by analysing paw perfusion in control, CD80/86-/-, CD70-/-, CD70/80/86-/- and 
CTLA-4+/- mice before ligation of the femoral artery and serially after surgery until 
sacrifice of the mice after 28 days. Paw perfusion was decreased directly after surgery 
and control mice showed 74% blood flow recovery in 28 days after surgery with a 
small drop in recovery between 7 and 13 days (figure 1a). CD80/86-/- and CTLA4+/- mice 
showed a similar blood flow recovery pattern in the paw as control mice, indicating 
that the CD28-CD80/86 T cell co-stimulation pathway is not a major co-stimulatory 
pathway in blood flow recovery. Blood flow recovery in CD70-/- mice (p=0.03) and 
CD70/80/86-/- (p=0.01) was significantly impaired 28 days after surgery. We observed 
a decreased blood flow recovery in CD70-/- mice in time with significantly lower paw 
perfusion ratios at all time points (except 13 days after surgery) compared to control 
mice. In CD70/80/86-/- mice, blood flow recovery was also impaired in time with lower 
paw perfusion ratios 3 days (p=0.006), 7 days (p=0.002) and 10 days (p=0.004) after 
surgery compared to control mice. With the comparable blood flow recovery of 
control mice and CD80/86-/- mice, and the reduced recovery in CD70-/- mice compared 
to control mice, we conclude that the impaired blood flow recovery of CD70/80/86-/- 
mice is most likely caused by the lack of CD70 co-stimulation.
Since paw perfusion was rapidly recovering in the first 10 days after surgery (figure 
1a), we performed a second paw perfusion experiment in which the mice were 
sacrificed 10 days after surgery. Blood flow recovery in CD80/86-/- and CTLA-4+/- 
mice was comparable to control mice (figure 1b). However, CD70-/- mice showed 
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Figure 1. Blood flow recovery after induction of hind limb ischemia. a. Paw perfusion was measured 
before and after surgery and 3, 7, 10, 13, 21 and 28 days after surgery. Control mice (n=11, light blue), 
CD80/86-/- mice (n=11, green), CD70-/- mice (n=7, orange), CD70/80/86-/- mice (n=8, red) and in CTLA-
4+/- mice (n=11, dark blue) were sacrificed after 28 days. b. Paw perfusion was measured before and 
after surgery and 3, 7 and 10 days after surgery. Control mice (n=9), CD80/86-/- mice (n=10), CD70-
/- mice (n=11), CD70/80/86-/- mice (n=10) and in CTLA-4+/- mice (n=6) were sacrificed after 10 days. 
Paw perfusion is expressed as a ratio of left (ischemic) to right (non-ischemic) paw perfusion. Data is 
presented as mean SEM; * p<0.05; ** p<0.01.
156
significantly impaired blood flow recovery after 3 days (p=0.002), 7 days (p=0.04) and 
10 days (p=0.01) compared to control mice. CD70/80/86-/- mice also showed impaired 
blood flow recovery after 3 days (p=0.0095), 7 days (p=0.003) and 10 days (p=0.002) 
after surgery compared to control mice. This confirms that the CD27-CD70 T cell co-
stimulation pathway has an important role in blood flow recovery.
Pre-existing collateral formation is affected by CD27-CD70 T cell  
co-stimulation. 
To determine if T cell co-stimulation affects collateral vasculogenesis, pre-existing 
collateral density was determined in pial circulation of the pia mater of CD70-/-, 
CD80/86-/-, CD70/80/86-/- and control mice. CD80/86-/- mice showed a similar pre-
existing collateral density compared to control mice (figure 2a). However, compared 
to control mice a decrease in pre-existing collateral density was observed in CD70-
/- (p=0.04) and CD70/80/86-/- mice (p=0.04) (figure 2b). This decreased formation of 
pre-existing collaterals, indicates an important role for the CD27-CD70 T cell co-
stimulation pathway in vasculogenesis and collateral development. 
T cell activation via vascular smooth muscle cells is mediated by  
CD27-CD70 T cell co-stimulation. 
VSMC are essential in vascular remodeling and may also act as APCs in T cell 
activation. To determine the role of VSMC co-stimulation in vitro, we used control, 
CD80/86-/-, CD70-/- and CD70/80/86-/- VSMC. We added OT-I T cells (recognizing the 
MHC class I SIINFEKL epitope of chicken ovalbumin) and LPS and measured the IFNy 
concentration in the supernatant, as measure of T cell activation, after 24 hours. CD70-
/- (p=0.002) and CD70/80/86-/- (p=0.001) VSMCs showed a decreased T cell activation 
since the IFNy concentration in the supernatant was significantly lower compared to 
control VSMCs (figure S3). CD80/86-/- VSMC showed no differences in T cell activation 
compared to control VSMC. Indicating that the CD27-CD70 pathway, rather than the 
CD28-CD80/86 pathway, might play an important role in T cell activation via VSMCs.
Decreased angiogenesis in soleus muscles of CD70-/- mice.
To demonstrate the presence of T cells in the proximity of capillaries in soleus 
muscles, a double staining was performed for CD31 and CD3 in soleus muscles of 
mice sacrificed at 28 days after HLI. We here show the presence of T cells (CD3+ cells) 
in the soleus muscle around the capillaries (CD31+ cells), suggesting a contribution of 
T cells in angiogenesis (figure 3a). Angiogenetic capillary formation was determined 
by measuring the number of CD31 positive cells in soleus muscles (typical example of 
CD31 IHC staining shown in figure 3b). In mice lacking either CD70 (p=0.04), CD80/86 
(p=0.02) or both (p=0.008), angiogenesis was significantly decreased compared 
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to control mice 10 days after surgery. CTLA4+/- mice did not show differences in 
angiogenesis (figure 3c). In CD70-/- mice, angiogenesis was still impaired after 28 
days (p=0.04) compared to control mice, but CD80/86-/-, CD70/80/86-/- and CTLA-
4+/- mice showed no difference compared to control mice after 28 days (figure 
3d). Comparison of angiogenetic capillary formation after 10 and 28 days showed 
increased angiogenesis in CD80/86-/- (p=0.04), CD70/80/86-/- (p=0.0005) and CTLA-
4+/- (p=0.03) mice in time and angiogenesis levels and showed no longer differences 
compared to control mice after 28 days, where angiogenesis in CD70-/- mice did not 
increase in time (figure 3e). These results suggest an important role for the CD27-
CD70 T cell co-stimulation pathway in angiogenesis.
Figure 2. Pre-existing collateral density in pial circulation. a. Representative image of pre-existing 
collaterals indicated by white stars (*) in pial circulation in control, CD80/86-/-, CD70/80/86-/- and CD70-
/- mice. b. Total number of pre-existing collaterals per mm2 in pial circulation is shown in control mice 
(n=5), CD80/86-/- mice (n=7), CD70-/- mice (n=7), CD70/80/86-/- mice (n=5). Data are calculated as mean 
SEM; * p<0.05. 
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Decreased arteriogenesis in adductor muscles of CD70-/- mice.
Arteriogenesis was determined by counting the number of collateral arterioles 
and measuring the diameter of collateral arterioles of smooth muscle cell 
(aSMActin) stained adductor muscles of mice sacrificed 10 and 28 days 
after surgery (typical example of aSMActin staining is shown in figure 4a) 
and is shown as a ratio of treated compared to untreated adductor muscle. 
Total number of collateral arterioles in the left paw after arterial ligation was 
significantly lower in CD70-/- mice 10 days (p=0.02) and 28 days (p=0.03) after arterial 
ligation compared to control mice (figure 4b and 4c), indicating decreased pre-
existing collaterals in CD70-/- mice. No differences in number of collateral arterioles 
were observed in CD80/86-/-, CD70/80/86-/- and CTLA-4+/- mice compared to control 
mice 10 and 28 days after surgery.
Figure 3. Angiogenesis in soleus muscles. a. Representative image of CD31 (green) and CD3 (magenta) 
immunofluorescent double staining in soleus muscles is shown with DAPI (blue). b. representative 
image of CD31 staining in soleus muscle of a control mice is shown which was used for quantification 
(20x magnification) c. Quantification as L/R (left ischemic/right non-ischemic) ratio of the number of 
CD31 positive cells in soleus muscles is shown in control mice (n=9), CD80/86-/- mice (n=10), CD70-/- 
mice (n=11), CD70/80/86-/- mice (n=10) and CTLA-4+/- mice (n=6) 10 days after surgery, d. and 28 days 
after surgery of control mice (n=11), CD80/86-/- mice (n=11), CD70-/- mice (n=7 ), CD70/80/86-/- mice 
(n=8) and CTLA-4+/- mice (n=11) and in e. both 10 and 28 days after surgery. Data are calculated as the 
ratio of L/R and presented as mean SEM; * p<0.05; ** p<0.01, ***p<0.001. 
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Figure 4. Arteriogenesis in adductor muscles. a. Representative image of αSMActin staining in 
adductor muscle tissue (20x magnification). b. Number of collateral arterioles is shown in the left 
paw 10 days after surgery in control (n=9), CD80/86-/- (n=10), CD70-/- (n=11), CD70/80/86-/- (n=10) 
and in CTLA-4+/- mice (n=6). c. Number of collateral arterioles is shown in the left paw 28 days after 
surgery in control (n=11), CD80/86-/- (n=11), CD70-/- (n=7), CD70/80/86-/- (n=8) and in CTLA-4+/- mice 
(n=11). d. Diameter of αSMActin positive collateral arterioles, presented as L/R (left ischemic/right 
non-ischemic) ratio, is shown 10 days after surgery, e. 28 days after surgery and f. in both 10 and 28 
days after surgery. Data are presented as mean SEM; * p<0.05; ** p<0.01, ***p<0.001.
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Collateral arterioles diameter L/R ratio was significantly increased 10 days after 
surgery in CD70-/- mice (p=0.01) compared to control mice and a trend towards 
an increased diameter of collateral arterioles was observed in CD70/80/86-/- mice 
(p=0.08) compared to control mice. No differences were observed in CD80/86-/- and 
CTLA-4+/- adductor muscles compared to control mice (figure 4d). The collateral 
arterioles were quantified for small (<20um2) and large (>20um2) collaterals 10 days 
after surgery to show an increase in large arterioles. No differences were found in the 
number of small collaterals (figure S4a). We showed more large collaterals (>20um2) 
in CD70-/- mice (p=0.04) compared to control mice (figure S4b). 
Collateral arteriole diameter was significantly increased in CTLA-4+/- mice (p=0.009), 
sacrificed 28 days after surgery (figure 4e). No differences were found in CD70-/-, 
CD80/86-/- and CD70/80/86-/- compared to control mice 28 days after surgery. Numbers 
of small and large collateral arterioles were higher in CTLA-4+/- mice compared to 
control mice (figure S4c and S42d). CD70-/- mice did not show an increased number 
of small or large collateral arterioles 28 days after surgery. Comparison of collateral 
arterioles diameter L/R ratio after 10 and 28 days showed significantly increased 
diameter of collateral arterioles in time in control, CD80/86-/- and CTLA4+/- adductor 
muscles and a decrease in collateral arterioles diameter in CD70-/- adductor muscles. 
CD70/80/86-/- mice showed no difference in collateral arterioles diameter L/R ratio in 
time (figure 4f ). In conclusion, these results suggest an important role for the CD27-
CD70 T cell co-stimulation pathway in arteriogenesis.
Discussion 
The current study demonstrates an important role for the CD27-CD70 T cell co-
stimulation pathway in angiogenesis, arteriogenesis and vasculogenesis. The 
CD28-CD80/86 T cell co-stimulation pathway showed to be of great importance in 
T cell activation in lymphoid organs and bone marrow. Blood flow recovery after 
induction of HLI showed to be significantly impaired in mice lacking CD70, while in 
CD80/86-/- mice andCTLA4+/- mice no effect was observed, which indicates a particular 
important role of the CD27-CD70 T cell co-stimulation pathway in neovascularization. 
CD70 deficiency resulted in impaired vasculogenesis, as the number of pre-existing 
collaterals was reduced in the pia mater. This impaired vasculogenesis also affected 
the skeletal muscle, as the number of pre-existing collaterals was also decreased in 
the adductor muscle of CD70-/- mice, which led to a severely impaired blood flow 
recovery after ischemia. Furthermore, mice lacking CD70 or CD80/86 showed reduced 
angiogenesis in soleus muscles 10 days after ligation. In conclusion, the CD27-
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CD70 T cell co-stimulation pathway showed to be most important in pre-existing 
collateral formation and post-ischemic blood flow recovery, by arteriogenesis and 
angiogenesis.
This conclusion was substantiated by the fact that the CD28-CD80/86 T cell co-
stimulation pathway did not show an effect on either vasculogenesis, arteriogenesis 
or blood flow recovery. CD80/86-/- mice demonstrated a similar number of pre-existing 
collaterals as the control mice and both CD80/86-/- mice and CTLA4+/- mice showed 
the same pattern of blood flow recovery as the control mice after induction of HLI. 
Since we observed no effect of the CD28-CD80/86 T cell co-stimulation pathway on 
blood flow recovery, the effect of CD70/80/86-/- mice on blood flow recovery is most 
likely explained by the lack of CD70 co-stimulation.
Previous studies showed that the CD28-CD80/86 T cell co-stimulation pathway 
and CD28-CTLA4 T cell inhibitory pathway regulate the development of native 
atherosclerosis23, 24 via reduced T cell activation and proliferation and thus decreased 
presence of IFNγ producing T cells, and regulatory T cells. Inhibition of the CD28-
CD80/86 T cell co-stimulation pathway with abatacept showed beneficial effects on 
interventional accelerated atherosclerosis, most likely caused by decreased CD4+ T 
cell activation25. These studies are in contrast with our study since we here describe an 
important role of the CD27-CD70 co-stimulation pathway and not the CD28-CD80/86 
T cell co-stimulation pathway in neovascularization. However, these studies were 
performed in an atherosclerosis model, and not in a HLI model. Furthermore, other T 
cell co-stimulatory and inhibitory pathways such as PD1, OX40, CD40 and 4-1BB also 
showed to be involved in vascular diseases42, although interesting, that is beyond the 
scope of this study. The CD27-CD70 T cell co-stimulation pathway showed beneficial 
effect on atherosclerosis, due to monocytes that were susceptible to apoptosis and 
in that way prevented atherosclerotic plaque formation31. This is line with our study 
where we show a detrimental effect of CD70 deficient mice in neovascularization, 
suggesting a beneficial effect of CD70 in neovascularization in mice without CD70 
deficiency. A particular important role of the CD27-CD70 and not the CD28-CD80/86 T 
cell co-stimulation pathway in our study could be due to the constitutively expression 
of CD27 and CD28 on T cells 18, 43, 44, while CD80, CD86, and CD70 are transiently up 
regulated upon activation on different APCs that contribute to neovascularization 
e.g. VSMCs, endothelial cells, macrophages or dendritic cells. We here showed that 
CD80/CD86 did not influence the VSMC functionality and only lack of CD70 resulted 
in an impaired function of VSMC which can contribute to impaired pre-existing 
collateral formation and arteriogenesis via decreased attraction of inflammatory cells 
via VSMCs. Although CD27 and CD28 are constitutively expressed on resting T cells, 
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CD27 and CD28 expression is lost after differentiation into effector T cells. Transient 
co-stimulation expression on these cell types might lead to differential functions 
of co-stimulation. Furthermore, it is shown previously that CD28 promotes T cell 
proliferation and activation, while CD27 stimulated cell survival. We suggest that 
the differential functions and expression of individual co-stimulation and inhibitory 
pathways might lead to differential effects on neovascularization. 
This study shows that a combination of all aspects of neovascularization is essential 
for post-ischemic blood flow recovery. Neovessel formation may be either de novo via 
vasculogenesis or under pathological conditions via angiogenesis45, 46. Together with 
arteriogenesis, the body can naturally restore a hampered blood flow. In this study, 
impaired angiogenesis, arteriogenesis and vasculogenesis showed all to be involved 
in the impaired blood flow recovery in mice lacking CD70, and only an increase in 
diameter of collateral arterioles was not sufficient to restore blood flow in the paw 
after ligation of the femoral artery. We expected a decrease in pre-existing collaterals 
since we also showed an impairment in the ability to activate T cells in CD70-/- and 
CD70/80/86-/- VSMCs in vitro and VSMCs contribute to the development of the pre-
existing collaterals via VEGF regulation47.
However, with an increase in diameter of collateral arterioles, an increase in post-
ischemic blood flow recovery could be expected. We here show a decreased post-
ischemic blood flow recovery in CD70-/- mice with an increased diameter of collateral 
arterioles in adductor muscles, which is counterintuitive. This could be explained by 
the reduced number of collateral arterioles observed in the adductor muscles of the 
ligated paws in CD70-/ mice which can lead to a higher blood pressure in the present 
collateral arterioles after induction of HLI. This can lead to shear stress and attraction 
of monocytes and macrophages, which can explain the increased diameter of 
collateral arterioles in CD70-/- mice 10 days after surgery. The impaired angiogenesis 
and reduced number of pre-existing collaterals in mice lacking CD70 contributed 
to a reduced blood flow recovery and only an increased diameter of collateral 
arterioles in the CD70 deficient mice could not restore blood flow. This indicates that 
after arterial obstruction, blood flow can only be restored when all components of 
neovascularization including vasculogenesis, angiogenesis and arteriogenesis, are 
fully functional. 
We here described a different function of co-stimulatory pathways in lymphoid 
organs, in the systemic circulation and in peripheral tissues. With an important 
role of the CD28-CD80/86 co-stimulation pathway for T cell activation in lymphoid 
organs and bone marrow, and the CD27-CD70 co-stimulation pathway in peripheral 
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tissues after ischemia is induced. Previous studies also showed opposed systemic 
and peripheral effects of monocytes. An enhanced systemic activation of Ly6Chi 
monocytes, but a reduced infiltration of Ly6Chi monocytes into peripheral muscle 
tissue was shown after HLI in RP105 (a TLR4 homologue) deficient mice, which 
resulted in reduced blood flow recovery in RP105 deficient mice48. Another study 
showed improved post-ischemic blood flow recovery after intravenous infusion of 
T cell pre-stimulated monocytes. Monocytes were circulating in the blood, but not 
present in the vessel wall, suggesting a more systemic effect of T cell pre-stimulated 
monocytes49. Furthermore, after HLI, CD4+ T cells were specifically accumulated in 
adductor muscles regulated via the CCR7‐CCL19/CCL21 axis50. Which can explain our 
opposed systemic and peripheral effects of co-stimulation. 
In conclusion, we here show an important role for T cell activation via co-stimulation 
in angiogenesis, arteriogenesis and vasculogenesis, were the CD27-CD70 T cell co-
stimulation pathway appears to be the most important T cell co-stimulation factor 
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Figure S1. Percentage of KLRG1+ CD62L-, CD4+ or CD8+ T cells. Blood, bone marrow, lymph node 
and spleen were analysed with FACS of control CD80/86-/-, CD70-/-, CD70/80/86-/- and CTLA4+/- mice, 
sacrificed 28 days after surgery. a. CD4+ T cells b. CD8+ T cells. n=3-6. Data is presented as mean SEM; 
*p<0.05, **p<0.01
Figure S2 Percentage of KLRG1+ CD62L-, CD4+ or CD8+ T cells. Blood, bone marrow, lymph node 
and spleen were analysed with FACS of control CD80/86-/-, CD70-/-, CD70/80/86-/- and CTLA4+/- mice, 
sacrificed 10 days after surgery. a. CD4+ T cells b. CD8+ T cells. n=3-6. Data is presented as mean SEM; 
*p<0.05, **p<0.01
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Figure S3. T cell activation via VSMC measured in control, CD80/86/-, CD70-/- and CD70/80/86-/- VSMCs. 
T cells of an OT-I mouse were added to the cultured VSMCs together with Ova and LPS (100ng/ml). 
IFNy (in pg/ml) concentration was measured in supernatant of VSMCs after 24 hours. CD80/86/-, CD70-
/- and CD70/80/86-/- n=4, control n=10. Data are calculated as mean SEM; **p<0.01
Figure S4. Diameter of αSMActin positive collateral arterioles divided in <20 μm2 and >20 μm2. Data 
presented as L/R (left ischemic/right non-ischemic) ratio. a. 10 days after surgery Ischemic/non-
ischemic ratio of number of collateral arterioles < 20 µm2 and b. > 20 µm2 was quantified. c. and also 







The protective role of Toll-like receptor 3 and 
type-I interferons in the pathophysiology of 
vein graft disease. 
K.H. Simons*, M.R. de Vries*, H.A.B Peters, J.W. Jukema, J.F. Hamming, P.H.A. Quax.
Journal of molecular and cellular cardiology. 2018 Aug;121:16-24 




Venous grafts are commonly used as conduits to bypass occluded arteries. 
Unfortunately, patency rates are limited by vein graft disease (VGD). Toll like receptors 
(TLRs) can be activated in vein grafts by endogenous ligands. This study aims to 
investigate the role of TLR3 in VGD.
Methods
Vein graft surgery was performed by donor caval vein interpositioning in the carotid 
artery of recipient Tlr2-/-, Tlr3-/-, Tlr4-/- and control mice. Vein grafts were harvested 
7, 14 and 28d after surgery to perform immunohistochemical analysis. Expression 
of TLR-responsive genes in vein grafts was analysed using a RT2-profiler PCR Array. 
mRNA expression of type-I IFN inducible genes was measured with qPCR in bone 
marrow-derived macrophages (BMM).
Results
TLR2, TLR3 and TLR4 were observed on vein graft endothelial cells, smooth muscle 
cells and macrophages. Tlr3-/- vein grafts demonstrated no differences in vessel wall 
thickening after 7d , but after 14d a 2.0-fold increase (p=0.02) and 28d a 1.8-fold 
increase (p=0.009) compared to control vein grafts was observed, with an increased 
number of macrophages (p=0.002) in the vein graft. Vessel wall thickening in Tlr4-/- 
decreased 0.6-fold (p=0.04) and showed no differences in Tlr2-/- compared to control 
vein grafts. RT2-profiler array revealed a down-regulation of type-I IFN inducible 
genes in Tlr3-/- vein grafts. PolyI:C stimulated BMM of Tlr3-/- mice showed a reduction 
of Ifit1 (p=0.003) and Mx1 (p<0.0001) mRNA compared to control.
Conclusions
We here demonstrate that TLR3 can play a protective role in VGD development, 




Autologous (saphenous) veins are commonly used as conduits for bypass surgery 
in patients with occlusive arterial disease in coronary or femoral arteries 1, 2. 
Unfortunately, patency rates after 10 years are limited due to vein graft disease (VGD) 
1-3. During the surgical procedure, the autologous vein is harvested, in which the 
graft undergoes a period of ischemia, and is prepared for surgical engraftment in the 
arterial circulation. Endothelial cell (EC) damage in the graft already starts when the 
graft is distended to check for leakage. 
Moreover, the use of a surgical mark pen is suggested to damage the outer layers 
of the vein graft4. After engraftment, arterialization of the vein graft starts to adapt 
to the high pressure arterial circulation 1. However, continuing arterialization, via 
smooth muscle cell (SMC) migration and proliferation and an inflammatory cell influx 
e.g. macrophages, can lead to occluded vein grafts. All changes before and after 
engraftment can contribute to vessel wall thickening of the vein graft, leading to 
VGD and poor clinical outcomes 5, 6. 
In the pathophysiological processes of VGD, inflammation is considered to be an 
important accelerating factor. Toll like receptors (TLRs) are part of the innate immune 
system. In humans and mice respectively, 10 and 12 Toll like receptors (TLR) have been 
identified 7, 8. In vein grafts, TLRs are important in the activation of an inflammatory 
response via their recognition of endogenous damage associated molecular patterns 
(DAMPs) 8. DAMPs are up regulated by cell death and tissue injury, which occurs during 
harvesting 9 and surgical preparation 10 of the saphenous vein graft and after placing 
the saphenous vein in the high pressure arterial circulation 6, 11, 12. TLR3 senses dsRNA 
derived from damaged cells 13, 14. Along this line, endogenous ligands for TLR2 and TLR4, 
such as the extracellular matrix component EDA (alternatively spliced domain A of 
Fibronectin), Heat shock protein 60 (HSP60), extracellular matrix protein Biglycan and 
chromatin protein, high-mobility group protein B1 (HMGB1), are abundantly present 
in remodeled vein grafts 15. TLR3, and partly TLR4, signals via a myeloid differentiation 
primary response gene 88 (MyD88)-independent pathway with a central role for the 
adapter TIR-domain-containing adapter-inducing interferon-β (TRIF) and interferon 
regulatory factor (IRF) 3 and IRF7 resulting in induction of type-I interferons (IFNs), 
such as IFNα and IFNβ 16. TLR4 can also signal via the MyD88 pathway, similar to TLR2 
and most other TLRs, which drives the induction of the transcription factor nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFĸB) resulting in induction 
of pro-inflammatory cytokines.
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Multiple TLRs are involved in vascular diseases, TLR4 signaling is involved in VGD and 
accelerated atherosclerosis since genetic TLR4 deficiency and TLR4 gene silencing 
using a short hairpin RNA against TLR4 resulted in a reduction in vessel wall thickening 
in vein grafts 15. TLR2 activation promotes the development of atherogenesis 17, 
and blocking TLR7 and TLR9 with a dual antagonist in vivo showed reduced post 
interventional remodeling 18. Interestingly, TLR3 and downstream signaling factors 
IRF3 and IRF7 have shown beneficial effects in vascular-and other diseases, opposed 
to other TLRs. Reduced neointima formation was shown in a perivascular collar-
induced injury model in a TLR3-dependent manner 19. Previous studies showed a 
protective role of IRF3 and IRF7 in VGD, which are downstream signaling factors of 
TLR3 20. Furthermore, stimulation of TLR3 showed beneficial effects in SLE 21, polyposis 
22, cancer 23, 24 and was essential in Severe Fever with Thrombocytopenia Syndrome 
(SFTS) 25 and T lymphocyte activation after viral infection 26 
With this knowledge we hypothesise that TLR3 might have a protective role in the 
prevention of pathophysiological vascular remodeling. In the current study, we 
investigate the role of TLR3 signaling in VGD, compared to TLR2 and TLR4, in vitro by 
using bone marrow macrophages (BMM) and in vivo in a murine vein graft model, 
using wild type, Tlr3/- , Tlr2-/- and Tlr4-/- mice.
Material and methods
Mice
This study was performed in compliance with Dutch government guidelines and 
the Directive 2010/63/EU of the European Parliament. All animal experiments were 
approved by the animal welfare committee of the Leiden University Medical Center. 
For the experiments 10 to 16 week old mice were used. We performed multiple in vitro 
and in vivo studies in wild type C57BL6/J mice and Tlr3-/- mice (B6.129S1-TLR3tm1Flvr/J) 
purchased from Charles River Laboratories. Tlr2-/- and Tlr4-/- were kindly provided by 
Dr. Akira (Osaka University, Japan). Tlr2-/-, Tlr3-/- and Tlr4-/- mice were backcrossed on a 
C57Bl6/J background. Mice were fed a chow diet ad libitum. 
Vein graft surgery
Vein graft surgery was performed in mice by donor caval vein interpositioning in 
the carotid artery of recipient mice as described before (Supplemental figure S1) 12, 
27. In brief, the right common carotid artery was dissected free from its surrounding 
from the bifurcation at the distal end toward the proximal end. The artery was cut 
in the middle and a cuff placed at the end on both sides. Next, both ends of the 
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artery were everted over the cuffs and ligated with an 8.0 silk ligature. The caval vein 
was harvested and grafted between the two ends of the carotid artery by sleeving 
the ends of the vein over the artery cuff and ligating them together with an 8.0 silk 
suture. All recipient mice received donor caval veins from genetic identical mice. 
C57Bl6/J mice received a donor caval vein from a C57Bl6/J mice, Tlr3-/- mice from a 
Tlr3-/- mice, Tlr2-/- mice from a Tlr2-/- mice and Tlr4-/- mice from a Tlr4-/- mice. At the 
day of the surgery, the caval vein was harvested to show the presence of TLRs in the 
donor vein graft at day 0. After 7 days, 14 days and 28 days mice were sacrificed and 
the vein graft was harvested. Number of total operated mice and deceased mice (†) 
are shown in supplemental table S1, as well as number of thrombotic vein grafts and 
number of analysed vein grafts.
Both before surgery and sacrifice, mice were anesthetized with a combination 
of intraperitoneal injected midazolam (5 mg/kg, Roche), medetomidine (0.5 mg/
kg, Orion) and fentanyl (0.05 mg/kg, Janssen). Buprenorphine (0.1 mg/kg, MSD 
Animal Health) was given after surgery to relieve pain in a fixed regime and when 
circumstances required this was repeated as described before20. 
Histological and immunohistochemical assessment of vein grafts
Vein graft samples were embedded in paraffin and sequential cross sections (5 µm 
thick) were made throughout the embedded vein grafts. To quantify the vessel wall 
thickening, HPS staining was performed using Hematoxylin, Phloxin 0.25%, and 
Saffron 0.3%. Total vessel area and lumen area was measured. Vessel wall thickening 
was defined as the area between lumen and adventitia and determined by subtracting 
the lumen area from the total vessel area (Supplemental figure S2). Antibodies 
directed at smooth muscle cell actin (aSMActin, Sigma), TLR3 (Sigma), TLR2 (Abcam), 
TLR4 (Santa Cruz), MAC-3 (BD Pharmingen) and Fibrin (Y22, Quickzyme) were used for 
immunohistochemical staining. Sirius red staining (Klinipath 80115) was performed 
to quantify the amount of collagen present in the vein grafts. The immuno-positive 
area measured was expressed as a percentage of the vessel wall area. Macrophages 
in vein grafts were scored in 6 consecutive sections per mouse in a semi-quantitative 
manner. 1: < 25 positive cells/section, 2: 25-50 positive cells/section, 3: >50 positive 
cells. Stained slides were photographed using microscope photography software 
(Axiovision; Zeiss) and image analysis software was used to quantify the vein graft 
intimal hyperplasia and composition (Qwin; Leica). 
Fluorescent double staining was performed as described previously 28 to identify 
the presence of TLRs on SMCs, ECs and macrophages. Vein grafts harvested after 28 
days of C57BL6/J mice were stained for either aSMActin, CD31 (Abcam) or MAC-3, in 
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combination with TLR2, TLR3 or TLR4. Slides were covered with Invitrogen Diamond 
Antifade Mountant (Invitrogen) with 4’,6-diamidino-2-phenylindole (DAPI). For each 
antibody isotype-matched antibodies were used as negative controls. Fluorescent 
double and triple staining were acquired with the fluorescent slide scanner 
(3DHistech)
Cell culture
BMM were acquired by isolating monocytes from femur and tibia bone marrow of 
C57BL6/J mice. 5 x 105 Cells were cultured per well of 6-wells FALCON® plates (BD 
Biosciences) with RPMI 1640 medium supplemented with 25% heat-inactivated 
FCS (Gibco® by Life Technologies) and 100 U/mL Penicillin/streptomycin (Gibco® 
by Life Technologies) in the presence of 0.1mg/ml macrophage colony-stimulating 
factor (M-CSF). After seven days, the BMM were seeded and after 24 hours, when 
BMM were fully attached, BMM were stimulated with either TLR2 ligand Pam3Cys-
Ser-(Lys)4 trihydrochloride (Pam3cys) 100ng/ml ( Abcam), TLR3 ligand Polyinosinic-
polycytidylic acid (PolyI:C) 30 μg/ml (InvivoGen) or TLR4 ligand Lipopolysaccharide 
from Escherichia coli K-235 (LPS) 100 ng/ml (Sigma-Aldrich). After 24 hours RNA was 
isolated from stimulated cells using TRIzol® (Ambion® by Life Technologies).
RNA isolation, cDNA synthesis and RT-qPCR from cell cultures
RNA was isolated from BMM and quantified using a NanoDrop 1000 Spectrophotometer 
(Thermo Scientific). cDNA was synthesized using a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). To measure the expression of the type-I IFN 
inducible genes, Ifit (Assay ID, Mm00515153_m1, ThermoFisher), Mx1 (Assay ID, 
Mm00487796_m1, ThermoFisher), Oas2 (Assay ID, Mm00460961_m1, ThermoFisher), 
Irf7 (Assay ID, Mm00516788_m1, ThermoFisher), Irf3 (Assay ID, Mm00516784_m1, 
ThermoFisher), Traf3 (Assay ID, Mm00495752_m1, ThermoFisher), Il6 (Assay ID, 
Mm00446190_m1, ThermoFisher) and Tnf (Assay ID, Mm00443258_m1, ThermoFisher) 
were used. RT-qPCR was performed using TaqMan (ThermoFisher). GAPDH (Applied 
Biosystems) was used as a housekeeping gene. All RT-qPCRs were performed on a 
7500/7500 Fast Real-Time PCR System (Applied Biosystems) and the 2-ΔΔCt method 
was used to analyse the relative changes in gene expression.
RNA isolation, cDNA synthesis and RT-PCR from vein graft tissue
Total RNA was isolated from 10 (20µm thick) paraffin sections of vein grafts 28 
days after surgery. RNA was isolated according to manufacturer’s protocol (FFPE 
RNA isolation kit, Qiagen). FFPE RNA was reverse transcribed using the RT² First 
Strand Kit (SA Biosciences). RNA for single qPCR was reverse transcribed using a 
High-Capacity cDNA Reverse Transcription Kit according to the manufacturer’s 
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protocol. Commercially available TaqMan gene expression assays for hypoxanthine 
phosphoribosyl transferase (HPRT1), and selected genes of interest were used (Applied 
Biosystems). qPCR analysis of 84 type-I IFN responsive genes was performed using a 
RT2 Profiler PCR Array (SA Biosciences) according to the manufacturer’s protocol. The 
complete list of the genes analysed is available at http://www.sabiosciences.com/
rt_pcr_product/HTML/PAMM-016Z.html. Prior to RT2 profiler array, all qPCRs were 
performed on a 7500/7500 Fast Real-Time PCR System. In total we used 6 vein grafts 
per group, 2 pools of 3 vein grafts were analysed. With the average of these two pools, 
the 2-ΔΔCt method was used to analyse the relative changes in gene expression. The 
fold change compared to the control vein graft was measured and shown as more 
than 2 fold up regulation or down regulation of genes. <-2 or <2 indicates that there 
is no up or down regulation measured. To validate our RT2 profiler array data, we 
confirmed several genes with RT-PCR and statistical analysis was performed on RT-
PCR data.
Statistical analysis
All data are presented as mean ± SEM. In statistics software GraphPad Prism 7.0, 
statistical analyses on parametric data were performed by using a 2-tailed Student’s 
t-test to compare individual groups, Mann-Whitney test was used for nonparametric 
data. A 1-way ANOVA was performed on parametric data comparing more than 2 
groups and a Kruskal-Wallis test was performed on nonparametric data. P value of 
<0.05 was considered significant.
Results
TLR2, TLR3 and TLR4 are present in vein grafts on ECs, macrophages and 
SMCs.
Since TLRs have vessel-specific profiles we first evaluated the expression of TLRs in 
native caval veins and 28 day old vein grafts of C57BL6/J mice. Immunohistochemical 
staining of the caval vein did not show TLR2, TLR3 or TLR4 expression in the caval vein 
prior to surgery (Supplemental figure S3). However, TLR2 (figure 1a), TLR3 (figure 1b) 
and TLR4 (figure 1c) were all present in vein grafts 28 days after surgery. TLRs showed 
diffuse expression in the vessel wall on several cell types. To specifically show on 
which cell types TLRs are expressed, fluorescent double staining was performed. TLR2, 
TLR3 and TLR4 were all present on endothelial cells (figure 1d-f, and supplemental 
figure S4). Macrophages also showed expression of TLR2 and TLR4 and pronounced 
expression of TLR3 (figure 1g-i). Clear staining of TLR2, TLR3 and TLR4 was also 
observed on smooth muscle cells (SMC) in the vein grafts (figure 1j-l). In conclusion, 
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Figure 1. Representative photographs of a vein graft of a C57BL6/J mice are shown a. TLR2 staining 
in vein graft, inset; overview of vein graft b. TLR3 staining in vein graft, inset; overview of vein graft. 
c TLR4 staining in vein graft, inset; overview of vein graft d. Double staining of TLR2 (in green) and 
endothelial cells (in red) in vein graft, inset; overview of vein graft. e. Double staining of TLR3 (in green) 
and endothelial cells (in red) in vein graft, inset; overview of vein graft. f. Double staining of TLR4 (in 
green) and endothelial cells (in red) in vein graft, inset; overview of vein graft. g. Double staining of 
TLR2 (in green) and macrophages (in magenta) in vein graft, inset; overview of vein graft. h. Double 
staining of TLR3 (in green) and macrophages (in magenta) in vein graft, inset; overview of vein graft. 
i. Double staining of TLR4 (in green) and macrophages (in magenta) in vein graft, inset; overview of 
vein graft. j. Double staining of TLR2 (in green) and vascular smooth muscle cells (in orange) in vein 
graft, inset; overview of vein graft. k. Double staining of TLR3 (in green) and vascular smooth muscle 
cells (in orange) in vein graft, inset; overview of vein graft. l. Double staining of TLR4 (in green) and 
vascular smooth muscle cells (in orange) in vein graft, inset; overview of vein graft. Vein graft zoom in 
40x magnification, inset: vein graft overview 5x magnification.
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TLR2, TLR3 and TLR4 are all present in vein grafts and expressed on ECs, macrophages 
and SMCs in vein grafts, which make TLRs interesting to investigate in VGD.
A protective role for TLR3 in the development of VGD.
To determine the effect of TLR3 on the total vessel area, vessel wall thickening and 
lumen area, vein grafts of Tlr3-/ mice were compared with vein grafts of control mice. 
Vein grafts of Tlr2-/- and Tlr4-/- mice were also compared with vein grafts of control 
mice. Vessel wall thickening of Tlr2-/-, Tlr3-/- and Tlr4-/- vein grafts increased over 
time after surgery (figure 2a and Supplemental figure S5a), with a remarkably high 
increase of the vessel wall thickening of Tlr3-/- vein grafts in time. After 7 days Tlr3-
/ vein grafts showed no differences in vessel wall thickening compared to control 
vein grafts (figure 2a), but both Tlr2-/- and Tlr4-/- vein grafts had a significantly 1.4 fold 
increased vessel wall thickening compared to control vein grafts (p=0.02). Tlr3-/ vein 
grafts showed no differences in lumen area compared to control vein grafts (figure 
2b and Supplemental figure S5b), but the total vessel wall area was significantly 1.6 
fold increased in Tlr3-/- vein grafts compared to control vein grafts (p=0.03) (figure 2c 
and Supplemental figure S5c). 
Interestingly, after 14 days Tlr3-/- vein grafts showed a significantly 2.0 fold increased 
vessel wall thickening compared to control vein grafts (p=0.02). In addition, Tlr3-/- vein 
grafts kept increasing in size over time and after 28 days the vessel wall thickening 
was significantly 1.8 fold increased in Tlr3-/- vein grafts (p=0.009) compared to control 
vein grafts (figure 2d). Furthermore, total vessel wall area was 1.6 fold increased 
In Tlr3-/- vein grafts compared to control vein grafts. In contrast, the vessel wall 
thickening in Tlr4-/- vein grafts (p=0.04) decreased 0.6 fold compared to control vein 
grafts. Tlr2-/- vein grafts showed no differences in vessel wall thickening 28 days after 
surgery compared to control vein grafts. Thus, here we show an increased vessel 
wall thickening in Tlr3-/- vein grafts, indicating that there might be an underlying 
protective role of TLR3 in VGD.
Increased numbers of macrophages in vein grafts of Tlr3-/- mice. 
To investigate differences in the composition of vein grafts, we compared vein grafts 
of control and Tlr3-/- mice in time. In vein grafts sacrificed after 7 days, Tlr3-/- vein grafts 
showed no differences in macrophages score, SMCs, collagen and fibrin compared 
to control vein grafts (figure 3a-d). Fibrin was analysed after 7 days since fibrin 
attaches to the vessel wall in the first stages after vein graft surgery. After 14 days, we 
previously showed that Tlr3-/- vein grafts showed an increased vessel wall thickening 
(figure 2a), however, no differences in macrophage score or SMCs were observed 
(figure 3e-f ). An increased collagen area was observed in Tlr3-/- vein grafts compared 
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to control vein grafts, indicating stable lesions in the vein grafts (figure 3g). After 28 
days, Tlr3-/- vein grafts showed a 1.5 fold increased number of macrophages (p=0.002) 
(figure 3h) compared to control vein grafts. The SMC area (figure 3i) and collagen 
area (figure 3j) were similar in Tlr3-/- vein grafts compared to control vein grafts. In 
Tlr2-/- vein grafts, only an increased collagen area was observed 7 days after surgery 
compared to control vein grafts (Supplemental figure S6). In Tlr4-/- vein grafts also an 
increased collagen area was observed 7 days after surgery (Supplemental figure S7) 
compared to control vein grafts. In time, no other differences in graft composition of 
Figure 2.a Vessel wall thickening (mm2) in vein grafts 7, 14 and 28 days after surgery (t=7, t=14 and 
t=28 respectively) of Tlr2-/- (orange), Tlr3-/ -(magenta), Tlr4-/- (blue) and control (green) mice. b. Lumen 
area (mm2) c. Total vessel area (mm2). d. Representative photographs of HPS stained vein grafts 28 
days after surgery are shown. From left to right; control, Tlr2-/-, Tlr3-/- and Tlr4-/- vein grafts are shown. 
Vein graft zoom in 20x magnification. Statistical analyses were performed by using 1-way ANOVA. 
*p<0.05, **p<0.01, ***p<0.001. 6-8 vein graft sections were analysed per mice. See detailed analysed 
number of mice per group in table S1.
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Tlr2-/- or Tlr4-/- vein grafts compared to control vein grafts were observed. 
In conclusion, we here show a macrophage accumulation in Tlr3-/- vein grafts 28 days 
after surgery, which can explain the observed differences in vessel wall thickening 
compared to control vein grafts 28 days after surgery. 
Type I interferon response genes involved in outward vein graft 
remodeling downstream TLR3
We hypothesized that the vessel wall thickening in the Tlr3-/- vein grafts was the result 
of type I interferon (inducible) gene expression profiles. To test this hypothesis we 
performed a specific RT2 profiler array with 84 type I interferon response genes on 
pools of Tlr3-/-, Tlr2-/-, Tlr4-/- and control vein grafts sacrificed 28 days after surgery. 
A low number of genes were found to be up regulated in various vein grafts of 
knockout mice (figure 4a). Tlr3-/- vein grafts showed a 17.4 fold up regulation of H2-
M10.1, known as the mouse major histocompatibility complex (Mhc). Interestingly, 
Myd88 was also 4.0 fold up regulated in Tlr3-/- vein grafts. Deficiency of TLR3 in vein 
grafts, resulted in a more then 2 fold down regulation of specific type-I IFN inducible 
genes such as Ifit1, Ifit3 and Isg15, suggesting type-I IFN regulation downstream TLR3 
(figure 4b). Irf7 was also down regulated in Tlr3-/- vein grafts. Remarkably, Tlr4-/- vein 
grafts only showed a decreased expression of Mal, the MyD88-adapter-like 
gene which is required for TLR4 signal transduction.
To assess the effect of TLRs on inflammatory cytokine expression of cytokines that are 
well known to contribute to VGD development, we explored the gene expression of 
Ccl2, TNFα and Il10 in the various vein grafts of knockout mice. mRNA levels of Ccl2 
(figure 4c) and TNFα (figure 4d) were significantly increased in the Tlr3-/- vein grafts 
compared to control vein grafts. Il10 was up regulated to a lesser extent, although 




Type I interferon response genes signal downstream TLR3.
To determine the role of TLRs, and especially TLR3, in the downstream signaling 
pathways of type-I IFNs in BMM, we measured type-I IFN inducible genes, Ifit, 
Mx1,Oas2, Irf7 and Irf3 in Tlr2-/-, Tlr3-/-, Tlr4-/- and control BMM stimulated with either 
Pam3Cys (exogenous TLR2 ligand), PolyI:C (exogenous TLR3 ligand) or LPS (exogenous 
TLR4 ligand). 
In control BMM stimulated with PolyI:C the mRNA expression of Ifit (figure 5a), Mx1 
(figure 5b), Oas2 (figure 5c), Irf7 (Supplemental figure S8a) and Irf3 (Supplemental 
figure S8b) was significantly increased compared PBS stimulated BMM. PolyI:C 
stimulated BMM of Tlr3-/- mice showed a 75% reduction of the mRNA expression 
of Ifit1 (p=0.003) (figure 5d), and a 63% reduction of the mRNA expression of Mx1 
(p<0.0001) (figure 5e). The Oas2 mRNA expression levels were not affected in BMM of 
Tlr3-/- mice compared to control mice (figure 5f ). In addition, in Tlr2-/- and Tlr4-/- BMM 
stimulated with Pam3Cys or LPS, the mRNA expression of Ifit, Mx1 and Oas2 was not 
affected compared to control BMM (Supplemental table S2). Confirming that type-I 
IFN are mainly regulated downstream TLR3.
< Figure 3. Vein grafts of Tlr3-/- and control mice sacrificed 7, 14 and 28 days after surgery were 
stained with antibodies directed at MAC-3 to stain for macrophages and quantified for the number 
of macrophages (expressed as macrophage score; 1: < 25 positive cells/section, 2: 25-50 positive 
cells/section, 3: >50 positive cells) (a.e.h. respectively), and smooth muscle cell actin (aSMActin) 
to stain smooth muscle cells and quantified for the smooth muscle cell (SMC) content (expressed 
in mm2) (b.f.i. respectively). Sirius red staining was performed to quantify the amount of collagen 
present in the vein grafts and expressed as collagen content (expressed in mm2) (c.g.j. respectively) 
d. Antibodies directed at fibrin (Y22) were used to quantify the fibrin content (expressed in mm2) 7 
days after surgery. Representative photographs of control and Tlr3-/- vein grafts stained with MAC-3 
(k. and n.), aSMActin (l. and o.) and Sirius red (m. and p.) are shown. Data is shown as mean ± SEM. 
Statistical analyses was performed by using a 2-tailed Student’s t-test or Mann-Whitney test. *p<0.05, 
**p<0.01, n=6-10 mice per group. 6-8 vein graft sections were analysed per mice.
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Figure 4a. RT2 profiler array of type-I IFNs on pools of TLR deficient vein grafts. Data are expressed as 
fold induction. Genes that are up regulated more than 2-fold in one of the strains are shown in bold. 
<2 indicates that there is no up regulation. b. Genes that are down regulated more than 2-fold are 
shown in bold. <-2 indicates that there is no down regulation. c. mRNA of vein graft of TLR2 (orange), 
TLR3 (magenta) and TLR4 (blue) deficient mice compared to control mice (green) were analysed 
with reverse-transcription real-time PCR normalized to housekeeping genes. Relative expression of 
inflammatory cytokines Ccl2, d. TNFα and e. Il10 are shown. n=12-18 per group. Data is shown as 
mean ± SEM. Statistical analyses was performed by using 1-way ANOVA. *p<0.05, ***p<0.001, **** 
p<0.0001. If p values are not shown, p=not significant.
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Figure 5. Relative type-I IFN mRNA expression of TLR ligand stimulated bone marrow macrophages. 
BMM of control mice were stimulated with 100 ng Pam3Cys, 30 μg/ml PolyI:C or 100 ng/ml LPS or PBS 
for 24 hour after which RNA was harvested for RT-qPCR analysis a. relative mRNA expression of a. Ifit1, 
b. Mx1 and c. Oas2 of control BMM stimulated with Pam3Cys, PolyI:C, LPS or PBS is shown. d. relative 
mRNA expression of Ifit1, e. Mx1 and f. Oas2 of control and Tlr3-/- BMM stimulated with PolyI:C or PBS 
is shown. Data is shown as mean ± SEM. Statistical analyses were performed by using Kruskal-Wallis 
test. *p<0.05, **p<0.01, *** p<0.001, **** p<0.0001. n=3 per group
To show the role of TLRs, and especially TLR2 and 4, in the downstream signaling 
pathways of pro-inflammatory cytokines in BMM, the mRNA expression of Il6, Tnf 
and Traf3 were measured (Supplemental figure S8c-e). In stimulated BMM, an up 
regulation of Il6 was shown after stimulation with Pam3Cys and LPS, compared to 
PBS stimulation. Tnf and Traf3 were up regulated in LPS stimulated BMM compared to 
PBS stimulated BMM, but also in PolyI:C stimulated BMM. 
Discussion
The current study describes a protective role of TLR3 in the development of VGD and 
we show regulation of type-I IFNs via TLR3. TLR2, TLR3 and TLR4 were present in vein 
grafts on ECs, SMCs and macrophages. Tlr3-/- vein grafts showed increased vessel 
wall thickening 14 and 28 days after surgery compared to control vein grafts. This 
was accompanied by an increased amount of macrophages in Tlr3-/- vein grafts. We 
observed a regulation of mRNA expression of type-I IFN regulated genes via TLR3 in 
vein grafts and in vitro in BMM, a prominent inflammatory cell type in VGD. 
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Although there is evidence of exogenous pathogens in vascular lesions 29, it seems 
unlikely that exogenous pathogens cause TLR activation during and after vein graft 
surgery. DAMP, endogenous ligand, mediated activation of TLRs is thought to be an 
important process that drives immune-activated diseases such as cardiovascular 
diseases, rheumatoid arthritis and lupus 30-32. We previously demonstrated the 
presence of several TLR DAMPs in remodeled vein grafts 15. TLR3 is known to respond 
to RNA from necrotic cells 33, 34, which are highly present in vein grafts during and 
after vein graft surgery as a result of the engraftment procedure, vein graft handling, 
flow disturbances and subsequent arterialization phase 6, 9-12. This makes TLR3 an 
interesting potential target to prevent VGD, increase patency rates and clinical 
outcome after vein graft surgery, all important since for the prevention of VGD, an 
unequivocally effective treatment has not been found yet. 
A prominent protective role of TLR3 in vein graft remodeling is suggested by the 
increased vein graft thickening as seen in the vein grafts of Tlr3-/- mice compared to 
vein grafts of control mice. This is in line with our previous study were we observed a 
protective effect on VGD in vein grafts of Irf3-/- and Irf7-/- mice, which are downstream 
factors of TLR320. Previous research also showed a protective role of TLR3, however, 
this was shown in a perivascular collar-induced injury model for atherosclerosis 19. 
Besides, stimulation of TLR3 showed beneficial effects in other diseases 21-23, 25, 26. The 
molecular mechanism of TLR3-induced protective effects is not fully unraveled, but 
we suggest that the TLR3 mechanism in VGD is dependent on the production of type 
I IFNs. 
Here we demonstrated down regulation of type-I IFN inducible genes in vein grafts 
and in vitro in BMM of Tlr3-/- mice and increased pro-inflammatory responses in Tlr3-
/- vein grafts compared to control vein grafts. Type-I IFNs are mainly known because 
of their role in the induction of an antiviral immune response, but the beneficial role 
after administration of type-I IFNs in certain diseases such as multiple sclerosis and 
ulcerative colitis is appreciated 35-37. Lack of type-I IFNs initially results in inflammatory 
responses in this diseases, which is in line with the increased inflammatory influx that 
was observed in the vein graft vessel wall of mice lacking TLR3 and the increased 
inflammatory cytokine gene expression in vein grafts of TLR3 knockout mice, 
suggesting that pro-inflammatory responses are responsible for the observed vessel 
wall thickening in Tlr3-/- vein grafts. In contrast, type-I IFNs can also contribute to 
progression of some autoimmune diseases by increased pro-inflammatory responses 
and the activation of Th17 cells 38, 39. Although, there is a considerable variation in the 
function of type-I IFNs in different conditions, we suggest a beneficial and protective 
effect of TLR3 stimulation and type-I IFNs in VGD. 
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Clinical implication of our knowledge of TLR3 in VGD can be stimulation of TLR3, 
IRF3, IRF7 or type-I IFNs via endogenous or exogenous ligands. Stimulation with 
endogenous ligands for TLR3, e.g. RNA released by damaged tissue or necrotic cells, 
is not clinically applicable yet. PolyI:C is the exogenous ligand for TLR3, and previous 
studies suggest that polyI:C may be a promising drug candidate, e.g. for the treatment 
of hepatitis B infections 40, 41. However, activation of intrahepatic TLR3 used in these 
studies by hydrodynamic injection (tail injection) cannot be applied to humans42. The 
selective activation of the immune system is not only a concurrent problem in the 
treatment of VGD, so recently a modular system was developed where polyI:C was 
incorporated into calcium phosphate nanoparticles to treat viral infections, which 
can be interesting for future treatments of VGD via TLR3. However, in vein graft 
surgery, future research should also focus on local stimulation of TLR3, since (open) 
harvesting of the saphenous vein gives opportunities for local TLR3 stimulation 
without affecting the systemic circulation.
In conclusion, these data suggest that TLR3 can play a protective role in VGD 
development, possibly regulated via type-I IFNs. We believe that TLR3 stimulation 
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Supplemental Tables and figures
t=28 Total operated † Thrombotic occlusions Analysed
Tlr2-/- 10 3 0 7
Tlr3-/- 9 1 0 8
Tlr4-/- 10 1 2 7
Control 10 1 2 7
t=14 Total operated † Thrombotic occlusions Analysed
Tlr2-/- 10 2 2 6
Tlr3-/- 9 1 3 5
Tlr4-/- 9 2 1 6
Control 7 2 1 4
t=7 Total operated † Thrombotic occlusions Analysed
Tlr2-/- 12 1 0 11
Tlr3-/- 12 1 3 8
Tlr4-/- 14 1 1 12
Control 12 0 2 10
Table S1. Number of total operated mice and deceased mice (†) are shown. Deceased mice are all 
mice that reached a human endpoint before the day of sacrifice (28 days after surgery) or had failed 
surgery. Number of vein grafts with thrombotic occlusions and number of analysed vein grafts is 
shown. Number of mice and vein grafts of Tlr2-/-, Tlr3-/-, Tlr4-/- and control mice are shown, sacrificed 28 
days after vein graft surgery (t=28), 14 days (t=14) or 7 days (t=7).
Pam3Cys PolyI:C LPS
Control Tlr2-/- Control Tlr3-/- Control Tlr4-/- 
Ifit1 0,019 0,001 16,862 4,243 0,035 0,002
Mx1 0,020 0,000 51,570 19,213 0,035 0,001
Oas2 0,015 0,001 1,789 0,127 0,009 0,001
Table S2. BMM of Tlr2-/-, Tlr3-/-, Tlr4-/- and control mice were stimulated with 100 ng Pam3Cys, 30 μg/ml 
PolyI:C or 100 ng/ml LPS for 24h after which RNA was harvested for RT-qPCR analysis. Relative mRNA 
expression of Ifit1, Mx1 and Oas2 of Tlr2-/- BMM stimulated with Pam3Cys (left), Tlr3-/- BMM stimulated 
with PolyI:C (middle) and Tlr4-/- BMM stimulated with LPS (right) are shown. Results are depicted as 
mean, n=3 per group.
192
Figure S1. Example of vein graft surgery. Vein graft surgery was performed in mice by donor caval 
vein interpositioning in the carotid artery of a genetically identical recipient mice. In brief, the right 
common carotid artery was dissected free from its surrounding from the bifurcation at the distal 
end toward the proximal end. The artery was cut in the middle and a cuff placed at the end on both 
sides. Next, both ends of the artery were everted over the cuffs and ligated with an 8.0 silk ligature. 
The caval vein of the genetically identical donor mice was harvested and grafted between the two 
ends of the carotid artery by sleeving the ends of the vein over the artery cuff and ligating them 
together with an 8.0 silk suture. All recipient mice received donor caval veins from genetic identical 
mice. C57BL6/J mice received a donor caval vein from a C57BL6/J mice, Tlr3-/- mice from a Tlr3-/- mice, 
Tlr2-/- mice from a Tlr2-/- mice and Tlr4-/- mice from a Tlr4-/- mice. 
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Figure S2. The total vessel area is enclosed by the light blue line. Intimal hyperplasia is enclosed by 
the green line and lumen area by the dark blue line. Vessel wall thickening was defined as the area 
between lumen area (dark blue line) and adventitia and determined by subtracting the luminal area 
(dark blue line) from the total vessel area (light blue line).
Figure S3. Representative photographs of caval veins of C57BL6/J mice. a. TLR2 staining, TLR2 was 
not detectable in the caval vein. b. TLR3 staining, the caval vein stained negative for TLR3, in contrast 
to the surrounding adipose tissue. c TLR4 staining, the caval vein showed no TLR4 staining. Caval vein 
10x magnification.
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Figure S4. Representative photographs of isotype-matched primary antibody negative controls 
of a. TLR2-aSMActin-CD31-MAC-3 fluorescent staining, b. TLR3-aSMActin-CD31-MAC-3 fluorescent 
staining, and c. TLR4-aSMActin-CD31-MAC-3 fluorescent staining, Vein graft zoom in 20x 
magnification, inset: vein graft overview 5x magnification.
Figure S5. a. Vessel wall thickening (mm2) 
in vein grafts 7, 14 and 28 days after surgery 
(t=7, t=14 and t=28 respectively) of Tlr2-
/-, Tlr3-/-, Tlr4-/- and control mice. b. Lumen 
area (mm2) c. Total vessel area (mm2). Data 
is shown as mean ±SEM. Tlr2-/-, Tlr3-/-, Tlr4-
/- are compared to control vein graft, and 
significant differences compared to control 
vein grafts are shown by asterisks. Statistical 
analyses were performed by using 1-way 
ANOVA. *p<0.05, **p<0.01, ***p<0.001. 6-8 
vein graft sections were analysed per mice. 
See detailed analysed number of mice per 
group in table S1.
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Figure S6. Vein grafts of Tlr2-/- and control mice sacrificed 7, 14 and 28 days after surgery were stained 
with Sirius red to quantify the amount of collagen present in the vein grafts and expressed as collagen 
content (expressed in mm2) (a.c.f. respectively). b. Antibodies directed at fibrin (Y22) were used to 
quantify the fibrin content (expressed in mm2) 7 days after surgery. Antibodies directed at MAC-3 to 
stain for macrophages and quantified for the number of macrophages (expressed as macrophage 
score, 1: < 25 positive cells/section, 2: 25-50 positive cells/section, 3: >50 positive cells) (d.g. 
respectively), and smooth muscle cell actin (aSMActin) to stain smooth muscle cells and quantified 
for the smooth muscle cell (SMC) content (expressed in mm2) (e.h. respectively). Data is shown as 
mean ± SEM. Statistical analyses was performed by using a 2-tailed Student’s t-test or Mann-Whitney 
test. *p<0.05, **p<0.01, 6-8 vein graft sections were analysed per mice. n=6-10 mice per group. 
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Figure S7 Vein grafts of Tlr4-/- and control mice sacrificed 7, 14 and 28 days after surgery were stained 
with Sirius red to quantify the amount of collagen present in the vein grafts and expressed as collagen 
content (expressed in mm2) (a.c.f. respectively). b. Antibodies directed at fibrin (Y22) were used to 
quantify the fibrin content (expressed in mm2) 7 days after surgery. Antibodies directed at MAC-3 to 
stain for macrophages and quantified for the number of macrophages (expressed as macrophage 
score, 1: < 25 positive cells/section, 2: 25-50 positive cells/section, 3: >50 positive cells) (d.g. 
respectively), and smooth muscle cell actin (aSMActin) to stain smooth muscle cells and quantified 
for the smooth muscle cell (SMC) content (expressed in mm2) (e.h. respectively). Data is shown as 
mean ± SEM. Statistical analyses was performed by using a 2-tailed Student’s t-test or Mann-Whitney 
test. *p<0.05, **p<0.01, 6-8 vein graft sections were analysed per mice. n=6-10 mice per group. 
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Figure S8. BMM of control mice were stimulated with 100 ng Pam3Cys, 30 μg/ml PolyI:C or 100 ng/
ml LPS or PBS for 24 hour after which RNA was harvested for RT-qPCR analysis a. relative mRNA 
expression of a. Irf7, b. Irf3, c. Traf3, d. Il6, e. and Tnf of control BMM stimulated with Pam3Cys, PolyI:C, 
LPS or PBS is shown. Data is shown as mean ± SEM. Statistical analyses were performed by using 
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Toll like receptors (TLR) play an important role in vein graft disease (VGD). Interferon 
regulatory factors (IRF) 3 and 7 are the transcriptional regulators of type-I interferons 
(IFN) and type-I IFN responsive genes and are downstream factors of TLRs. Relatively 
little is known with regard to the interplay of IRFs and TLRs in VGD development. The 
aim of this study was to investigate the role of IRF3 and IRF7 signaling downstream 
TLRs and the effect of IRF3 and IRF7 in VGD.
Methods and Results 
In vitro activation of TLR3 induced IRF3 and IRF7 dependent IFNβ 
expression in bone marrow macrophages and vascular smooth muscle cells. 
Activation of TLR4 showed to regulate pro-inflammatory cytokines via IRF3. 
Vein graft surgery was performed in Irf3-/-, Irf7-/- and control mice. After 14 days Irf3-/- 
vein grafts had an increased vessel wall thickness compared to both control (p=0.01) 
and Irf7-/- (p=0.02) vein grafts. After 28 days, vessel wall thickness increased in Irf3-/- 
(p=0.0003) and Irf7-/- (p=0.04) compared to control vein grafts and also increased in 
Irf7-/- compared to Irf3-/- vein grafts (p=0.02). Immunohistochemical analysis showed a 
significant higher influx of macrophages after 14 days in Irf3-/- vein grafts and after 28 
days in Irf7-/- vein grafts compared to control vein grafts. 
Conclusions 
The present study is the first to describe a protective role of both IRF3 and IRF7 in VGD. 
IRFs regulate VGD downstream TLRs since Irf3-/- and Irf7-/- vein grafts show increased 




Arterial occlusive disease is an atherosclerosis driven chronic disease that causes 
impaired blood flow. In case of severe arterial occlusive disease, bypass surgery is 
performed with the vena saphena magna as the most used conduit. Unfortunately, 
long term graft patency rates are low due to vein graft disease (VGD)1, 2. Development 
of intimal hyperplasia (IH) in vein grafts consist of several phases, the first days an 
influx of inflammatory cells such as macrophages occurs, followed by extracellular 
matrix breakdown and subsequent remodeling as well as proliferation and migration 
of vascular smooth muscle cells (VSMCs).
We and others have shown that Toll-like receptors (TLRs), important members of the 
innate immune system, are involved in intimal hyperplasia formation, accelerated 
atherosclerosis and vein graft remodeling3-5 via recognition of pathogen-associated 
molecular patterns and damage associated molecular patterns6. Interestingly, a 
protective role of TLR3 was found on the onset of atherosclerosis formation7. TLR3 
stimulation also impaired endothelial function8 and deficiency of TLR3 resulted 
in increased atherosclerotic lesion burden9. TLRs, except TLR3, signal via myeloid 
differentiation primary response gene 88 (MyD88) pathway, which drives the 
induction of the transcription factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-ĸB) resulting in pro-inflammatory cytokines production10. TLR3, 
and sometimes TLR4, signals via a MyD88-independent pathway which induces 
type-I IFN production, and sometimes pro-inflammatory cytokine production, via 
TIR-domain-containing adaptor protein inducing IFNβ (TRIF) in various cell types11. 
Interferon regulatory factor (IRF) 3 and 7 are downstream factors of TLRs and play 
important roles in innate immunity through the transcriptional regulation of type-I 
IFNs such as IFNα and IFNβ. IFNα and IFNβ have shown to play a role in cardiovascular 
diseases with analogous pathophysiology as vein graft disease 12. IRF3 is a potent 
activator of the IFNβ gene but not the IFNα genes, except the IFNα4 gene, whereas 
IRF7 efficiently activates both IFNα and IFNβ genes4, 13. IRF3 is primarily responsible 
for the induction of type-I IFN genes in the early induction phase14. IRF3 resides in the 
cytosol in a latent form and after activation by phosphorylation, IRF3 causes IFNβ 
synthesis and signal transduction through the type-I IFN receptor IFNAR4, 15. IRF7 
also resides in the cytosol, but is expressed in a low amount. However, IFNAR signal 
transduction increases IRF7 protein expression16 and IRF7 then causes a late induction 
of both IFNα and IFNβ, where it induces a positive-feedback loop via repeated IFNAR 
binding17-19. Blocking the IFNAR resulted in the induction of vascular remodeling in a 
mouse model for hind limb ischemia12. 
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Recent studies have shown that IRFs play critical roles in diseases with (partial) 
analogous pathophysiology as vein graft disease such as antiviral defence17, cardiac 
remodeling20, multiple sclerosis21 and inflammasome activation22, indicating 
that there might also be a role for IRFs in VGD. However, the signaling pathways 
downstream TLR3 and TLR4 in VSMCs and bone marrow macrophages (BMM) are not 
yet completely clarified and the exact role of IRF3 and IRF7 signaling downstream 
TLRs and type-I IFNs in VGD is unclear. 
In the current study, we investigate the role of IRF3 and IRF7 signaling downstream 
TLRs in vitro by using VSMCs and BMM and the role of IRF3 and IRF7 in vivo in vein 
graft disease in a murine vein graft model, using wild type, Irf3/- and Irf7-/- mice. 
Material and methods
Mice
This study was performed in compliance with Dutch government guidelines and 
the Directive 2010/63/EU of the European Parliament. All animal experiments were 
approved by the animal welfare committee of the Leiden University Medical Center. 
For the experiments 10 to 18 week old male mice were used. We performed multiple 
in vitro and in vivo studies in wild type C57BL/6 mice purchased from Charles River 
Laboratories and Irf3-/- and Irf7-/- mice that were kindly provided by Dr. Taniguchi 
(University of Tokyo, Japan) and bred in our facility. Mice were fed a chow diet ad 
libitum. 
Vein graft surgery
Vein graft surgery was performed by donor caval vein interpositioning in the carotid 
artery of recipient mice23. At day of the surgery caval veins were harvested (t=0). After 
7 days (t=7), 14 days (t=14) and 28 days (t=28) mice were sacrificed and vein grafts 
were harvested. Both before surgery and sacrifice, mice were anesthetized with a 
combination of intraperitoneal injected Midazolam (5 mg/kg, Roche), Medetomidine 
(0.5 mg/kg, Orion) and Fentanyl (0.05 mg/kg, Janssen). Buprenorphine (0.1 mg/kg, 
MSD Animal Health) was given after surgery to relieve pain in a fixed regime and 
when circumstances required this was repeated.
Histological and immunohistochemical assessment of vein grafts
Vein graft samples were embedded in paraffin and sequential cross sections (5 µm thick) 
were made throughout the embedded vein grafts. To quantify the vein graft thickening 
(vessel wall area), HPS staining was performed using Hematoxylin, Phloxin 0.25%, and 
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Saffron 0.3%. Total size of the vein graft (total vessel area) and lumen was measured. 
Thickening of the vessel wall (vessel wall thickening) was defined as the area between 
lumen and adventitia and determined by subtracting the luminal area from the total 
vessel area. Antibodies directed at alpha smooth muscle cell actin (aSMActin, Sigma), 
IRF3, IRF7 (Abcam) and Mac-3 (BD Pharmingen) were used for immunohistochemical 
staining. Sirius red staining (Klinipath 80115) was performed to quantify the amount of 
collagen present in the vein grafts. The immuno-positive area measured is expressed 
as a percentage of the vessel wall area. Stained slides were photographed using 
microscope photography software (Axiovision, Zeiss) and image analysis software was 
used to quantify the vein graft intimal hyperplasia and composition (Qwin, Leica). 
Proliferation analysis
Immunohistochemical staining was performed for proliferation marker Ki67, 
combined with aSMActin, on vein grafts of Irf3-/-, Irf7-/- and control mice sacrificed 
at 28 days. The number of proliferating cells (Ki67 positive cells) and the number of 
proliferating smooth muscle cells (Ki67 and aSMActin positive cells) was quantified by 
manual counting of the number of cells per high power magnification and expressed 
as percentage of total cells. 
Cell culture
BMM were acquired by isolating monocytes from femur and tibia bone marrow of 
Irf3-/-, Irf7/- and control mice. 5 x 105 Cells were cultured per well of 6-wells FALCON® 
plates, with 3 wells per group (BD Biosciences) with RPMI 1640 medium supplemented 
with 25% heat-inactivated FCS (Gibco® by Life Technologies) and 100 U/mL Penicillin/
streptomycin (Gibco® by Life Technologies) in the presence of 0.1mg/ml macrophage 
colony-stimulating factor (M-CSF). After seven days, the BMM were seeded and 
after 24 hours, when macrophages were fully attached, they were stimulated with 
established exogenous ligands for TLR3 and TLR4: 100 μg/ml Polyinosinic-polycytidylic 
acid (PolyI:C) purchased from InvivoGen (CA) and 100ng/ml Lipopolysaccharide from 
Escherichia coli K-235 (LPS) purchased from Sigma-Aldrich (MO, USA) respectively. 
After 1, 3, 7 and 24 hour supernatant was collected for ELISA and RNA was isolated 
from stimulated cells using TRIzol® (Ambion® by Life Technologies).
Irf3-/-, Irf7/- and control VSMCs were acquired by isolating VSMCs from mice aortas. 
Cells were cultured in medium containing DMEM Glutamax with 20% FCS, non-
essential amino acids (MEM 100x, Gibco® by Thermo Fisher) and 100 U/mL Penicillin/
streptomycin. Cells were passaged when a confluence of 90-95% was reached. 105 
VSMCs were plated in a 48 wells plate, and stimulated with culture medium. After 24 
hours, cells were stimulated with 100 μg/ml PolyI:C and 100ng/ml LPS respectively. 
204
After 1, 3, 7 and 24 hour, supernatant was collected for ELISA and RNA was isolated 
from stimulated cells using TRIzol®. 
Detection of protein levels of IFNβ, CCL2 and TNFa. 
IFNβ production was measured after 1, 3, 7 and 24 hour in supernatant of VSMCs and 
BMM using a LEGEND MAX™ mouse IFNβ ELISA kit with pre-coated plates (BioLegend) 
according to manufacturer’s protocol. Pro-inflammatory cytokines CCL2 and TNFα 
was measured using a BD OptEIA™ mouse ELISA kit (BD Biosciences) in supernatant 
of VSMC and BMM, according to manufacturer’s protocol. 
RNA isolation, cDNA synthesis and RT-qPCR from cell cultures
RNA was isolated from BMM and VSMCs after 1, 3, 7 and 24 hour of PolyI:C or LPS 
stimulation and was quantified using a NanoDrop 1000 Spectrophotometer (Thermo 
Scientific). cDNA was synthesized using a High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). To measure the expression of the type-I IFN inducible genes, 
Ifit (Assay ID, Mm00515153_m1, Thermo Fisher) and Mx1 ((Assay ID, Mm00487796_m1, 
Thermo Fisher), RT-qPCR was performed using TaqMan (Thermo Fisher). To measure 
the expression of type-I IFN, IFNβ (forward GGAGATGACGGAGAAGATGC, reverse 
CCCAGTGCTGGAGAAATTGT), RT-qPCR was performed using QuantiTect SYBR Green 
PCR Kit (Qiagen). GAPDH (Applied Biosystems) was used as a housekeeping gene. 
All RT-qPCRs were performed on a 7500/7500 Fast Real-Time PCR System (Applied 
Biosystems) and the 2-ΔΔCt method was used to analyse the relative changes in gene 
expression.
RNA isolation, cDNA synthesis and RT-PCR from vein graft tissue
Total RNA was isolated from 10 (20µm thick) paraffin sections of vein grafts 28d after 
surgery (n=6/strain). RNA was isolated according manufacturers protocol (FFPE RNA 
isolation kit, Qiagen). FFPE RNA was reverse transcribed using the RT² First Strand Kit 
(SA Biosciences). RNA for single Q-PCR was reverse transcribed using a High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s 
protocol. Commercially available TaqMan gene expression assays for hypoxanthine 
phosphoribosyltransferase (HPRT1), and selected genes of interest were used (Applied 
Biosystems). qPCR analysis of 84 type-I IFN responsive genes was performed using a 
RT2 Profiler PCR Array (SA Biosciences) according to the manufacturer’s protocol. The 
complete list of the genes analysed is available at http://www.sabiosciences.com/
rt_pcr_product/HTML/PAMM-016Z.html. Prior to RT2 profiler array, all qPCRs were 
performed on a 7500/7500 Fast Real-Time PCR System and the 2-ΔΔCt method was 




All data are presented as mean ± SEM. In statistics software GraphPad Prism 7.0, 
statistical analyses on parametric data were performed by using a 2-tailed Student’s 
t-test to compare individual groups, Mann-Whitney test was used for nonparametric 
data. A 1-way ANOVA was performed on parametric data comparing more than 2 
groups and a Kruskal-Wallis test was performed on nonparametric data. P value of 
<0.05 was considered significant.
Results
Type-I IFN production in VSMCs is exclusively regulated downstream TLR3 
and pro-inflammatory cytokine production downstream TLR3 and TLR4.
To investigate whether the production of the type-I IFN IFNβ and pro-inflammatory 
cytokine production of CCL2 is regulated downstream TLR3 or TLR4 pathways in 
VSMCs, we stimulated VSMC with TLR3 ligand PolyI:C , TLR4 ligand LPS or PBS as control. 
After 6 hours and 8 hours IFNβ production of VSMCs stimulated with PolyI:C showed 
a respectively 3.2 fold increase (p=0.04) and 3.7 fold increase (p=0.02) compared to 
control (figure 1a). LPS and control showed no increase in IFNβ production over time, 
indicating that IFNβ production is specific downstream TLR3 in VSMCs. 
CCL2 production of LPS stimulated VSMC showed a significant 10.2 fold increase 
(p=0.003) after 6 hours and also after 8 hours with an 18.4 fold increase (p<0.0001) 
compared to control (figure 1b). In PolyI:C stimulated VSMCs an 8.7 fold increase 
after 6 hours was observed (p=0.001) and a 9.6 fold increase after 8 hours (p=0.003) 
compared to control, indicating a regulation of pro-inflammatory cytokine production 
downstream TLR3 and TLR4 in VSMCs. 
IRF3 and IRF7 signal downstream TLR3 and IRF3 downstream TLR4  
in BMM. 
To determine the role of IRF3 and IRF7 in the downstream signaling pathways of TLR3 
and TLR4, type-I IFN inducible genes, Ifit and Mx1, were measured in Irf3-/-, Irf7-/- and 
control BMM. In Irf3-/- BMMs stimulated with PolyI:C the mRNA expression of Ifit was 
significantly reduced by 75% compared to the control group whereas the mRNA 
expression of Mx1 was significantly reduced by 80%. Also in Irf7-/- BMMs stimulated with 
PolyI:C the mRNA expression of Ifit was significantly reduced by 79% and the mRNA 
expression of Mx1 was significantly reduced by 96% compared to the control group 
(figure 2a), indicating a strong signaling pathway of IRF3 and IRF7 downstream TLR3 
in BMM. Interestingly, Mx1 mRNA expression showed a 81% reduction in Irf7-/- BMM 
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compared to Irf3-/- BMM (p=0.0005), suggesting a stronger effect of IRF7 on type-I IFN 
transcription then IRF3 downstream TLR3 in BMM. 
Figure 1. Stimulation of control VSMCs with either PolyI:C, LPS or control medium. After 1, 3, 6 
and 8 hour supernatant was collected and cytokine production was measured with ELISA. a. IFNβ 
concentration (pg/ml) is shown b. CCL2 concentration (ng/ml) is shown. Results are depicted as mean 
± SEM *p<0.05, **p<0.01, *** p<0.001. **** p<0.0001. n=3
Figure 2 BMM of Irf3-/-, Irf7-/- and control mice were stimulated for 24h after which RNA was harvested 
for RT-qPCR analysis a. stimulation with 30 μg/ml PolyI:C b. stimulation with 100 ng/ml LPS. Results 
are depicted as mean ± SD versus control. *p<0.05, **p<0.01, *** p<0.001. n=3
We evaluated whether IRF3 and IRF7 were also involved in downstream TLR4 
signaling pathway, by stimulation of BMM with LPS. Irf3-/- BMM showed a significant 
down regulation of 77% of Ifit1 and 88% of Mx1 mRNA expression compared to the 
controls (Figure 2b). Moreover, the type-I IFN inducible gene mRNA expression levels 
were not affected in BMM of Irf7-/- mice, indicating that IRF7 signaling is not regulated 
downstream TLR4, whereas IRF3 signaling is more specifically regulated downstream 







Figure 3. Irf3-/-, Irf7-/- and control BMM were stimulated with 100 μg/ml PolyI:C for 1, 3, 7 and 24 hour 
after which RNA was harvested for RT-qPCR analysis. Relative IFNβ mRNA expression to GAPHD is 
shown. *p<0.05, **p<0.01, Irf3-/- n=3, Irf7-/- n=9, control n=12
Type-I IFN transcription downstream TLR3 is IRF3 and IRF7 dependent in 
BMM. 
To determine whether IRF3 and IRF7 are involved in the transcription of the type-I 
IFN IFNβ downstream TLR3, we stimulated BMM of Irf3-/-, Irf7-/- and control mice with 
PolyI:C and measured IFNβ mRNA expression. In Irf3-/- BMM IFNβ mRNA expression 
was decreased after 1 hour (p=0.02) compared to control (figure 3). Both Irf3-/- 
(p=0.001) and Irf7-/- (p=0.009) BMM expressed significantly lower IFNβ mRNA levels 
compared to control after 7 hours of stimulation. Moreover, IFNβ mRNA levels after 1 
hour and 7 hours showed a trend towards a decrease in Irf3-/- compared to Irf7-/- BMM. 
In conclusion, IRF3 and IRF7 were shown to be responsible for IFNβ transcription 
in BMM, were IRF3 showed to regulate early IFNβ mRNA expression levels and IRF7 
showed to be a late regulator.
IRF3 but not IRF7 is involved in pro-inflammatory cytokine production in 
BMM.
We have shown that pro-inflammatory cytokine production can be induced via 
TLR3 and TLR4 signaling (figure 1) and that type-I IFNs can be regulated via IRF3 and 
IRF7downstream TLR3 and downstream TLR4 via IRF3 (figure 2). To determine the role 
of IRF3 and IRF7 in pro-inflammatory cytokine production, we measured CCL2 and 
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TNFα production of PolyI:C stimulated BMM of Irf3-/-, Irf7-/- and control mice. Irf3-/- BMM 
showed a significant reduction in CCL2 production after 7 hours compared to both 
control (p=0.02) and Irf7-/- BMM (p=0.007) (figure 4a). Moreover, TNFα production of 
Irf3-/- BMM was significantly decreased compared to control after 3 hours (p=0.004) 
and 7 hours compared to both control (p<0.0001) and Irf7-/- BMM (p=0.003) (figure 
4b). Irf7-/- BMM showed no differences in both CCL2 and TNFα production compared 
to control. In conclusion, we here show an IRF3 dependent, and not IRF7 dependent, 
regulation of in vitro pro-inflammatory cytokine production in BMM. 
Figure 4 Irf3-/-, Irf7-/- and control BMM were stimulated with 100μg/ml PolyI:C . a. After 1, 3 and 7 
hour supernatant was collected and cytokine production of CCL2 (pg/ml) and b. TNFα (ng/ml) was 
measured with ELISA. t=1h and t=7h; n=8, t=3h; n=4. c. IFNβ production (pg/ml) was measured after 
7 and 24 hours. n=4 Results are depicted as mean ± SEM. *p<0.05, **p<0.01, **** p<0.0001. 
Type-I IFN production downstream TLR3 is IRF3 and IRF7 dependent.
To determine the role of IRF3 and IRF7 in the production of the type-I IFN IFNβ 
downstream TLR3, we stimulated BMM of Irf3-/-, Irf7-/- and control mice with PolyI:C and 
measured IFNβ production. In Irf3-/- BMM a decreased IFNβ production was measured 
after 7 hours in compared to both control (p=0.004) and Irf7-/- BMM (p=0.002) (figure 






opposite results with lower IFNβ production of Irf7-/- BMM compared to Irf3-/- BMM 
(p=0.05). After 24 hours, both Irf7-/- BMM (p=0.009) and Irf3-/- BMM (p=0.007) showed 
a decreased IFNβ production compared to control. In conclusion, we here show an 
important role of IRF3 in early type-I IFN production and a role of IRF7 in late type-I 
IFN production.
IRF3 and IRF7 deficiency causes increased vein graft remodeling in time. 
Both IRF3 and IRF7 are expressed in vein grafts of control mice after 28 days. Both 
cytoplasmic as well as nuclear staining was seen indicating that latent and active forms of 
IRF3 (figure 5a) and IRF7 (figure 5b) are present. Vein graft showed a more intense nuclear 
staining of IRF3 and showed both nuclear and cytoplasmic staining of IRF7, indicating 
not only a constitutive expression of IRF7, but also an induced IRF7 expression in mature 
vein grafts. 
To determine the effect of IRF3 and IRF7 on the total size of the vein graft (total vessel 
area), thickening of the vessel wall (vessel wall thickening) and lumen area of Irf3-/- 
and Irf7-/- vein grafts were compared with control vein grafts. Vessel wall thickening in 
control, Irf3-/- as well as Irf7-/- mice increased over time after surgery (figure 5c). At day of 
the surgery caval veins of Irf3-/- mice were significantly 2.1 fold smaller in size (p=0.03)
(supplemental figure 1a,c,e,g) and had a significantly 2.6 fold thinner vessel wall (p=0.007)
(figure 5d) compared to control caval veins, whereas no differences were observed in 
lumen size (supplemental figure 1b,d,f,h). No differences were observed between Irf7-/- 
caval veins compared to controls and Irf3-/- caval veins (figure 5d and supplemental figure 
1). After 7 days, no differences in total vessel area, lumen area (supplemental figure 1) 
and vessel wall thickening (figure 5d) were observed between Irf3-/-, Irf7-/- and control 
vein grafts. After 14 days Irf3-/- vein grafts had a significantly 1.8 fold increased vessel 
wall thickening compared to control (p=0.0099) and 1.5 fold increase compared to Irf7-/- 
(p=0.02) vein grafts (figure 5d), but no differences were observed in total vessel area and 
lumen area (supplemental figure 1b,d,f,h). However, after 28 days vessel wall thickening 
was significantly 1.7 fold increased in Irf7-/- (p=0.0003) and 1.4 fold increased in Irf3-/- 
(p=0.04) vein grafts compared to control vein grafts (figure 5d) and Irf7-/- also showed an 
significantly 1.2 fold increase in vessel wall thickening compared to Irf3-/- vein grafts after 
28 days (p=0.02). Total vessel wall area was significantly 1.4 fold increased in Irf7-/- vein 
grafts (p=0.04) and lumen area showed no differences (supplemental figure 1).
Here we show an increased vessel wall thickening in vein grafts of Irf3-/- and Irf7-/- 
mice, indicating a protective effect of both IRF3 and IRF7 with a stronger protective 
effect of IRF3 in vein graft disease compared to IRF7 after 14 days, and a stronger 









Intimal hyperplasia formation in IRF3 and IRF7 deficient mice is caused by 
macrophage accumulation.
To determine the percentage of inflammatory cells in the vein graft lesion, percentage 
of macrophages was determined. No differences were observed for the percentage 
macrophages in the vein grafts of Irf3-/- and Irf7-/- mice compared to control (table 1) 
sacrificed after 7 days. In vein grafts sacrificed after 14 days, Irf3-/- vein grafts showed 
a 89% increase of macrophages compared to control vein grafts (p=0.008) and no 
differences compared to Irf7-/- vein grafts (table 1). However, analysis of the vein grafts 
of mice sacrificed after 28 days, showed that the macrophage score was increased by 
23% in Irf7-/- (p=0.04) vein grafts compared to control vein grafts and showed a trend 
towards an increase in Irf3-/- (p= 0.06) vein grafts compared to the control vein grafts 
(figure 6a). No differences between Irf7-/- and Irf3-/- vein grafts were observed after 28 
Figure 5. a. Representative picture of a vein graft of control mice stained with IRF3 and b. IRF7. 20x 
magnification. c. and d. Vessel wall area (mm2) in caval veins at day of the surgery (t=0) and vein 
grafts 7, 14 and 28 days after sacrifice (t=7, t=14 and t=28 respectively) of Irf3-/-, Irf7-/- and control 
mice. *p<0.05, **p<0.01, ***p<0.001. n=3-9 e. Representative picture of a control vein graft after 28 
days, stained with Hematoxylin, Phloxine and Saffron f. vein graft of Irf3-/- mice g. and a vein graft of 





Figure 6 (Immuno)histological analysis of vein grafts of Irf3-/-, Irf7-/- and control mice sacrificed after 
28 days. a. Macrophage score b. Percentage of the collagen content and c. absolute numbers of the 
collagen content (mm2). d. Percentage of the SMC actin content and e. absolute numbers of the 








days. In conclusion, we here show an increased macrophage accumulation in the vein 
grafts of Irf3-/- mice after 14 days and vein grafts of Irf7-/- mice compared to control 
vein grafts 28 days after surgery.
  Irf3-/- Irf7-/-
t=7 t=14 t=28 t=7 t=14 t=28
MAC-3 -8,13 89,68** 19,63 0,85 40,55 23,73*
aSMActin -0,25 17,17 40,75 -9,51 39,75 22,38
Collagen 21,82 -74,38* -15,47 1,11 -29,70 -19,33*
Table 1. In vein grafts of Irf3-/-, Irf7-/- and control mice (immuno)histochemical stainings of, 
macrophages (MAC-3), smooth muscle cells (aSMActin) and collagen were performed to determine 
plaque composition. Stainings were performed on vein grafts harvested 7 days after surgery (t=7), 14 
days (t=14) or 28 days after surgery (t=28). Percentages of changes compared to control vein grafts 
are shown. *p<0.05, **p<0.01
IRF7 deficiency induces smooth muscle cell proliferation.
To determine lesion stability, collagen content was determined. To determine the 
percentage of VSMCs and the percentage of proliferating VSMCs in Irf7-/- compared 
to Irf3-/- vein grafts, we performed a double immunohistochemical staining for 
proliferation marker Ki67 with vascular smooth muscle cell marker aSMActin. 
No differences were observed in the percentage collagen in the vein grafts of Irf3-
/- and Irf7-/- mice compared to control vein graft sacrificed after 7 days (table 1). The 
percentage of collagen in the vessel wall was significantly decreased in vein grafts 
of Irf3-/- mice compared to control vein grafts (p=0.001) and compared to Irf7-/- vein 
grafts (p=0.008) after 14 days and decreased in vein grafts of Irf7-/- mice (p=0.03) 
compared to control vein grafts after 28 days (figure 6b), indicating unstable lesions 
in Irf3-/- vein grafts after 14 days and in Irf7-/- vein grafts after 28 days. However, no 
differences were observed in the collagen area (mm2) after 28 days (figure 6c). 
The percentage of VSMCs (figure 6d) and the SMC area (mm2) (figure 6e) was similar 
in both Irf3-/- and Irf7-/- mice compared to the control group after 28 days. In time, the 
percentage of SMCs increased in Irf3-/-vein grafts compared to control vein grafts.
We detected a higher percentage of proliferating VSMCs in Irf7-/- vein grafts compared 
to control vein grafts (figure 7a), with a trend toward an increase in Irf3-/- vein grafts 
compared to control vein grafts. 
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IRF3 and IRF7 differentially regulate type-I interferon (inducible) genes in 
vein grafts.
We previously showed a regulation of type-I IFN mRNA expression (figure 2) and 
IFNβ mRNA expression (figure 3) via IRF3 and IRF7 in vitro in VSMCs and BMM. To 
show that type-I IFN (inducible) genes are regulated by IRF3 and IRF7 in vivo in vein 
grafts, we performed a specific RT2 profiler array with 84 type-I IFN response genes 
on pools of Irf3-/-, Irf7-/- and control vein grafts (n=6 mice/group) sacrificed after 28 
days. Up regulation of expression in the Irf3-/- and Irf7-/- mice was only found for a few 
genes (table 2a). Deficiency of IRF3 and IRF7 resulted in a decrease in specific type-I 
IFN inducible genes such as Ifit1, Ifit3 and Isg15. Irf3-/- vein grafts showed a down 
regulation of more than 2 fold in 16 specific type-I IFN inducible, were Irf7-/- vein graft 
showed a down regulation in 27 specific type-I IFN inducible genes (table 2b), which 
is 1.7 fold more compared to IRF3 vein grafts. In conclusion, we here show an IRF3 and 
IRF7 dependent regulation of type-I IFN (inducible) genes, with a more prominent 
role of IRF7 in the regulation of type-I IFN (inducible) genes. 
Discussion 
The present study is the first to describe a role for both IRF3 and IRF7 in vein graft 
disease and we here show that IRF3 and IRF7 regulate type-I IFNs via TLRs. IRF3 and IRF7 
are highly expressed in vein grafts and IRF3 and IRF7 deficient mice show an increase in 
vein graft vessel wall thickening in comparison to control mice, indicating a protective 
role of both IRF3 and IRF7 in vein graft disease. Interestingly, deficiency of either IRF3 
or IRF7 had a different effect on the vessel wall thickening in time. We here show an 
increased vessel wall thickening in vein grafts of Irf3-/- mice after 14 days, whereas vein 
grafts of Irf7-/- mice showed increased vessel wall thickening after 28 days. We also show 
a regulation of type-I IFNs via both IRF3 and IRF7 downstream of TLR3 activation and 
of pro-inflammatory cytokines only via IRF3 downstream TLR4 activation in vitro, in 
VSMCs and macrophages, prominent cell types in vein graft disease. 
Previous studies showed a protective effect of IRF7 against VSMC proliferation and 
neointima formation in a mouse carotid artery wire injury model and carotid artery 
balloon injury model24. A protective effect of IRF3 on neointima formation was observed 
through inhibition of VSMC proliferation via PPARγ activation in a mouse carotid artery 
wire injury model25. All these findings are in line with our study, since we also showed a 
protective effect of both IRF3 and IRF7 in a vein graft model (figure 5c) and a decrease 
in VMSC proliferation in Irf3-/- mice compared to Irf7-/- mice (figure 7). 
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Gene Symbol Irf3-/- Irf7-/- Gene Symbol Irf3-/- Irf7-/- Gene Symbol Irf3-/- Irf7-/-
Crp 2,52 6,17 Ccl2 < -2 < -2 Ifitm2 -2,01 < -2
H2-Bl 3,6 3,79 Cxcl10 < -2 -9,07 Mx1 -2,28 -20,99
H2-M10.1 3,39 2,62 Ifit1 -3,86 -9,97 Mx2 -2,87 -5,48
Met 2,13 4,1 Ifit2 -3,73 -8,12 Nos2 -2,12 < -2
MGDC <2 2,02 Ifit3 -5,31 -10,27 Oas2 -6,06 -11,47
Ifne <2 5,36 Il6 -6,34 < -2 Stat1 < -2 -2,59
Ifna2 <2 2,23 Isg15 -4,01 -8,08 Stat2 -2,1 -2,8
Ifna4 2,18 <2 Oas1a < -2 -6,86 Timp1 -3,31 < -2
Myd88 <2 <2 Oas1b < -2 -4,08 Ccl5 < -2 -2,62
Gbp1 <2 <2 Tlr7 < -2 < -2 Cd69 < -2 -7,36
Il10 <2 <2 Mal < -2 -2,04 Cd70 < -2 -4,44
Irf1 <2 <2 Bst2 < -2 -2,04 Eif2ak2 < -2 -2,07
Irf2 <2 <2 Ifnz < -2 < -2 Gbp1 < -2 -2,29
Casp1 <2 <2 Irf7 -5,37 -159,22 H2-K1 < -2 -2,67
Nos2 <2 <2 Sh2d1a < -2 -4,63 H2-T10 < -2 -2,96
Psme2 <2 <2 Tlr3 < -2 < -2 Ifih1 < -2 -3,95
Stat1 <2 <2 Tlr7 < -2 < -2 Socs1 < -2 -2,35
Vegfa <2 <2 Tlr9 < -2 -3,15 Tap1 < -2 -2,74
Sh2d1a 2,57 <2 Ddx58 -2,01 -2,88
Ccl5 3,89 <2 Ifi204 -2,04 < -2
Cav1 <2 2,04 Ifih1 -3,15 < -2
a.                     b.
Table 2. RT2 profiler array of type-I IFNs on pools of vein grafts of Irf3-/- and Irf7-/- mice are shown 
compared to control vein grafts. Data are expressed as fold induction. a. Genes that are up regulated 
more than 2-fold in one of the strains are shown in bold. b. Genes that are down regulated more than 
2-fold are shown in bold. 
IRF3 and IRF7 signaling pathways are extensively investigated in various processes 
and cell types. However signaling downstream TLRs is complex and can be different 
per cell type26. We here investigated VSMCs and macrophages. Based on our in vitro 
and in vivo experiments, we suggest the current model (figure 8) as downstream TLR3 
and TLR4 signaling pathways, playing a role in vein graft disease. TLR3 signaling is 
known to be TRIF mediated, leading to type-I IFN activation27, whereas TLR4 signaling 
is TRIF and Myd88 dependent, leading to pro-inflammatory cytokine activation and 
type-I IFN activation4, 10. However, we showed that TLR3 activation can also lead to 
pro-inflammatory cytokine production (figure 1). Previously it was shown that IRF3 is 
a downstream transcription factor that regulates the expression of IFNβ induced by 
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TRIF-dependent TLRs28, 29. However, NF-κB can also induce IFNβ gene expression in 
presence of IRF3 and it was shown that IRF3 can also be regulated downstream TLR427, 
30-32, which is in line with our results (figure 1 and 2), since we also show an increased 
IFNβ gene expression regulated via IRF3 after TLR4 stimulation in BMM compared 
to unstimulated BMM . NF-κB was shown to induce interferon-stimulated genes 
independently of type-I IFN in vivo33. Besides, in response to LPS, it had been shown 
that IRF3 can be activated in a MyD88-independent manner34, 35. IFNβ gene induction 
in response to TLR4 ligation can be mediated by IRF3 in peritoneal macrophages 
and fibroblasts28, but under certain conditions, IRF7 might also participate in TLR4 
signaling, which was shown in dendritic cells36, presumably also being activated by 
TBK1, an essential components of the IRF3 signaling pathway31. However, we showed 
that IRF7 is only involved in type-I IFN production and IRF3 in both type-I IFN and 
pro-inflammatory cytokine production in BMMs (figure 4). 
Besides different signaling pathways downstream TLRs, IRF3 and IRF7 also showed to 
have different functions in time. Vessel wall thickening was increased in vein grafts of 
Irf3-/- mice after 14 days compared to vein grafts of Irf7-/- and control mice, whereas 
vein grafts of Irf7-/- mice showed a remarkable vessel wall thickening compared to vein 
grafts of Irf3-/- and control mice after 28 days. In line with this, in vein grafts of Irf3-/- 
mice, macrophage accumulation was seen after 14 days with a lower percentage of 
collagen in the vessel wall, whereas more macrophages and less collagen were seen 
in vein grafts of Irf7-/- mice after 28 days, indicating that a thickening of the vein graft 
vessel wall is unstable. Besides, after 28 days, the expression of type-I IFN was up 
regulated in Irf7-/- vein grafts compared to Irf3-/- vein grafts (table 2) and Irf7-/- vein grafts 
showed more proliferating VSMCs compared to Irf3-/- vein grafts. This different function 
of IRF3 and IRF7 in time can be explained by the fact that IRF3 is primarily responsible 
for the early induction phase of type-I IFNs and IRF7 is involved in the late induction 
phase of type-I IFNs as reported previously in responses to viral infections17-19. IRF3 
is constitutively expressed and resides in the cytosol in a latent form and undergoes 
nuclear translocation following a stimulus such as a viral infection. IRF7 also resides in 
the cytosol and can be translocated to the nucleus following infection stimulus, but 
unlike IRF3, IRF7 is expressed in low amounts and is strongly induced by type-I IFNs via 
binding the type-I IFN receptor 4, 15. IRF7 is in this way an inducer of a positive feedback 
loop of enhanced activation of type-I IFN 18, 19 which can result in stronger induction of 
type-I IFN (inducible) genes in the late phase, compared to IRF3 who act in the early 
phase with type-I IFN production37. In line with this, here we showed a more prominent 
role of IRF3 early in time and a late role for IRF7 in vitro (figure 4c) and in vivo (figure 
5c). We here show a protective effect of IRF7 and IRF3 since vein grafts of Irf3-/- and Irf7-
/- mice showed a reduction in vessel wall thickening compared to control vein grafts. 
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Figure 7. Vein grafts sacrificed after 28 days of Irf3-/-, Irf7-/- and control mice were stained with 
proliferation marker Ki67 and with vascular smooth muscle cell marker aSMActin. a. percentage of 
dividing VSMCs (Ki67+ and aSMActin+) of total cells in shown. n=4, *p<0.05 b. Representative image 
of aSMActin (green) and Ki67 (magenta) immunofluorescence double staining in vein grafts are 






Furthermore, it has been shown that the contribution of IRF3 is minor in the absence 
of IRF7, probably due to the lack of IRF3 and IRF7 interaction4. So, to benefit from the 
protective effects of IRF3 and IRF7 in VGD, type-I IFN production must be increased 
in the early phase to induce IRF7 gene expression in the early phase, so IRF7 can 
contribute to the type-I IFN production along IRF3. However, in future experiments it 
must be taken in consideration that IRF3 and IRF7 can be present in an active or resting 
form, and their function can be cell specific. To investigate cell specific functions of 
IRF3 and IRF7, inducible knockouts can be used in the future, which will also exclude 
the genetically induced morphological differences in grafts used in our knockout mice. 
We show an anti-inflammatory effect of type-I IFNs on vein graft vessel wall thickening, 
however, the mechanism behind this anti-inflammatory effect of type-I IFNs is 
complex. At first, the IFN system was shown to be part of the host innate immunity, 
through its antiviral functions, although activation of type-I IFN mediates a variety of 
immunoregulatory effect, suggesting an important link between innate and adaptive 
immunity38. Previous studies showed that in vitro, IFNβ inhibited human VSMC growth 
and VSMCs expressed the IFNβ gene and could thereby inhibit neointima formation39. 
In vivo, it was shown that an adenoviral vector encoding IFNβ reduced VSMC 
proliferation and intima hyperplasia in a porcine balloon injury model40. In line with 
these studies we showed an increased VSMC proliferation in Irf7-/- vein grafts compared 
to Irf3-/- vein grafts. Besides, it is shown that IFNβ has some anti-inflammatory roles in 
certain diseases41, such as familiar Mediterranean fever 42, Behcet’s syndrome43 and 
relapsing-remitting MS44. A recent study described two potential anti-inflammatory 
mechanisms of type-I IFNs22, via the inhibition of NLRP1 and NLRP3 inflammasome, 
or via induction of IL-10 who then through activation of STAT3 transcription factor 
reduced the abundance of pro-IL-1a and pro-IL-1β. Indicating that IFNβ can induce IL-
10 and inhibit the inflammasome and thereby regulate vein graft disease, which is in 
line with previous studies who described an important role of the inflammasome in 
the pathophysiology of vein graft remodeling45. However, the exact mechanism of the 
protective effect of type-I IFNs in vein graft disease is still unknown and needs to be 
further investigated for optimal therapeutic application. 
In conclusion, our study revealed a role for IRF3 and IRF7 in the regulation of vein graft 
vessel wall thickening via type-I IFNs. So far a protective role for IRF3 and IRF7 on vein 
graft vessel wall thickening is observed, giving rise to potential new strategies to use 
IRF3, IRF7 or type-I FNs in a therapeutic approach. 
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Figure 8. Model of signaling pathways through TLR3 and TLR4. Summary of in vitro and in vivo results.
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Figure S1. Total vessel wall area (a,c,e,g) and lumen area (b,d,f,h) of Irf3-/-, Irf7-/- and control mice, 





CD8+ T cells protect during vein graft disease 
development
K.H. Simons, M.R. de Vries, H.A.B. Peters, J.W. Jukema, P.H.A. Quax*, R. Arens*
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Vein grafts are frequently used conduits for arterial reconstruction in patients with 
cardiovascular disease. Unfortunately, vein graft disease (VGD) causes diminished 
patency rates. Innate immune system components are known to contribute to VGD. 
However, the role of T cells has yet to be established. The purpose of this study was 
to investigate the role of T cells and T cell activation pathways via the T cell receptor 
(TCR), co-stimulation and bystander effect in VGD.
Methods and results
Here we show upon vein graft surgery in mice depleted of CD4+ T cells or CD8+ T 
cells, that CD8+ T cells are locally activated and have a major protective role for vein 
graft patency. In presence of CD8+ T cells vein grafts appear patent while CD8+ T cell 
depletion results in occluded vein grafts with increases apoptosis. Importantly, the 
protective effect of CD8+ T cells in VGD development was TCR and co-stimulation 
independent. This was demonstrated in vein grafts of OT-I mice, CD70-/-, CD80/86-/- 
and CD70/80/86-/- mice compared to C57BL/6 mice. Interestingly, cytokines including 
IL-15, IL-18, IL-33 and TNF are up-regulated in vein grafts. These cytokines are 
cooperatively capable to activate CD8+ T cells in a bystander-mediated fashion, in 
contrast to CD4+ T cells. 
Conclusions
T cells are modulators of VGD with a specific protective role of CD8+ T cells, which 
are locally activated in vein grafts. CD8+ T cells may protect against occlusive lesions 





The vena saphena magna is the preferred conduit for arterial reconstruction in 
patients with cardiovascular disease. After vein graft surgery, intimal hyperplasia 
development through proliferation and migration of vascular smooth muscle 
cells (VSMCs), deposition of extracellular matrix and macrophage accumulation 
and proliferation, leads to narrowing of the vessel lumen, called vein graft disease 
(VGD)1. Therefore, vein grafts display limited patency, with a rate of occlusion of 
approximately 60% in 10 years after surgery. Whereas the innate immune system has 
been shown to be involved in VGD2, the role of T cells of the adaptive immune system 
has yet to be established. 
Previous studies have shown that T cells play a role in other cardiovascular diseases 
such as atherosclerosis3, 4. Both CD4+ and CD8+ T cells are present in atherosclerotic 
plaques. Th1 CD4+ T cells have pro-atherogenic effects via production of IFNγ and 
TNFα, while Th2 CD4+ T cells and regulatory T cells limit atherosclerotic plaque 
formation via IL-10 and TGFβ production5-8. Remarkably, CD8+ T cells seem to be 
locally activated in atherosclerotic plaques9. CD8+ T cells have demonstrated both 
protective and pathogenic roles in atherosclerosis10, 11. Whether CD4+ and CD8+ T 
cells are positive or negative modulators of VGD, is yet unknown.
T cells can be activated via different stimulatory signals provided by antigen 
presenting cells (APCs). Antigenic stimulation (signal 1) occurs via the T cell receptor 
(TCR) upon binding cognate peptide-MHC complexes. The Ig family member CD28 
is constitutively expressed on naive T cells, and provides imperative co-stimulation 
(signal 2) that cooperates with TCR triggering to achieve proper T cell activation. 
The ligands of CD28, i.e. CD80 and CD86, are up-regulated upon activation of APCs. 
Interaction of CD80/86 with the inhibitory receptor CTLA-4 leads to dampening of T 
cell activation12, 13,14. The co-stimulatory receptor CD27, belonging to the TNFR family, 
is also present on the majority of T cells15 and interacts with its unique ligand CD70. 
Expression of CD70 is transiently up-regulated on subsets of activated APCs, and this 
constricted regulation is essential to avoid immune over-activation16, 17 Inflammatory 
cytokines such as IL-12, IL-18 and type I interferons (IFN) can provide additional 
bystander signals (signal 3) for T cell activation18. Macrophages and dendritic cells are 
well studied APCs known to provide all these important signals to T cells, and both 
are present in vein grafts1, 19. Notably VSMCs are also able to express MHC molecules 
and co-stimulatory molecules, especially after stimulation with interferon-g (IFNg)20, 
21 and in this way, VSMCs might be capable of T cell activation and function as APCs 
in vein grafts. 
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In this study, we examined the role of T cells in the development of VGD, and dissected 
the underlying mechanism of T cell activation pathways involved. Investigations in a 
murine VGD model revealed a strong protective effect of locally activated CD8+ T 
cells by depletion of either CD4+ T cells or CD8+ T cells. This protective effect was 
associated with increased apoptosis in CD8+ T cell depleted mice. Remarkably, by 
using TCR transgenic mice and co-stimulation knockout mice, we showed that this 
protective effect of CD8+ T cells in VGD development is TCR and co-stimulation 
independent In addition, multiple bystander cytokines are present in the vein 
grafts and are able to induce CD8+ T cell activation. Thus, CD8+ T cells protect VGD 
development in a TCR independent and co-stimulation independent way, but most 
likely via bystander cytokines.
Material and methods
Study approval and mice
This study was performed in compliance with Dutch government guidelines and 
the Directive 2010/63/EU of the European Parliament. All animal experiments were 
approved by the animal welfare committee of the Leiden University Medical Center. 
C57BL/6 mice were purchased from Charles River Laboratories and crossbred in our 
own colony for at least 18 generations. CD70-/-, CD80/86-/- and CD80/86/70-/- were 
bred in house on a C57BL/6 background22. T cell receptor (TCR) transgenic mice 
recognizing the MHC class I-restricted SIINFEKL epitope derived from Ovalbumin (OT-
I mice)23 were obtained from The Jackson Laboratory. The TCR transgenic OT-I mouse 
is known to have an almost exclusive monoclonal TCR population (Va2/Vb5)24. This is 
caused by the strong transgenic TCR expression, which accelerates passing of T cells 
via the double positive (DP) stage resulting in negligible endogenous segments to 
be rearranged. The transgenic beta chain induces allelic exclusion and suppresses 
rearrangement of endogenous beta chains. In TCR beta chain transgenic mice 
~90% of peripheral T cells carry the transgenic beta chain and only 0-20% expresses 
endogenous ones. In the OT-I mice we used, 99.1% of the CD3+CD8+ T cells had a 
Va2+Vb5+ TCR (figure S1). All used mice were male and aged 10 to 18 weeks. 
Vein graft surgery
Vein graft surgery was performed in mice by donor caval vein interpositioning in the 
carotid artery of recipient mice25. All recipient mice received donor caval veins from 
genetic identical littermates. After 28 days mice were sacrificed and blood, draining 
and non-draining lymph nodes, spleen and vein graft or vena cava were harvested 
for flow cytometric analysis and/or (immuno)histochemical analysis. Mice were 
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anesthetized by intraperitoneal injection of a combination of midazolam (5 mg/kg, 
Roche), medetomidine (0.5 mg/kg, Orion) and fentanyl (0.05 mg/kg, Janssen) before 
surgery and at sacrifice. Flumazenil (0.7 mg/kg, Fresenius Kabi) was intraperitoneal 
injected after surgery to antagonise anaesthesia. After surgery and on indication, 
buprenorphine (0.1 mg/kg, MSD Animal Health) was given as an analgesic. Patency of 
vein graft was macroscopically determined at sacrifice and stated as clearly pulsatile, 
not clearly pulsatile or occluded.
Gene set enrichment analysis 
Vein grafts of male mice were harvested 14 days after surgery and compared with 
vein grafts harvested at surgery (day 0) (n=4/group). Total RNA was isolated from 
vein grafts using TRIzol® (Ambion® by Life Technologies) and was quantitated using a 
NanoDrop 1000 Spectrophotometer (Thermo Scientific). cDNA was synthesized using 
a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to 
the manufacturer’s protocol.
Gene set enrichment analysis (GSEA) was performed with the curated gene sets 
from Kegg, Biocarta, the Reactome and published studies, resulting in a total of 1564 
gene sets. For each gene set an enrichment score (ES) is calculated representing 
the difference between expected and observed ranking, which correlates with 
the phenotype of the vein grafts. By permuting the phenotype labels, a statistical 
significance (nominal P value) for the ES is provided. An adjustment for the gene set 
size generates the normalized enrichment score (NES). To correct for multiple testing 
the proportion of false positives is calculated to provide the false discovery rate (FDR) 
corresponding to each NES. A FDR less than 5% was considered significant. Method 
is fully described previously26. 
In vivo CD4+ and CD8+ T cell depletion
Depletion of either CD4+ T cells, CD8+ T cells or both was performed by intraperitoneal 
injections of depleting antibodies. Male mice were divided in five groups; CD4+ T 
cell depletion group (n=12), CD8+ T cell depletion group (n=12), CD4+ and CD8+ T 
cell depletion group (n=12), control group (n=12) and a naïve (not operated group) 
group (n=7). At one day prior to operation and 3, 10, 17 and 24 days after operation 
mice were injected with antibodies to deplete CD4 T cells (anti-CD4 clone GK1.5), 
CD8+ T cells (anti-CD8 clone 2.43), or both CD4+ T cells and CD8+ T cells or were 
injected with a control antibody (control mAb clone GL113). Prior to operation the 
injected amount was 200 µg mAb per mouse and, postoperative 100 µg per mouse 
was provided. Blood from tail vein was obtained 7 and 14 days after surgery and at 
sacrifice to check T cell subset depletion with flow cytometry. 
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Vein graft mouse experiments
To examine if donor caval veins, used as a vein graft, contain (activated) T cells prior 
to operation, we performed vein graft surgery in male C57BL/6 mice (n=3) and 
harvested the vein graft after 28 days, or performed no surgery (n=3) and harvested 
the caval vein after 28 days. Vein grafts or caval veins were used for flow cytometry. 
Vein graft surgery was performed in CD80/86/70-/- mice (n=14), CD80/86-/- mice (n=14), 
CD70-/- mice (n=12) and C57BL/6 mice as a control (n=11), fed a chow diet ad libitum 
and sacrificed after 28 days. Vein grafts were harvested for immunohistochemical 
analysis. 
Vein graft surgery was performed in male OT-I mice (n=5) and male C57BL/6 mice as 
a control (n=11). Vein grafts were used for flow cytometry.
Flow cytometry
Flow cytometry was performed on blood, spleen, draining and non-draining lymph 
nodes, vena cava and/or vein grafts. Single-cell suspensions were prepared from 
spleens and draining and non-draining lymph nodes, by mincing the tissue through 
a 70 µm cell strainer (BD Biosciences). Vein grafts and vena cavae were pre-treated 
with a liberase enzyme mix for 30 minutes and washed with 10 ml Iscove’s Modified 
Dulbecco’s Medium (IMDM, Lonza), 8% fetal calf serum (FCS, Life Technologies) and 100 
U/mL penicillin/streptomycin (PS, Life Technologies). Erythrocytes were lysed in a red 
blood cell lysis buffer (hypotonic ammonium chloride buffer). Conjugated monoclonal 
antibodies to mouse CD11b (V450, eBioscience), Class II (V500, BD Horizon), Ly6C 
(fluorescein isothiocyanate [FITC], Biolegend), CD11c (phycoerythrin [PE], Biolegend), 
CD86 (Allophycocyanin [APC], Biolegend), F4/80 (PE-Cy7, Biolegend), Ly6G (Alexa 
Fluor 700, Biolegend), CD19 (APC-Cy7, eBioscience), CD44 (V450, eBioscience), 
CD8 (FITC, Biolegend), TCR Beta (PE, eBioscience), CD25 (APC, eBioscience), KLRG1 
(PE-Cy7, eBioscience), CD62L (APC-Cy7, eBioscience), CD4 (Brilliant Violet 605, 
Biolegend). Dead cells were excluded by positivity for 7-aminoactinomycinD (7-
AAD) (Invitrogen). Flow cytometric acquisition was performed on a BD LSR II flow 
cytometer (BD Biosciences). Data were analysed using FlowJo V10.1 software (BD). 
Flow cytometry gating strategies are shown in figure S2.
RNA isolation, cDNA synthesis and RT-PCR from vein graft tissue
Total RNA was isolated from 10 (20µm thick) paraffin sections of vein grafts 3, 7, 14 and 
28 days after surgery. The method and analysis of RNA isolation, cDNA synthesis and 
RT-PCR was performed as previously described27. In brief, RNA was isolated according 
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to manufacturer’s protocol (FFPE RNA isolation kit, Qiagen). FFPE RNA was reverse 
transcribed using the RT² First Strand Kit (SA Biosciences). RNA for single qPCR was 
reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit according 
to the manufacturer’s protocol. Commercially available TaqMan gene expression 
assays for hypoxanthine phosphoribosyl transferase (HPRT1), and selected genes of 
interest were used (Applied Biosystems). qPCR analysis was performed using a RT2 
Profiler PCR Array (SA Biosciences) according to the manufacturer’s protocol. The 
complete list of the genes analysed is available at http://www.sabiosciences.com/
rt_pcr_product/HTML/PAMM-016Z.html. Prior to RT2 profiler array, all qPCRs were 
performed on a 7500/7500 Fast Real-Time PCR System. In total we used 6 vein grafts 
per group, 2 pools of 3 vein grafts were analysed. With the average of these two pools, 
the 2-ΔΔCt method was used to analyse the relative changes in gene expression. The 
fold change compared to the control vein graft was measured. 
Vascular wall lesion analysis
Vein graft samples were embedded in paraffin and sequential cross sections (5 µm 
thick) were made throughout the embedded vein grafts. To quantify the vein graft 
thickening (intimal hyperplasia), HPS staining was performed using Hematoxylin, 
Phloxin 0.25%, and Saffron 0.3%. Vessel wall area (vein graft thickening) was defined 
as the area between lumen and adventitia and determined by subtracting the luminal 
area from the total vessel wall area. Antibodies directed at Mac-3 (BD Pharmingen) 
to quantify macrophages and alpha smooth muscle cell actin (αSMactin, Sigma) to 
quantify smooth muscle cells were used for immunohistochemical staining 28. And in 
addition a Caspase 3 staining was performed to analyse apoptosis. Sirius red staining 
(Klinipath 80115) was performed to quantify the amount of collagen present in the 
vein grafts. The immuno-positive area measured is expressed as a percentage of the 
vessel wall area. Stained slides were photographed using microscope photography 
software (Axiovision; Zeiss) and image analysis software was used (Qwin; Leica, 
Wetzlar). 
Cell culture
VSMCs were acquired by isolating them from male mouse aortas29. VSMCs were 
cultured using medium consisting of DMEM Glutamax with 20% fetal bovine serum 
(FBS, Sigma), 1% non-essential amino acids and 1% PS. 
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D1 cells are a long-term growth factor-dependent immature myeloid dendritic cell 
line of splenic origin derived from a female C57BL/6 mouse. D1 cells were cultured 
in IMDM containing 10% heat inactivated FBS, 2 mM GlutaMax (GIBCO), 50 μM 
β-mercaptoethanol and 30% supernatant from R1 cells (mouse fibroblast NIH/3T3 
cells transfected with mouse GM-CSF gene), which was collected from confluent 
cultures and filtered.
In vitro CD8+ T cell activation 
CD8+ T cells of OT-I mice were isolated from the spleen of male and female mouse, 
by using the mouse CD8+ T lymphocyte enrichment set (BD Biosciences). VSMC 
ability to activate T cells was measured in supernatant of 50.000 VMSCs cultured with 
500.000 CD8+ T cells of OT-I mice, and stimulated for 24 hour with Ovalbumin (Ova) 
and lipopolysaccharide (LPS) 100 ng/mL from Escherichia coli K-235 ( Sigma-Aldrich). 
DCs (as described above) were used as positive control. As VSMC control groups, 
VSMCs were cultured without OTI T cells or without Ovalbumin, or OTI T cells were 
stimulated with Ovalbumin without VSMCs. 
To test the impact of cytokine combinations, 100.000 CD8+ T cells or CD4+ T cells 
isolated from spleens of C57BL/6 mice, were stimulated for 24 hours with agonistic 
antibodies against CD3 (0.1µg/ml), or with the following cytokines (either single 
or combined): IL-2 (20ng/ml), IL-18 (20ng/ml), IL-12 (20ng/ml), IL-33 (20ng/ml), IL-
15 (100ng/ml) and TNFα (20ng/ml). Culture medium was used as a control. In all 
experiments, the concentration of IFNγ was measured in supernatant using ELISA 
assays (BD Biosciences). 
Statistical analysis
All data are presented as mean ± SEM. GraphPad Prism 7.0 software was used for 
statistical analyses. Analysis of parametric data, that passed normality and equal 
variance tests, were performed by using a 2-tailed Student’s t-test to compare 
individual groups and a 2-way ANOVA comparing more than 2 groups. Mann-Whitney 
test was used for nonparametric data to compare individual groups that did not pass 
normality and equal variance tests, and a Kruskal-Wallis test was used to compare 
more than 2 groups. P value of <0.05 was considered significant.
Results
Presence of inflammatory cells in vein grafts
To examine whether genes of the adaptive immune system are actively transcribed 
in vein grafts, we performed pathway analysis by gene set enrichment analysis 
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Figure 1. a. Pathway analysis by gene set enrichment analysis (GSEA) on 1564 available gene sets. The 
top 35 of significantly up-regulated gene sets found in vein grafts sacrificed after 14 days compared 
to vena cavae at day 0 are shown. Normalised enrichment score (NES) is shown. For each gene set 
(pathway) an enrichment score (ES) is calculated that represents the difference between expected 
and observed rankings which correlate with the phenotype. An adjustment for the gene set size 
generates the normalized enrichment score (NES). Colours are similar to the illustration in figure. b. 
with TCR/CD8 pathways in bright blue, cytokine/chemokine pathways in green and Toll like receptors/
Nod like receptors in baby blue. The bigger the size of the circle, the higher the up-regulation of the 
gene. c. Vein graft cell composition measured with FACS analysis. Percentage of CD4+, CD8+, CD19+, 
CD11b+ and remaining cells in vein grafts as a percentage of all hematopoietic cells is shown, n=4. d. 
ratio of CD8+/CD4+ T cells in vein grafts, blood, spleen and draining lymph node is shown, n=4. CD8+ 
and CD4+ T cells are a percentage of total CD3+ T cells. e. Example of flow cytometry plot is shown 
of CD3+ CD8+ T cells in vein grafts (n=1) and f. CD3+ CD4+ T cells (n=1) in vein grafts. **p<0.01, *** 
p<0.001, one-way ANOVA.
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(GSEA) on 1564 available gene sets. We identified 176 significantly up-regulated 
curated gene sets in vein grafts sacrificed after 14 days compared to vena cavae at 
day 0, whereas 52 gene sets were down-regulated. In the top 35 of significantly up-
regulated gene sets found in vein grafts, TCR and CD8+ T cell pathways are found 
besides the expected extracellular matrix organization pathways, (figure 1a-b). 
Cytokine/chemokine pathways and Toll and Nod-like receptors are also found among 
the most up-regulated gene sets, illustrating that pathways of the immune system 
are active in the development of VGD.
To show that immune cells are present in vein grafts, we analysed vein grafts 
compared to blood, non-draining lymph nodes, draining lymph nodes and spleens 
with flow cytometry. Both CD4+ and CD8+ T cells are abundantly present in vein 
grafts. Interestingly, CD8+ T cells constitute 8.32% ±3.15 while the percentage of 
CD4+ T cells is 6.95%±2.13 (figure 1c). An elevated CD8/CD4+ T cell ratio in vein grafts 
was not observed in other organs (figure 1d-f ). Other abundant immune subsets in 
vein grafts are F4/80+ macrophages (35.91%±2.83), CD11c+ dendritic cells (30.22%± 
1.44) and CD19+ B cells (8.48%±1.58). Thus, compared to lymphoid organs such as 
spleen and draining and non-draining lymph nodes (figure S3), vein grafts have a 
higher CD8/CD4+ T cell ratio, relatively fewer B cells and more myeloid cells.
T cells are locally activated in vein grafts
Next, we examined the activation status of the T cells upon vein graft surgery. CD4+ 
and CD8+ T cells were phenotypically divided in naive T cells (CD44-CD62L+), effector 
T cells (CD44+CD62L-), or central memory T cells (CD44+CD62L+) (figure 2a). In vein 
grafts of control mice we observed a 4 fold increased percentage of CD8+ (figure 
2b) and CD4+ (figure 2c) effector T cells compared to other organs. Blood, spleen, 
draining and non-draining lymph nodes mainly consisted of naïve T cells and central 
memory T cells (figure S4). The activation status of T cells in vein grafts was validated 
using the activation markers KLRG123 and CD25. The percentage of KLRG1+CD62L- of 
total CD8+ and CD4+ T cells in vein grafts, as well as the percentage of CD25+CD44+ 
of total CD8+ T cells (but not total CD4+ T cells), was strikingly increased compared 
to blood, spleen, draining and non-draining lymph nodes (figure 2d-i). In addition, 
the percentage of activated effector T cells (CD44+CD62L-KLRG1+ and CD44+CD62L-
CD25+) of total CD8+ and CD4+ T cells was significantly higher in vein grafts compared 
to other organs (figure S5). A higher percentage of activated T cell in vein grafts 
compared to the surrounding draining and non-draining lymph nodes indicates local 
T cell activation in vein grafts. Furthermore, we compared blood, the spleen and non-
draining lymph nodes from operated mice with blood, the spleen and non-draining 
lymph nodes from naive, not operated mice. No differences were observed between 
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Figure 2a. Blood, spleen, (non) draining lymph nodes and vein grafts were analysed with FACS. CD44 and 
CD62L are used to quantify the percentage of effector (memory) T cells. Example of flow cytometry plot of 
a vein graft sample is shown. b. The percentage of effector (memory) CD8+ T cells (CD44+ CD62L- of total 
CD8+ T cells) is shown. c. The percentage of effector (memory) CD4+ T cells (CD44+ CD62L- of total CD4+ T 
cells) is shown. d. T cell activation was analysed with KLRG1 and CD62L. Example of flow cytometry plot of a 
vein graft sample is shown. e. The percentage of activated CD8+ T cells (KLRG1+ CD62L- of total CD8+ T cells) 
is shown. f. The percentage of CD4+ T cells (KLRG1+ CD62L- of total CD4+ T cells) is shown. g. T cell activation 
was analysed with CD25 and CD44. Example of flow cytometry plot of a vein graft sample is shown. h. The 
percentage of activated CD8+ T cells (CD25+ CD44+ of total CD8+ T cells) is shown. i. The percentage of CD4+ 
T cells (CD25+ CD44+ of total CD8+ T cells) is shown. a-i n=4/group. *p<0.05, **** p<0.0001, one-way ANOVA 
and Kruskal-Wallis test.
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control and naive mice in the percentage of activated T cells (KLRG1+CD62L- of total 
CD8+ and CD4+ T cells) and effector T cells (CD44+CD62L- of total CD8+ and CD4+ 
T cells) (figure S6). This indicated that the vein graft operation on its own had no 
systemic T cell activation effect. Importantly, the vena cavae that were used as donor 
grafts showed comparable percentages of CD8+ T cells and CD4+ T cells as vein grafts 
(figure S7a-b), but did not contain activated T cells prior to surgery (figure S7c-d). 
Together, these data indicate that T cells are locally activated in vein grafts upon 
surgery without systemic T cell activation.
CD8+ T cells are instrumental in preventing vein graft occlusions.
To investigate the particular role of CD4+ and CD8+ T cells in VGD, we depleted these 
subsets in mice undergoing vein graft surgery, and subsequently investigated vein 
graft patency. All mice were successfully depleted of either CD4+, CD8+ T cells or 
both in the blood, spleen, draining and non-draining lymph node and vein graft after 
antibody injection at 7 and 14 days after surgery and at sacrifice (figure S8 and S9). 
Postoperative 28 days after surgery, in both control and CD4+ T cell depleted group 
70% of the vein grafts was clearly pulsatile and patent (figure 3a-f ). A statistically 
significant difference in the pulsatility of the vein grafts postoperative was seen 
(p=0.04), with less clearly pulsatile vein grafts in the CD8+ T cell depleted group 
and in the CD4/8 T cell depleted group compared to the control group (respectively 
70% vs 10% and 70% vs 12.5%) (figure 3g-h). Thus, CD8+ T cells mediate a robust 
protective role in VGD. To provide insight into the mechanism of the CD8+ T cell 
necessity, we performed a Caspase 3 staining to identify apoptotic cells. In the patent 
control and CD4 T cell depleted mice, almost no cells in the vein grafts were positive 
for caspase 3 (figure 4). In contrast, in the occluded CD8 T cell depleted and CD4/CD8 
T cell depleted mice the vein grafts were stained abundantly for caspase 3. So, many 
cells in the vein grafts lacking CD8+ T cells are apoptotic, suggesting that the absence 
of CD8+ T cells induces apoptosis in vein grafts, which results in occluded vein grafts.
TCR independent T cell activation in vein grafts.
Next, given the local activation of CD8+ T cells in vein grafts and the importance of 
this T cell subset in the prevention of vein graft occlusions, we aimed to dissect the 
mechanisms underlying the local stimulation of CD8+ T cells. First, we questioned 
whether antigenic triggering via the TCR (signal 1) is required for the protective effect 
of CD8+ T cells in VGD development. For this we used OT-I mice in which all CD8+ 
T cells bear the same TCR recognizing chicken ovalbumin, an antigen that is not 
present in mice. Vein graft surgery was performed in these TCR transgenic OT-I mice, 
and patency of the grafts and T cell activation was determined after 28 days. The vast 
majority of the control vein grafts (75%) were patent as well as the OT-I mice (100%), 
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Figure 3a. Representative picture of a clearly pulsatile vein graft, 28 days after surgery b. and an 
occluded vein graft. c. Percentage of clearly pulsatile, not clearly pulsatile and occluded vein graft 
is shown in control (n=10), CD4+ T cell depleted (n=10), CD8+ T cell depleted (n=10) and CD4/CD8+ 
T cell depleted mice (n=8). A statistically significant difference with a Kruskal-Wallis test was seen 
(p=0.04) in the pulsatility of the vein grafts postoperative, with less clearly pulsatile vein grafts in the 
CD8+ T cell depleted group and in the CD4/8 T cell depleted group compared to the control group 
(respectively 70% vs 10% and 70% vs 12.5%). Representative pictures are shown of HPS stained d. 
vena cava prior to operation, e. control vein graft f. vein graft of CD4+ T cell depleted mice g. CD8+ 
T cell depleted mice and h. CD4/CD8+ T cell depleted mice, 28 days after surgery. 5x magnification, 
scale bar 200 µm.
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Figure 4a. Vein graft patency of control and OTI mice is shown. Percentage of clearly pulsatile and occluded 
vein graft is shown in control and OTI mice, not statistically different (p=0.236). A 2-tailed Student’s t-test 
was used. b. The percentage of activated CD8+ T cells (CD8+ KLRG1+ CD62L-) and c. effector (memory) 
CD8+ T cells (CD8+CD62L-CD44+) is shown of control and OTI mice in blood, spleen, (non) draining lymph 
nodes and vein grafts. a-c control n=4, OTI n=5. Mann-Whitney test was used. d. Production of inflammatory 
cytokines was measured in supernatant of DCs and VMSCs cultured with OTI T cells and Ovalbumin (Ova), 
stimulated with LPS for 24 hours. As control groups, VSMCs were stimulated without OTI T cells or without 
Ovalbumin and OTI T cell with Ovalbumin were stimulated without VSMCs. The concentration of IFNγ was 
measured in supernatant. n=6. **p<0.01, **** p<0.0001. One-way ANOVA was used. e. vein graft patency 
of control (n=11) and f. CD70-/- (n=12), g. CD80/86-/- (n=14) and h. CD70/80/86-/- (n=14) mice is shown 28 
days after surgery. Percentage of clearly pulsatile, not clearly pulsatile and occluded vein graft is shown. A 
statistically significant difference was not shown (p=0.679), Kruskal-Wallis test was used. 
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which was not statistically different (p=0.236) (figure 5a). Only 1 vein graft was 
occluded in the control group. Moreover, the percentage of KLRG1+CD62L-CD8+ T 
cells in the control and OT-I mice vein grafts were comparable, and clearly significantly 
increased compared to other tissues (figure 5b). In addition, no differences in effector 
CD44+CD62L-CD8+ T cells between vein grafts of control mice and OT-I mice were 
observed (figure 5c). Thus, in presence of a transgenic TCR, CD8+ T cells can still be 
activated in vein grafts, and CD8+ T cells can still mediate a protective effect in VGD 
development, indicating that this is TCR independent. 
The lack of requirement for TCR triggering may be caused by the absence of cell 
types able to present antigen to CD8+ T cells. Therefore, we examined if VSMCs, a 
prominent cell type in vein grafts, can function as APCs to activate T cells via the TCR. 
VSMCs and DCs, known as professional APCs, were stimulated with LPS in absence or 
presence of OT-I T cells and Ovalbumin. Albeit less than DCs, VSMCs were capable of 
T cell activation as evidenced by induction of IFNγ production in OT-I cells (figure 5d). 
T cell co-stimulation independent VGD development.
T cell co-stimulation cooperates with antigenic triggering. Since we observed that 
the protective effect of CD8+ T cells in VGD development is independent of TCR 
triggering, we investigated whether co-stimulation (signal 2) contributes to CD8+ 
T cell dependent VGD protection. We performed vein graft surgery in mice deficient 
in one or more co-stimulatory ligands; i.e. CD70-/-, CD80/86-/- and CD80/86/70-/- mice. 
After 28 days, in both control and CD70-/- mice 64% of the vein grafts were clearly 
pulsatile and patent (figure 5e-f ) and respectively 77% and 85% of the vein grafts of 
CD80/86-/- and CD80/86/70-/- mice were clearly pulsatile (figure 5g-h). A statistically 
significant difference was not revealed (p=0.679). The pulsatility of the vein grafts, 
was supported by histology since HPS stained vein grafts showed open grafts and 
comparable lumen area and total vessel area in all co-stimulation knockout and 
control mice vein grafts (figure S10). Only a small decrease in vessel wall area in 
CD80/86/70-/- mice compared to control mice vein grafts was observed, showing that 
co-stimulation is not essential for CD8+ T cells to obtain a robust protective effect in 
vein grafts. 
Cytokines mediating bystander CD8+ T cell activation are present 
in vein grafts.
The above described TCR and co-stimulation independent effect of CD8+ T cells in 
VGD, suggests a role for bystander (non-antigen specific) cytokines (signal 3) of CD8+ 
T cells in vein grafts. Hence, we examined using the Illumina micro array, whether 
different cytokines which are capable to provide signals to CD8+ T cells without TCR 
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Figure 5a. Heat map of cytokine and cytokine receptor regulation in time in vein grafts. RT2 
profiler array was performed on RNA isolated of vein grafts 3 days, 7 days, 14 days and 28 days after 
surgery. n=6 vein grafts per groups, pooled as n=2. With the average of these two pools, the 2-ΔΔCt 
method was used to analyse the relative changes in gene expression. The fold change compared 
to the control vein graft is shown. b. CD8+ T cells were stimulated for 24 hours with agonistic CD3 
antibodies, interleukins and TNFα in different combinations. Statistical tests performed compared 
cytokine combinations to cytokines alone. IFNγ was measured as CD8+ T cell activation marker with 
ELISA. *p < 0.05, **p<0.01, One-way ANOVA was used.
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and co-stimulation activation, are present in vein grafts. Interleukins such IL-6, IL-12a, 
IL-15, IL18, IL-33 and the effector cytokines TNFα and IFNγ are present and regulated 
in time in vein grafts after surgery (figure 6a). Also present are interleukin receptors 
such as the IL-1, IL-2 and IL-15 receptor. Furthermore, the IFNα and IFNβ receptor 
Ifnar2 was also up-regulated as well as the Toll-like receptors TLR2 and TLR4, known 
to induce inflammatory cytokines and up-regulation of co-stimulatory molecules 
upon ligation.
To investigate CD8+ T cell bystander activation in relation to the plethora of signals 
present in vein grafts, single and combinatorial effects of interleukins and co-signals 
from the TCR were examined ex vivo (figure 6b). Single interleukins such as IL-2, IL-
12, IL-15, IL-18 and IL-33 were not capable to elicit IFNγ secretion of CD8+ T cells 
significantly. Conversely, combinations of interleukins, such as IL-2/IL-18, IL-12/IL-2, 
IL-12/IL-18, or IL-2/IL-33 induced substantial CD8+ T cell activation as compared to 
interleukins alone or TCR triggering (mimicked by anti-CD3 monoclonal antibody) 
alone. Interestingly, CD8+ T cell bystander activation was stronger compared to 
CD4+ T cell bystander activation (figure S11). Single interleukins or combinations of 
interleukins, such as IL-2/IL-18, IL-12/IL-2 or IL-2/IL-33 did not induce IFNγ secretion by 
CD4+ T cells. Mainly a combination of IL-12 and IL-18 induced CD4+ T cell activation. 
Collectively, these data indicate that bystander cytokines are present in vein grafts, 
and can collectively activate CD8+ T cells.
Discussion
In the current study we show that T cells are modulators of VGD with a specific 
protective role of CD8+ T cells. Both CD4+ and CD8+ T cells are present in vein grafts 
and locally activated without systemic activation. Depletion of CD8+ T cells resulted 
in fully occluded vein grafts, and this was associated with increased apoptosis. 
Remarkably, the protective effect of CD8+ T cells in vein grafts was TCR and co-
stimulation independent. However, bystander signals provided via cytokines can, in a 
collective manner, activate CD8+ T cells. Importantly, these cytokines are abundantly 
present in vein grafts. 
Previous studies showed that CD8+ T cells modulate cardiovascular diseases30 and 
are present in atherosclerotic lesions31, however, others showed that CD8+ T cells are 
not functional in atherosclerosis32, 33. Recent studies have described a role for CD8+ T 
cells in atherosclerosis, either pro-atherogenic or anti-atherogenic34. Pro-atherogenic 
effects of CD8+ T cells 35, 36 have been revealed via their impact on circulating monocyte 
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Figure 6a. Heat map of cytokine and cytokine receptor regulation in time in vein grafts. RT2 profiler 
array was performed on RNA isolated of vein grafts 3 days, 7 days, 14 days and 28 days after surgery. In 
total 2 pools were analysed (n=3 vein grafts per pool). With the average of these two pools, the 2-ΔΔCt 
method was used to analyse the relative changes in gene expression. The fold change compared 
to the control vein graft is shown. b. CD8+ T cells were stimulated for 24 hours with agonistic CD3 
antibodies, interleukins and TNFα in different combinations. Statistical tests performed compared 
cytokine combinations to cytokines alone. IFNγ was measured as CD8+ T cell activation marker with 
ELISA. *p < 0.05, **p<0.01, One-way ANOVA was used.
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levels though increased CCL2 and VCAM1 expression, leading to macrophage 
accumulation in the arterial intima promoting atherosclerotic lesion formation35. This 
is in distinction with our results of occlusive vein grafts after depletion of CD8+ T 
cells. Anti-atherogenic effects of CD8+ T cells have been shown after arterial injury 
in mice37. All pro-atherogenic studies described above showed no effect in CD4+ 
T cell levels after CD8+ T cell depletion, indicating that there is no compensation 
mechanism of the CD8+ T cell loss by CD4+ T cells. This is in line with our observations 
in both CD4+ and CD8+ T cell depleted mice where no compensation mechanism 
after depletion of a T cell subset was observed. 
A striking impact of CD8+ T cells was apparent since vein grafts of CD8 T cell depleted 
mice were occluded. Previous studies showed that CD8+ T cells play a role in anti-tumor 
immunity38, 39 and immune checkpoint inhibitors can be effective in the activation of 
CD8+ T cell responses and can restore anti-tumor immune responses40. CD8+ T cells in 
tumors can function via direct and indirect tumor killing. CD8+ T cells are described to 
recognize target cells via the expression of antigens, which causes direct tumor killing. 
After recognition, they kill target cells by apoptosis, via the release of perforin and 
granzymes out of cytotoxic granules. However, CD8+ T cells in vein grafts are activated 
in an antigen independent manner, which is more similar to indirect tumor killing. Via 
the release of cytokines, CD8+ T cells can indirectly kill the tumor cells41, 42. Presence of 
CD8+ T cells in the tumor environment is associated with beneficial clinical outcomes in 
several tumor types39. However, in the studies described above, not only effector CD8+ 
T cells are described, but also memory CD8 T+ cells that have been previously activated 
by their cognate antigen are described as indirect tumor killers. Here we observed that 
many cells in the CD8+ T cell depleted vein grafts and CD4/CD8+ T cells depleted vein 
grafts are apoptotic, suggesting that the absence of CD8+ T cells induces apoptosis in 
vein grafts, which results in occluded vein grafts. Thus, CD8 T cells may protect against 
occlusive lesions by providing survival signals in vein grafts.
We questioned whether the protective CD8+ T cell effect was TCR and co-stimulation 
dependent. In presence of a transgenic TCR, specific for an antigen that is not present 
in mice, we showed that CD8+ T cells are still activated in vein grafts. Furthermore, vein 
grafts of OT-I mice were clearly pulsatile, which suggests that the CD8+ T cells can still 
mediate their protective effect in VGD development, and indicates that the protective 
CD8+ T cell is TCR independent. In vivo we showed no effects of the co-stimulation 
pathways CD27-CD70 and CD28-CD80/CD86 in VGD development. We showed that 
vein grafts occlude in CD8+ T cell depleted mice, but in the presence of activated 
CD8+ T cells, vein grafts are clearly pulsatile. Deficiency of one or both co-stimulatory 
pathways did not lead to a reduction in vein graft pulsatility, which indicates that the 
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protective effect of CD8+ T cells in VGD development is co-stimulation independent. 
Interestingly, the vein graft vessel wall area was decreased in CD70/80/86-/- mice 
compared to control mice, suggesting that the protective CD8+ T cell response is 
stronger than the CD4+ T cell effect. In figure 6 and S9 we showed that CD8+ T cells 
can be activated via a plethora of bystander cytokines, in contrast to CD4+ T cells. With 
the lack of co-stimulation molecules, CD8+ T cells can still be activated via bystander 
cytokines and may explain the strong CD8+ T cell effect.
We here showed that T cells present in vein grafts are locally activated. Even in the 
draining lymph nodes, located close to the vein grafts, no activated T cells were 
detected. The CD8+ T cell activation in vein grafts was found to be TCR independent. 
In infection models it is clear that TCR triggering is, by definition, essential to activate 
antigen-specific T cells. T cell activation, however, can also occur in absence of the 
TCR43-48. TCR independent CD8+ T cell activation, allows CD8+ T cells to modulate e.g. 
non pathogen specific diseases such as VGD, where a vein graft is placed in a sterile 
environment18. Here we describe TCR independent T cell activation in vein grafts of 
mice, and propose that CD8+ T cell activation in vein grafts is due to bystander signals. 
Certain cytokines can induce bystander proliferation and activation of CD8+ T cells18, 
49. Especially IL-12 and IL-18 are key regulators of CD8+ T cell activation50, 51. IFNγ leads 
to production of IL-12, IL-18 and especially IL-15, which can activate CD8+ T cells49,52. 
CD4+ T cells are mainly activated via a combination of IL12 and IL18. Interestingly, as 
shown in the heatmap of figure 6a, IL33 and TNFα are the highest expressed cytokines 
in vein grafts. However, IL15, IL33 and TNFα could not activate CD4+ T cells (figure S11), 
in contrast to CD8+ T cells (figure 6b). Type I interferons, IFNα and IFNβ also showed to 
enhance IFNγ production, synergistically with IL-18 in human T cells53. In contradiction, 
CD8+ T cell inhibition via type I Interferons was shown via suppression of the IL-12 
pathway54. Several other cytokines, including IL-1β and TNF-α, can enhance IFN-γ 
production in CD8+ T cells18, 55. IL-33 is mainly expressed by Th2 cells and mast cell, 
but IL-33 has also been shown to enhance TCR independent virus specific CD8+ T cell 
activation18, 56. However, in line with our results, these cytokines do not activate CD8+ 
T cells individually, but combinations of cytokines are functional and show synergic 
effects. 
In conclusion, we here show that T cells play a role in VGD, with a specific protective 
role of CD8+ T cells. The protective effect of CD8+ T cells in vein grafts is TCR and co-
stimulation independent. Bystander cytokines are abundantly present in vein grafts 
and have the capacity to activate CD8+ T cells in a collective manner independent of 
TCR and co-stimulation signals. This gives rise to potential new strategies to use T cell 
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Supplemental figures
Figure S1. Expression of Va2 and Vb5 on splenic CD3+CD8+ cells of OT-I mice. Percentage is shown.
Figure S2. Flow cytometry gating strategies. Representative plots show the gating strategy for 
detecting activated T cells and effector, central and naive T cells as depicted in figure 1,2 and 4. In 
this sequential gating, cells were first gated on lymphocytes (forward-scatter (FSC-A) vs. side-scatter 
(SSC-A)). The cells were analysed for their uptake of 7AAD to exclude dead cells and were subsequently 
gated on singlets (FSC-A vs. FSC-H). The cells were further analysed on their CD3 and CD8 expression. 
CD3+ CD8+ T cells were gated on KLRG1, CD62L, CD44 and CD25.
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Figure S3. Cell composition measured with FACS analysis. Percentage of CD4+, CD8+, CD19+, 
F4/80+, CD11c+ and other cells are shown in a. blood b. spleen c. non-draining lymph node and d. 
draining lymph node. Percentage is shown. n=4/group.
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Figure S4a. Blood, spleen, non-draining and draining lymph nodes and vein grafts were analysed 
with FACS. CD44 and CD62L are used to quantify the percentage of central memory T cells and naïve 
T cells. Example of flow cytometry plot is shown of a blood sample. b. The percentage of central 
memory CD8+ T cells (CD44+ CD62L+ of total CD8+ T cells) is shown. c. The percentage of naive CD8+ 
T cells (CD44- CD62L+ of total CD8+ T cells) is shown. d. The percentage of central memory CD4+ T 
cells (CD44+ CD62L+ of total CD4+ T cells) is shown. e. The percentage of naive CD4+ T cells (CD44- 
CD62L+ of total CD8+ T cells) is shown. b-e n=4/group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
One-way ANOVA test was used.
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Figure S5. Blood, spleen, (non) draining lymph nodes and vein grafts were analysed with FACS. CD44 
and CD62L are used to quantify the percentage of effector T cells. T cell activation was analysed with 
KLRG1 and CD25. a. The percentage of activated effector CD8+ T cells is shown as CD44+ CD62L-
KLRG1+ of total CD8+ T cells. b. The percentage of activated effector CD4+ T cells is shown as CD44+ 
CD62L-KLRG1+ of total CD4+ T cells. c. The percentage of activated effector CD8+ T cells is shown 
as CD44+ CD62L-CD25+ of total CD8+ T cells. d. The percentage of activated effector CD4+ T cells is 
shown as CD44+ CD62L-CD25+ of total CD4+ T cells. 1-d n=4/group. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. One-way ANOVA test was used.
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Figure S6. Blood, the spleen and non-draining lymph nodes of control mice and naive mice were 
analysed with FACS. KLRG1 and CD62L are used to quantify the percentage activated T cells. a. 
percentage of KLRG1+CD62L- of total CD8+ T cells b. percentage of CD44+CD62L- of total CD8+ T 
cells c. percentage of KLRG1+CD62L- of total CD4+ T cells d. percentage of CD44+CD62L- of total 
CD4+ T cells. Percentage is shown. a-k n=4/group. Mann-Whitney test was used. 
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Figure S7. a. Vena cava and vein grafts were analysed with FACS. Percentage of CD3+CD8+ T cells of 
total lymphocytes is shown and b. percentage of CD3+CD4+ T cells of total lymphocytes. c. percentage 
of KLRG1+CD62L- of total CD8+ T cells d. percentage of KLRG1+CD62L- of total CD4+ T cells. Percentage 
is shown. a-d n=4/group. *p<0.05, **p<0.01, ***p<0.001. Mann-Whitney test was used. 
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Figure S8. T cell depletion in blood. Example of flow cytometry plot is shown of a. CD4+ T cells and 
b. CD8+ T cells in CD4 T cell depleted mice. c. CD4+ T cells and d. CD8+ T cells in CD8+ T cell depleted 
mice. e. CD4+ T cells and f. CD8+ T cells in CD4/CD8+ T cell depleted mice. g. CD4+ T cells and h. CD8+ 
T cells in control mice. 
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Figure S9. T cell depletion in blood, spleen, draining lymph node (ln), non-draining ln and vein 
graft. Percentage is shown of CD3+ CD4+ T cells in CD4 T cell depleted mice, CD8+ T cell depleted 
mice, CD4/CD8+ T cell depleted mice and control mice in a. blood, b. spleen, c. draining lymph 
node d. non-draining lymph node e. vein graft. Percentage is shown of CD3+ CD8+ T cells in CD4 
T cell depleted mice, CD8+ T cell depleted mice, CD4/CD8+ T cell depleted mice and control mice 
in f. blood, g. spleen, h. draining lymph node i. non-draining lymph node j. vein graft. n=4/group. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. One-way ANOVA test was used.
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Figure S10. Vein graft composition of co-stimulation knockout mice. a. Representative pictures 
of HPS stained vein graft 28 days after surgery is shown of control mice, b. CD70-/- mice, c. 
CD80/86-/- mice, d. CD70/80/86-/- mice. 5x magnification, scale bar 200 µm. e. Vessel wall area (mm2) 
in vein grafts 28 days after surgery, f. Total vessel area (mm2) and g. lumen area (mm2) in control, 
CD70-/-, CD80/86-/- and CD70/80/86-/- mice is shown. (Immuno)histochemical staining of vein grafts 
is shown of h. Collagen area (mm2), i. Macrophage area (mm2), j. SMC area (mm2). Control (n=10), 
CD70-/- (n=8), CD80/86-/- (n=11) and CD80/86/70-/- (n=12) mice. *p < 0.05, **p < 0.01, Kruskal-Wallis 
test was used.
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8Figure S11. Bystander cytokine contribution to CD4+ T cell activation. CD4+ T cells were stimulated 
for 24 hours with agonistic CD3 antibodies, interleukins and TNFα in different combinations. Statistical 
tests performed compared cytokine combinations to cytokines alone. IFNγ was measured as CD4+ T 











General summery and future perspectives
Vascular remodeling is an active process of structural changes in the vasculature due 
to changes in the blood flow1. It comprises all diseases described in this thesis such 
as occlusive arterial disease (OAD), peripheral artery disease (PAD), coronary artery 
disease (CAD), neovascularization (angiogenesis and arteriogenesis) and vein graft 
disease (VGD), that are covered by cardiovascular diseases (CVD). The main underlying 
pathology of CVD is atherosclerosis which can narrow arteries due to atherosclerotic 
lesion formation and can cause ischemia distal to the occlusions2. Initially when 
atherosclerosis occurs, the body naturally prevents ischemia via neovascularization. 
Via the maturation of arterioles into functional arteries (arteriogenesis)3-6 a natural 
bypass develops, and together with the sprouting of new capillaries from a pre-
existing vasculature (angiogenesis)7, the blood flow to the tissue distal of the 
occlusion is restored. However, when the neovascularization capability of the body 
is not sufficient and if left untreated, this can lead to limb amputation or death. 
Symptomatic OAD patients can be treated with revascularization interventions such 
as angioplasty, using a balloon catheter which can be inflated at the site of occlusion 
to relieve the narrowing of the artery. In case of severe atherosclerotic lesions, when 
angioplasty in no longer possible, bypass surgery is indicated. However, due to e.g. 
VGD the patency rates of vein grafts after 10 years are low.
The aim of this thesis was to elucidate the function of the innate and adaptive immune 
system in vascular remodeling. Currently there is no textbook treatment to improve 
neovascularization, or inhibit or prevent VGD. Therefore, investigating the underlying 
mechanism of vascular remodeling is essential to find targets to treat CVD. We found 
several targets of the innate and adaptive immune system that can give rise to the 
development of new therapeutic strategies.
In chapter 2 we describe the cellular and molecular mechanisms behind the 
pathophysiology of vein graft failure (VGF) and review therapeutic options to 
improve the patency of both coronary and peripheral bypasses. Due to the serious 
consequences of vein graft failure, this needs appropriate attention. We described 
that to prevent early VGF due to thrombosis, antiplatelet and antithrombotic 
medication is recommended. For long term prevention of VGF statin treatment has 
been proven beneficial. New therapies like gene therapy and external stenting are 
promising but the positive effect on vein graft patency still needs to be proven. In 
addition to medication prevention strategies, vein graft harvesting, duration of the 
surgery, handling, size and condition of conduit and target vessel also influence the 
vein graft patency rates after surgery. Pre-clinical and clinical studies have gained 
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insight in the cellular and molecular processes of the mechanisms contributing to 
VGF, which can be interesting for future studies to find a treatment to prevent VGF. 
Both the innate and adaptive immune system play an important role in the 
development of VGD, but an unequivocally effective treatment to target this has 
not been found yet. However, in the recent years several treatments to stimulate or 
inhibit T cells of the adaptive immune system have been developed. Modulation of 
the immune response towards malignant cells has been successfully introduced in 
cancer treatment and showed beneficial effects with the use of Immune Checkpoint 
Inhibitors (ICIs). ICIs can block co-inhibitory pathways on T cells, causing T cell 
activation which can results in tumor cell lysis. However, the role of co-stimulation and 
inhibitory pathways in CVD are poorly described, so the outcomes of the use of ICI in 
CVD are unknown. In the review in chapter 3, we provided an overview of the major 
co-stimulatory and inhibitory pathways in the pathogenesis of a number of CVD. 
Blocking of co-stimulation pathways, resulting in T cell anergy, might be interesting 
therapeutic targets for CVD. On the other hand, ICIs and stimulation of co-stimulation 
receptors, resulting in activated T cells, might poses serious cardiovascular risks. Thus, 
although ICIs are revolutionary in cancer treatment, the risk of cardiovascular toxicity 
should be taken into consideration. Subsequently, focussing on the inhibition of co-
stimulation pathways in the future could be world-shattering for the treatment of 
CVD. 
As neovascularization is an essential natural mechanism to prevention ischemia, we 
focussed on contributing mechanistic factors of neovascularization in chapter 4 that 
might be suitable targets to stimulate neovascularization in symptomatic patients. 
We observed that interferon regulatory factor (IRF)3 and IRF7 of the innate immune 
system are inevitable involved in neovascularization. In mice deficient of IRF3 and 
IRF7 we found a decreased inflammatory respond distal to induced occlusions. In line 
with this, we observed a decrease in angiogenesis and arteriogenesis resulting in an 
impaired post-ischemic blood flow recovery. This confirmed the contribution of IRF3 
and IRF7 to neovascularization. Furthermore, since IRFs regulated the inflammatory 
response, this indicates that there might be a linkage between the TRIF-IRF and TRIF-
NFĸB pathway.
In addition to the innate immune system, an involvement of T cells of the adaptive 
immune system was suggested in neovascularization. The contribution of co-
stimulation in T cell activation in neovascularization was studies in chapter 5. Both 
the CD28-CD80/86 and CD27-CD70 T cell co-stimulation pathways were investigated 
in a hind limb ischemia model with the use of CD70-/-, CD80/CD86-/- and CD70/80/86-
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/- mice. Post-ischemic blood flow recovery was only impaired in mice lacking CD70. 
In mice lacking CD70, the embryologic development of the circulatory system 
was already compromised, since we observed an impaired vasculogenesis, as the 
number of pre-existing collaterals was reduced in the pia mater and in the skeletal 
muscle. In addition, angiogenesis in soleus muscles 10 days after ligation was also 
impaired in mice lacking CD70, which all contributes to a diminished post-ischemic 
blood flow recovery. Interestingly, the CD27-CD70 T cell co-stimulation pathway, 
and not the CD28-CD80/86 T cell co-stimulation pathway, validated their purpose in 
neovascularization
As mentioned before, if the body is incapable of sufficient neovascularization to 
prevent ischemia after arterial occlusions, venous bypass grafting is a surgical option. 
However, VGD halts high patency rates. In chapter 6 we focused on the innate 
immune system in the development of VGD. In the pathophysiological processes 
of VGD, Toll like receptors (TLR) are considered to be important accelerating factors 
via the activation of an inflammatory response. We hypothesised that especially 
TLR3 is essential in the development of VGD as these TLRs are activated via dsRNA 
derived from damaged cells. During harvesting and preparation of the vein graft, 
during and after the surgical procedure, vascular cells are damaged and can release 
dsRNA. Indeed, TLR3 was involved in VGD development and we even showed a 
prominent protective role of TLR3 compared to control, TLR2 and TLR4 deficient mice. 
An increased vein graft thickening in TLR3 deficient mice was accompanied by an 
increase in macrophages in the vessel wall. We provide evidence that the molecular 
mechanism of the TLR3-induced protective effect is dependent on the production of 
type-I IFNs. A regulation of the mRNA expression of type-I IFN regulated genes via 
TLR3 in vein grafts and in vitro in BMM was observed. To validate that this protective 
effect in VGD development was regulated via type-I IFNs, the role of IRF3 and IRF7 
in VGD development was investigated in chapter 7. IRF3 and IRF7 are downstream 
factors of TLRs and regulate the transcription of type-I IFNs; IFNα and IFNβ. We showed 
that IRF3 and IRF7 are both activated downstream TLR3 and able to produce type-I 
IFNs, but IRF3 can also be activated downstream TLR4 and regulate the production of 
inflammatory cytokines in vitro, in VSMCs and macrophages. It was observed that IRF3 
and IRF7 deficient mice have similar protective effects in the development of VGD as 
TLR3 deficient mice, but IRF3 and IRF7 have different effects on VGD development in 
time. IRF3 is an early regulator of type-I IFNs, whereas IRF7 regulated late type-I IFN 
production. Thus, the data in chapter 6 and 7 suggest that the TLR3-IRF3/IRF7-type-I 




In chapter 8 we investigated the role of the adaptive immune system, in addition to 
the innate immune system. CD4+ and CD8+ T cell and their activation pathways via 
the T cell receptor (TCR), co-stimulation and bystander cytokines were investigated. 
Among the top 35 of significantly up-regulated gene sets found in vein grafts were 
TCR and CD8+ T cell pathways. We demonstrated in vivo in a vein graft mice model 
that both CD4+ and CD8+ T cells are abundantly present in vein grafts, with a 
higher percentage of CD8+ T cells. Interestingly, depletion of CD8+ T cells resulted 
in occluded vein grafts after 28 days, showing that CD8+ T cells mediate a robust 
protective role in VGD. We questioned whether antigenic triggering via the TCR is 
required for CD8+ T cells activation in vein grafts. Interestingly, after vein graft 
surgery was performed in TCR transgenic OT-I mice and control mice, we found 
similar vein graft patency rates and CD8+ T cell activation, showing that CD8+ T cell 
activation in vein grafts is TCR independent. Furthermore, bystander T cell activation-
inducing cytokines are present in the vein grafts and these cytokines are collectively 
able to activate CD8+ T cells. A synergistic effect of bystander cytokines to activated 
CD8+ T cells was observed with co-stimulation signals. Knocking out co-stimulation 
exhibited a modulating role of co-stimulation in VGD. Thus, T cells are modulators 
of the development of VGD with a specific and local protective role of CD8+ T cells. 
Activation of the CD8+ T cells in vein grafts is TCR independent and bystander signals 
via cytokines and additionally co-stimulation are imperative. 
Future perspectives 
In this thesis, we reviewed that the therapeutic options to improve the patency 
of both coronary and peripheral bypasses and stimulate neovascularization, are 
insufficient. Therefore, we investigated the role of several components of the innate 
and adaptive immune system on vascular remodeling. TLRs, IRFs, type-I FNs of the 
innate immune system, as well as T cells and T cell co-stimulation of the adaptive 
immune system were identified as essential regulators of vascular remodeling. This 
gives rise to potential new strategies to use these targets in a therapeutic approach 
to prevent or treat CVD. 
Most components that we investigated show a wide variety of interactions due to 
their serried signaling pathways as shown in figure 1. TLR3 stimulation can activate 
a TRIF dependent pathway, leading to the phosphorylation of IRF3 and IRF7. 
Subsequently IRF3 and IRF7 produce type-I IFNs, IFNα and IFNβ. TLR2 stimulation 
can activate a Myd88 dependent pathway, while TLR4 signaling can be via either the 
MyD88 or TRIF pathway. The Myd88 dependent pathway mainly activates NFĸB which 
results in pro-inflammatory cytokine production, such as the innate immune related 
TNFα and CCL2, but also IL12 and IL2, which are potent inducers of the adaptive 
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immune response. Pro-inflammatory cytokines IL12, IL2 and type-I IFNs, IFNα and 
IFNβ can bind to their receptor present on T cells, respectively IL12R, IL2R and IFNAR. 
Together with the TCR and/or co-stimulation molecules, these bystander cytokines 
can induce T cell activation. As we showed, this can be independent of the TCR in 
CD8+ T cells. The signaling pathways downstream TLR2, TLR3 and TLR4 connect all 
components of the innate and adaptive immune system. Interestingly, we showed 
beneficial effects of TLR3, IRF3, IRF7 and CD8+ T cells on vascular remodeling, which 
are all in sequentially involved in this signaling pathway. 
With regard to IRF it might be interesting to see the effect of type-I IFNs directly on 
vascular remodeling. We show that they are produced via the innate immune system 
and they can induce T cell activation, however they might also have a direct effect on 
vascular remodeling. This might be therapeutically interesting, since IFNs are already 
therapeutically available. IFNs are used to treat renal cell cancer, malignant melanoma, 
multiple myeloma, multiple sclerosis and some types of leukaemia8, 9. The therapeutic 
use of IFNs is based on their antiviral and anti-proliferative effect via the activation of 
cytotoxic CD8+ T cells and can be injected easily subcutaneously or intraperitoneal9, 
10. IFNs have been shown to increase class I MHC expression on tumor cells, activating 
CD8+ T cells that subsequently attack tumor cells. If IFN can also protect arteries to 
occlude or stimulates neovascularization, might be interesting to investigate. However, 
as we showed in chapter 7, the IFN treatment period after surgery should also be 
determined, since IRF3 and IRF7 are differently functional in time. 
In addition to type-I IFNs, we showed that bystander cytokines IL2, IL12, IL18 and IL33 
are cooperatively capable to activate CD8+ T cells in a bystander-mediated fashion 
and in synergy with co-stimulation. In chapter 8 a protective effect of CD8+ T cells 
in VGD was suggested, since CD8+ T cell depletion caused fully occluded vein grafts. 
Clinically it would be interesting to investigate the effect on VGD after local CD8+ 
T cell activation. This could be established via a CD8+ T cell expansion in vein grafts via 
a cocktail of bystander cytokines and co-stimulation, or monoclonal antibodies that 
can induce a clonal CD8+ T cell expansion. However, a clonal CD8+ T cell expansion 
should only be induced locally, since systemic clonal CD8+ T cell expansion could result 
in serious adverse effects. For future experiments it would be interesting to test several 
local delivery strategies, to create a clonal expansion of CD8+ T cells via bystander 
cytokines. Local delivery is mainly interesting for VGD, since (open) harvesting of the 
saphenous vein gives therapeutic opportunities without systemic side effect. For local 
delivery of e.g. IL2-IL12-IL18, lentiviral vectors or adeno-associated viral (AAV) vector could 
be used. In addition to viral vectors, monoclonal antibodies that induce a clonal CD8+ T 
cell expansion could be tested. Previously it was demonstrated that anti-4-1BB mAb is a 
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successful rheumatoid arthritis treatment. Anti-4-1BB mAb induced a clonal expansion 
of CD8+CD11c+ T cells which produced IFNγ and subsequently suppressed CD4+ T cells 
through an indoleamine 2,3-dioxygenase-dependent mechanism11. Therefore, anti-4-
1BB might also be beneficial in vascular remodeling. 
The recently published CANTOS trial regained attention to the immune system as 
a potential target for CVD, by using IL1β inhibitor canakinumab as a treatment for 
atherosclerosis12. If the effect of canakinumab is specifically due to the inhibition of 
IL1β, a different approach to block IL1β may also be used. Targeting the inflammasome 
may be beneficial in vascular remodeling. The inflammasome is a component of 
the innate immune system and is a protein complex that regulates the activation 
of the caspase-1. Activated caspase-1 functions to cleave the pro-inflammatory 
IL-1 family of cytokines into their bioactive forms, IL-1β and IL1813. Targeting the 
inflammasome may reduce both IL-1β and IL18, which we observed as a key 
cytokine in addition to IL12 and IL2 to activate CD8+ T cells, and thereby reduce or 
even prevent CVD. Monocytes, VSMC and EC express Il-1β and IL18 receptors and 
can proliferate and migrate after activation and thereby contribute to vascular 
remodeling. In addition, inflammasome activation causes pyroptosis, a rapid type of 
inflammatory cell death. There are different forms of inflammasomes containing a 
Nod-like receptor, of these NLRP3 is the most well know and unique receptor14. An 
inflammasome inhibitor targeting NLRP3 may be an interesting new target for CVD 
via the inhibition of vascular remodeling.
Clinical application of our knowledge obtained in the pre-clinical studies described 
in this thesis, could be via stimulation or inhibition of TLRs, IRFs, type-I IFNs or T cells. 
TLR stimulation might be a useful and realistic therapeutic target, since this receptor 
is constantly expressed on APCs, whereas phosphorylated IRFs translocate to the 
nucleus and activated the transcription of IFNα and IFNβ, which makes IRFs harder to 
target. TLR signaling can be induced via endogenous or exogenous ligands, however, 
this is not clinically applicable yet. TLR treatments should focus on differential 
methods due to the variety in CVD, e.g. the pathophysiology of neovascularization is 
different than VGD. For VGD, local stimulation or inhibition of TLRs is optional, since 
(open) harvesting of the saphenous vein gives therapeutic opportunities without 
systemic side effect. For neovascularization, soluble, injectable treatments should be 
investigated, to stimulate neovascularization in the lower legs. 
Recently nanoparticles were introduced as a promising new strategy for co-delivery of 
genes and therapeutic agents15. Drugs, e.g. targeting TLRs, IRFs or T cells, conjugated 
to nanoparticles could aid targeted delivery16. Seijkens et al. already successfully used 
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nanotherapy to target the co-stimulation CD40-TRAF pathway in an atherosclerotic 
mice model, which resulted in a decrease in atherosclerotic plaque development17. 
In addition, Sokolova et al. incorporated TLR3 ligand PolyI:C into calcium phosphate 
nanoparticles to treat viral infections18, which can be interesting for future treatments 
of VGD and neovascularization via TLR3. 
As extensively reviewed in chapter 3, blocking of co-stimulation pathways and 
stimulating co-inhibition pathways, could be interesting therapeutic targets for CVD. 
However, opposing therapies, resulting in activated T cell, revolutionized cancer 
treatments e.g. immune checkpoint inhibitors (ICIs) blocking the inhibition pathways 
and stimulators of co-stimulation pathways. ICIs may induce cardiovascular toxicity via 
the activation of T cells, thus the risk of cardiovascular toxicity should be taken into 
consideration and investigated. Future pre-clinical studies should focus on beneficial 
treatments for CVD; therapeutic targeting of co-stimulation via e.g. abatacept and 
belatacept blocking CD80/86, CD40-TRAF6 inhibitor blocking CD40, anti-OX40 
blocking the OX40-OX40L interaction or anti-4-1BB antibodies blocking 4-1BB. Clinical 
studies should teach us whether the cardiovascular outcomes of therapeutic targeting 
of co-stimulation are as promising as expected.
In conclusion, in this thesis we obtained new knowledge on several contributing factors 
in vascular remodeling. Described molecules of the innate and adaptive immune system 
might be used as targets to prevent vein graft failure and stimulate neovascularization 
and this thesis can serve as a fundamental basis for the development of new medication 
in the future. 
> Figure 1. Schematic overview of the discovered signaling pathways of TLR2, TLR3 and TLR4, 
regulating vascular remodeling in this thesis. In the pathophysiological processes of VGD, TLRs are 
considered to be important accelerating factors via the activation of an inflammatory response. In 
chapter 6 we showed that TLR3 was involved in VGD development and we even showed a prominent 
protective role of TLR3 compared to control, TLR2 and TLR4 deficient mice. TLR3, and partly TLR4, 
signals via a MyD88-independent pathway with a central role for TRIF and IRF3 and IRF7 resulting in 
induction of type-I IFNs, such as IFNα and IFNβ. TLR4 can also signal via the MyD88 pathway, similar 
to TLR2 and most other TLRs, which drives the induction of NFĸB, resulting in induction of pro-
inflammatory cytokines. We provide evidence that the molecular mechanism of the TLR3-induced 
protective effect is dependent on the production of type-I IFNs. IRF3 and IRF7 are downstream factors 
of TLRs and regulate the transcription of type-I IFNs; IFNα and IFNβ. We showed that IRF3 and IRF7 
are both activated downstream TLR3 and able to produce type-I IFNs, but IRF3 can also be activated 
downstream TLR4 and regulate the production of pro-inflammatory cytokines. IRF3 and IRF7 
deficient mice have similar protective effects in the development of VGD as TLR3 deficient mice, but 
IRF3 and IRF7 have different effects on VGD development in time. IRF3 is an early regulator of type-I 
IFNs, whereas IRF7 regulated late type-I IFN production. TLR = toll like receptor, TRIF = TIR-domain-
containing adapter-inducing interferon-β, Myd88 = Myeloid differentiation primary response 88, IRF 
= Interferon regulatory factor, NFĸB = nuclear factor kappa-light-chain-enhancer of activated B cells, 
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Graag wil ik hier mijn dank uitspreken naar iedereen die mee heeft geholpen met het 
tot stand komen van dit proefschrift.
Professor Quax, beste Paul, wie had gedacht dat wij een paar jaar later weer in het 
academie gebouw samen zouden staan! Ik ben je enorm dankbaar dat je tijdens mijn 
artsenbul uitreiking al vertrouwen in mij had als onderzoeker. Wat een prachtige 
jaren, wat een interessante projecten hebben we opgezet en wat een mooie congres 
reizen hebben we gemaakt met als hoogtepunten toch wel Athene, New Orleans, 
Rhode Island en Straatsburg. Bedankt voor alle wetenschappelijke discussies en later 
ook de niet wetenschappelijke discussies over de zorg, het onderzoek en beurzen.
Professor Jukema, beste Wouter, bedankt dat je vanaf onze eerste ontmoeting 
positief was. Wat heb ik gelachen tijdens onze meeting over al je mooie verhalen. Je 
input was zeer waardevol, en ik ben trots dat het ons tot 2 keer toe gelukt is om een 
prachtig review te publiceren. Dankzij jou wijze woorden ‘slapen is overrated’ denk ik 
dat Margreet en ik altijd onze deadlines zullen halen, bedankt!
Margreet, wat was het gezellig dat ik de eerste jaren naast jou mocht zitten op de 
kamer. Ik heb zo ontzettend veel geleerd van je, over de muizen, de operaties, de 
(immuno)histochemie kleuringen, de analyses, het PDC en over je paarden en pony’s. 
Altijd heb ik veel respect voor het feit dat je zoveel artikelen leest en altijd overal van 
op de hoogte bent, daar kan iedereen wat van leren. 
Prof. Hamming, beste Jaap. Dank voor je support en klinische blik. Hierdoor verloren 
wij in dit pre-klinische proefschrift de kliniek niet uit het oog.
Ramon, dankzij jou heb ik mijn passie voor de immunologie ontwikkeld. Vanaf dag 1 
begon ik met FACSen en het T cel project en daar hebben we samen echt iets moois 
gemaakt! Bedankt voor alle leuke werkbesprekingen over de projecten en onze 
sportambities, en dat ik altijd bij jou en het IHB lab terecht kon. 
Erna, wat heb ik niet van jou geleerd? Van het prutten van test miltjes in mijn eerste 
weken tot een groots experiment met vein grafts waar we trots op mogen zijn. Van 
het eindeloos kweken van gladde spiercellen, macrofagen en T cellen tot aan al je 
wijze adviezen bij het kopen van mijn eerste racefiets! Gelukkig wist je altijd precies 
of ik al op werk was (met dank aan strava) en konden we dan gezellig koffie drinken 
op p1 inclusief koekjes zodat ik jou mooie ringvaart rondes kon bekijken. Ik blijf je 
volgen!
Regi, mijn c7 buddy! Als enige van c7 heb jij echt elk hoofdstuk van dit proefschrift 
voorbij zien komen. Samen zaten we te zwoegen en klagen op rebuttals en konden 
we onze vreugde delen als experimenten geslaagd waren, abstracts geaccepteerd 
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waren, of we samen naar congres mochten! Dankzij onze verschillende werktijden 
hebben we ervoor gezorgd dat er bijna 24/7 licht brandt op C7, en toch zorgde we 
ervoor dat we elkaar dagelijks wel even zagen. Jaren hebben we geprobeerd om 
onze projecten te combineren, en eindelijk is het toch gelukt om iets samen te doen. 
Laura and Fabiana, you completed the C7 Squad! We had so much fun and I’m really 
glad you joined the Quax team. I will never forget the moments when we; ‘Borrowed’ 
coffee at c7 and got busted, failed to introduce a Dutch word every day, sailed at 
Kaagdag, had our awesome trip to Wenen, had PhD drinks at Laura’s place and saw 
Archie grow up. Thank you for walking the stairs with me every day.  
Abby en Graziella bedankt voor de leuke samenwerking bij de HGF trial. Hard 
gewerkt, veel tijd aan besteed, helaas zonder resultaat, maar gelukkig hebben we 
wel een prachtige reis naar Athene gemaakt!
Natuurlijk wil ik ook alle andere leden van de Quax groep bedanken; Eva, Evelien, 
Rob, Alwin, Valerie, ChunYu, Zeen, Taya, Yael, Sabine, Anouk en Nigel en ook 
mijn studenten Nazike, Dennis, Daisy en Rhianne. Daarnaast ook veel dank aan het 
Heelkunde en Eindhoven lab voor alle support. 
Alle andere onderzoekers van de heelkunde mogen uiteraard niet ontbreken in dit 
dankwoord, met name Suzan waarmee ik een prachtige tijd in Boston heb gehad, 
en de ‘actieve menschen’. Uiteraard bedankt ik ook al mijn zwem vrienden van de 
Dolfijn, DSZ, WZK, en D’elft met wie ik in de vroege uurtjes en laat in de avond 
kon ontspannen en buffelen tijdens de trainingen van wedstrijdzwemmen en 
synchroonzwemmen. Tot slot bedank ik mijn vriend Lars, zonder deze promotie 
had ik jou nooit ontmoet, maar zonder jou had ik deze promotie ook nooit zo mooi 
kunnen afsluiten! Papa en mama, Erik en Anne bedankt voor alle support en het 
vertrouwen wat jullie altijd in mij hebben.
 
 

